Kit or device for detecting breast cancer and detection method

Abstract

The invention provides a kit or device for detecting breast cancer, and a detection method. A kit or device for detecting breast cancer, which contains a nucleic acid capable of specifically binding to miRNA in a specimen of a subject, and a method for detecting breast cancer, which includes measuring the miRNA in vitro.

Description

[0001] This application is a divisional application of a patent application filed on June 12, 2015, with application number 202110418361.8 and invention name “Detection kit or device and detection method for breast cancer”. Technical Field

[0002] The present invention relates to a breast cancer detection kit or device for examining whether a subject has breast cancer, the kit comprising a nucleic acid capable of specifically binding to a specific miRNA, and a breast cancer detection method comprising using the nucleic acid to measure the expression level of the miRNA. Background Art

[0003] The breast is composed of milk-producing glands, lobules that separate from the glands, milk ducts that separate from the lobules and carry milk, and the fat that supports them. Approximately 90% of breast cancers originate in the milk ducts, while approximately 5-10% originate in the lobules (Non-Patent Document 1). According to statistics on cancer mortality rates by site in Japan in 2011, published by the Cancer Information Center of the National Cancer Center, a national research and development organization, breast cancer deaths rose to 12,731, affecting approximately 1 in 14 Japanese women, making it the most common cancer site in women. Furthermore, in the United States, breast cancer is said to develop in approximately 1 in 8 women, and the estimated number of breast cancer cases in 2014 reached 232,670, with 40,000 deaths estimated (Non-Patent Document 1).

[0004] Non-Patent Document 2 defines the progression of breast cancer, dividing it into stages 0, IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and IV based on tumor size, invasiveness, lymph node metastasis, and distant metastasis. The five-year relative survival rate for breast cancer varies significantly depending on the progression of the cancer, with reported rates of 100% for stages 0 and 1, 93% for stage 2, 72% for stage 3, and 22% for stage 4 (Non-Patent Document 1). Therefore, early detection of breast cancer is associated with improved survival rates, and there is a strong desire for methods that enable early detection.

[0005] While breast cancer is generally treated surgically, medication and radiation therapy are sometimes used in combination, depending on the stage of progression, metastasis, general condition, and type of breast cancer. In particular, breast-conserving therapy may be used in combination with radiation therapy for early-stage breast cancer, particularly in stages 1 or 2 (Non-Patent Document 1).

[0006] According to Non-Patent Document 1, primary breast cancer screening involves not only visual and palpation examinations but also imaging tests such as mammography (a breast-specific X-ray examination) and ultrasound (echo) examinations. If breast cancer is suspected from the primary examination, a secondary examination involves a pathological examination in which a needle is inserted into the lesion to collect cells and tissues for microscopic examination. Furthermore, imaging tests such as CT, MRI, abdominal ultrasound, bone scintigraphy, and PET are also performed as needed to investigate the condition and spread of the lesion.

[0007] Known tumor markers for breast cancer detection include CEA, CA-15-3, and CA27-29. While reports indicate that these blood tumor markers may increase when breast cancer metastasizes to other organs such as bones and liver, some patients may not experience increases, suggesting that their usefulness is limited (Non-Patent Document 1).

[0008] Although still in the research stage, as shown in Patent Documents 1 to 4, there are reports that breast cancer can be detected by measuring the expression level of microRNA (miRNA) in biological samples such as blood, or by combining the expression level of miRNA with the expression levels of other protein markers.

[0009] Specifically, Patent Document 1 discloses a method for detecting other cancers including prostate cancer and breast cancer by combining hsa-miR-602 and hsa-miR-135a-3p in blood with known protein markers.

[0010] Patent Document 2 discloses a method for detecting various cancers including breast cancer by combining hsa-miR-23b-3p and hsa-miR-135a-3p in blood or tissue with five or more other miRNAs.

[0011] Patent Document 3 discloses a method for detecting breast cancer using hsa-miR-92a-3p, hsa-miR-92a-2-5p, hsa-miR-92b-5p, and the like in blood cells.

[0012] Patent Document 4 discloses a method for detecting breast cancer using hsa-miR-451a, hsa-miR-296-5p, hsa-miR-16-5p, and the like in tissues.

[0013] Non-Patent Document 3 shows that hsa-miR-760 and the like are significantly expressed in the blood of breast cancer patients.

[0014] Non-Patent Document 4 shows that hsa-miR-423-5p, hsa-miR-486-5p, etc. in the blood decrease after breast cancer surgery.

[0015] Non-Patent Document 5 shows that hsa-miR-4257, hsa-miR-1915-3p, hsa-miR-718, etc. are significantly expressed in the blood of breast cancer patients.

[0016] Non-Patent Document 6 shows that hsa-miR-940 and the like are significantly expressed in the blood of breast cancer patients.

[0017] Prior art literature

[0018] Patent Literature

[0019] Patent Document 1: Japanese Patent Application No. 2012-507300

[0020] Patent Document 2: Japanese Patent Application No. 2008-500837

[0021] Patent Document 3: International Publication No. 10 / 123043

[0022] Patent Document 4: U.S. Patent Application Publication No. 2008 / 0076674

[0023] Non-patent literature

[0024] Non-patent document 1: American Cancer Society “Breast Cancer”, 2013, pp. 6-9, 13, 27-28, 41-46, 52-54, 63-64, 106

[0025] Non-patent document 2: Sobin, L. et al., "TNM Classification of Malignant Tumors 7th Edition" 2010, pp. 171-181

[0026] Non-patent document 3: Godfrey, AC. et al., 2013, Breast Cancer Research, Vol. 15(3), p. R42

[0027] Non-patent document 4: Cookson, VJ. et al., 2012, Cellular Oncology, Vol. 35(4), pp. 301-8

[0028] Non-patent document 5: Schrauder, MG. et al., 2012, PLoS One, Vol. 7(1), p.e29770

[0029] Non-patent document 6: Leidner, RS. et al., 2013, PLoS One, Vol. 8(3), p.e57841

[0030] Non-patent document 7: Tamaki, K. et al., 2013, Japanese Journal of Clinical Oncology, Vol. 43(2), pp. 208-213

[0031] Non-patent document 8: Guadagni, F. et al., 2001, Clinical Cancer Research, Vol. 7, pp. 2357-2362 Summary of the Invention

[0032] Problems to be solved by the invention

[0033] The present invention aims to find a new breast cancer tumor marker and to provide a method for effectively detecting breast cancer using a nucleic acid that can specifically bind to the marker. As described in Non-Patent Document 1, in addition to visual inspection and palpation, a primary examination for breast cancer includes mammography, which is a breast-specific X-ray examination, and imaging examinations such as ultrasound examination. Mammography is considered effective for breast cancer screening in women over 40 years old, and the American Cancer Society recommends annual diagnosis (Non-Patent Document 1). However, mammography is considered to be limited in detecting breast cancer present in high-density breasts before menopause and early-stage micro-breast cancer (Non-Patent Document 1). In addition, in Japan, the acceptance rate for mammography was only 24.3% in 2010, and improving this acceptance rate is considered to be a problem for improving breast cancer survival rates (Non-Patent Document 7).

[0034] Among the tumor markers used for breast cancer detection, the aforementioned CEA, CA-15-3, and CA27-29 are known. However, while these tumor markers can sometimes be useful for confirming the effectiveness of treatment for recurrent breast cancer, they rarely rise in early-stage breast cancer and are therefore considered ineffective for breast cancer diagnosis (Non-Patent Document 1). Furthermore, according to Non-Patent Document 8, the sensitivity of CEA and CA15-3 is 6.4% and 12.2% in stage 1, making them practically useless. Furthermore, in stage 4, the sensitivity is only 25.0% and 62.5%, respectively, making tumor marker measurement insignificant for preoperative testing. Furthermore, these blood tumor markers can sometimes rise for reasons other than breast cancer, making it difficult to determine the presence of breast cancer. Misdiagnosing other cancers as breast cancer can lead to missed opportunities for appropriate treatment, or inappropriate medical treatment can impose unnecessary financial and physical burdens on patients.

[0035] Furthermore, although still in the research stage, there are reports such as the following that use the expression levels of microRNA (miRNA) in biological samples such as blood to discriminate breast cancer, but none of these reports have been put into practical use.

[0036] Patent Document 1 describes a method for detecting other cancers, including prostate and breast cancer, by combining hsa-miR-602 and hsa-miR-135a-3p in blood with known protein markers. However, measuring both miRNA and protein markers increases testing costs and complicates the process, making this method undesirable. Furthermore, this method lacks specific accuracy, sensitivity, and specificity for breast cancer diagnosis, lacking industrial applicability.

[0037] Patent Document 2 describes a method for detecting various cancers, including breast cancer, by combining hsa-miR-23b-3p and hsa-miR-135a-3p in blood and tissues with five or more other miRNAs. However, the method lacks industrial practicality, as it does not describe the specific accuracy, sensitivity, and specificity of the detection performance for breast cancer.

[0038] The method described in Patent Document 3 describes the use of hsa-miR-92a-3p, hsa-miR-92a-2-5p, and hsa-miR-92b-5p for breast cancer detection. However, the method lacks specific accuracy, sensitivity, and specificity for breast cancer detection, thus lacking industrial practicality. Furthermore, these miRNA markers have not been validated using independent sample panels, thus lacking reliability.

[0039] Patent Document 4 describes a method for detecting breast cancer using hsa-miR-451a, hsa-miR-296-5p, and hsa-miR-16-5p in tissue. However, this method requires surgical tissue removal to obtain a specimen, a procedure that places a heavy physical strain on the patient and is therefore not a suitable diagnostic method. Furthermore, this method lacks specific information regarding its accuracy, sensitivity, and specificity for breast cancer diagnosis, lacking industrial applicability.

[0040] Non-patent document 3 shows that hsa-miR-760 and other proteins are significantly expressed in the blood of breast cancer patients. However, there is no description of the detection performance, such as accuracy, sensitivity, and specificity, for breast cancer diagnosis. Furthermore, a specific breast cancer detection method is not described, thus lacking industrial practicality.

[0041] Non-patent document 4 shows that hsa-miR-423-5p, hsa-miR-486-5p, and other genes in the blood decrease after breast cancer surgery. However, there is no description of the detection performance, such as accuracy, sensitivity, and specificity, for breast cancer diagnosis. Furthermore, a specific breast cancer detection method is not described, thus lacking industrial practicality.

[0042] Non-patent document 5 shows that hsa-miR-4257, hsa-miR-1915-3p, hsa-miR-718, etc. in the blood are significantly expressed in breast cancer patients. However, 240 miRNAs are used to detect breast cancer, and there are concerns about increased testing costs and the complexity of the discrimination algorithm, making it impractical in industry.

[0043] Non-Patent Document 6 shows that hsa-miR-940 and other markers are significantly expressed in the blood of breast cancer patients. However, the authors conclude that this marker lacks reproducibility and ultimately abandon the research. Furthermore, there is no description of the detection performance, such as accuracy, sensitivity, and specificity, for breast cancer diagnosis. Furthermore, no specific breast cancer detection method is described, thus lacking industrial practicality.

[0044] As such, existing tumor markers have low performance in breast cancer detection. Furthermore, the performance and detection methods of research-stage markers are not specifically documented. Therefore, their use can lead to unnecessary additional testing due to misidentification of healthy individuals as breast cancer patients, or missed breast cancer cases, resulting in lost treatment opportunities. Furthermore, measuring dozens to hundreds of miRNAs increases testing costs, making it difficult to use for large-scale screening, such as health diagnostics. Furthermore, collecting breast tissue for tumor marker measurement is highly invasive and undesirable. Therefore, there is a need for breast cancer markers that can be detected using blood samples collected minimally, accurately distinguishing breast cancer patients from those with breast cancer and healthy subjects from those without. In particular, early detection and treatment of breast cancer can significantly reduce the risk of recurrence and enable breast-conserving therapy. Therefore, there is a strong demand for highly sensitive breast cancer markers that can detect even low-stage breast cancer. Furthermore, it is envisioned that by providing a simpler one-time breast cancer screening test, the acceptance rate of mammography will be increased.

[0045] Methods for solving problems

[0046] The present inventors conducted intensive studies to solve the above-mentioned problems and, as a result, discovered that by identifying multiple genes that can be used as detection markers for breast cancer from blood that can be collected minimally invasively and using nucleic acids that can specifically bind to these genes, breast cancer can be significantly detected, leading to the completion of the present invention.

[0047] <Overview of the Invention>

[0048] That is, the present invention has the following features.

[0049] (1) A kit for detecting breast cancer, which comprises substances capable of binding to miR-4783-3p, miR-4730, miR-1307-3p, miR-4634, miR-663a, miR-4532, miR-7704, miR-3178, miR-6729-5p, miR-6090, miR-4732-5p, miR-3184-5p, miR-6727-5p, miR-6088, miR-4674, miR-8073, miR-4787-5p, miR-1469, miR-125a-3p, miR-1233-5p, miR-885-3p, miR-6802-5p, miR-328-5p, miR-6787-5p, miR-8069, miR-6875-5p, miR-1246, miR-4734, miR-6757-5p, miR-6756-5p, miR-3665, miR-6836-3p, miR-6821-5p, miR-6805-5p, miR-4728-5p, miR-6726-5p, miR-197-5p, miR-149-3p, miR-6850-5p, miR-4476, miR-6858-5p, miR-564, miR-4763-3p, miR-575, miR-6771-5p, miR-1231, miR-1908-3p, miR-150-3p, miR-3937, miR-887-3p, miR-3940-5p, miR-4741, miR-6808-5p, miR-6869-5p, miR-5090, miR-615-5p, miR-8072, miR-128-1-5p, miR-1238-5p, miR-365a-5p, miR-204-3p, miR-4492, miR-6785-5p, miR-6511a-5p, miR-4525, miR-1915-5p, miR-3180, miR-6879-5p, miR-1199-5p, miR-6746-5p, miR-711, miR-663b, miR-4707-3p, miR-6893-5p, miR-4675, miR-4638-5p, miR-4651, miR-6087, miR-4665-5p, miR-4758-5p, miR-6887-5p, miR-3620-5p, miR-1909-3p, miR-7641, miR-6724-5p, miR-1343-3p, miR-6780b-5p, miR-4484, miR-4690-5p, miR-4429, which are used as breast cancer markers.miR-1227-5p, miR-4725-3p, miR-6861-5p, miR-6812-5p, miR-3197, miR-8059, miR-3185, miR-4706, miR-4497, miR-3131, miR-6806-5p, miR-187-5p miR-3180-3p, miR-6848-5p, miR-6820-5p, miR-6800-5p, miR-6717-5p, miR-6795-5p, miR-4632-5p, miR-665, miR-6778-5p, miR-3663-3p, miR-4689 miR-211-3p, miR-6511b-5p, miR-4750-5p, miR-6126, miR-614, miR-7110-5p, miR-744-5p, miR-6769a-5p, miR-4792, miR-5787, miR-6798-5p, miR-6 781-5p、miR-4419b、miR-4446-3p、miR-4259、miR-5572、miR-6075、miR-296-3p、miR-6891-5p、miR-4745-5p、miR-6775-5p、miR-6870-5p、miR-920、mi R-4530, miR-6819-5p, miR-6825-5p, miR-7847-3p, miR-6131, miR-4433-3p, miR-1228-5p, miR-6743-5p, miR-1268a, miR-3917, miR-6786-5p, miR-31 54, miR-638, miR-6741-5p, miR-6889-5p, miR-6840-3p, miR-6510-5p, miR-3188, miR-551b-5p, miR-5001-5p, miR-1268b, miR-7107-5p, miR-6824-5p miR-6732-5p, miR-371a-5p, miR-6794-5p, miR-6779-5p, miR-4271, miR-5195-3p, miR-6762-5p, miR-939-5p, miR-1247-3p, miR-6777-5p, miR-6722 -3p、miR-3656、miR-4688、miR-3195、miR-6766-5p、miR-4447、miR-4656、miR-7108-5p、miR-3191-3p、miR-1273g-3p、miR-4463、miR-2861、miR-3196、A nucleic acid that specifically binds to at least one polynucleotide among miR-6877-5p, miR-3679-5p, miR-4442, miR-6789-5p, miR-6782-5p, miR-486-3p, miR-6085, miR-4746-3p, miR-619-5p, miR-937-5p, miR-6803-5p, miR-4298, miR-4454, miR-4459, miR-7150, miR-6880-5p, miR-4449, miR-8063, miR-4695-5p, miR-6132, miR-6829-5p, miR-4486, miR-6805-3p, miR-6826-5p, miR-4508, miR-1343-5p, miR-7114-5p, miR-3622a-5p, miR-6765-5p, miR-7845-5p, miR-3960, miR-6749-5p, miR-1260b, miR-6799-5p, miR-4723-5p, miR-6784-5p, miR-5100, miR-6769b-5p, miR-1207-5p, miR-642a-3p, miR-4505, miR-4270, miR-6721-5p, miR-7111-5p, miR-6791-5p, miR-7109-5p, miR-4258, miR-6515-3p, miR-6851-5p, miR-6125, miR-4749-5p, miR-4726-5p, miR-4513, miR-6089, miR-6816-5p, miR-4466, miR-4488, miR-6752-5p, and miR-4739.

[0050] (2) The kit according to (1), wherein miR-4783-3p is hsa-miR-4783-3p, miR-4730 is hsa-miR-4730, miR-1307-3p is hsa-miR-1307-3p, miR-4634 is hsa-miR-4634, miR-663a is hsa-miR-663a, miR-4532 is hsa-miR-4532, miR-7704 is hsa-miR-7704, miR-3178 is hsa-miR-3178, miR-6729-5p is hsa-miR-6729-5p, and miR-6090 is hsa -miR-6090, miR-4732-5p is hsa-miR-4732-5p, miR-3184-5p is hsa-miR-3184-5p, miR-6727-5p is hsa-miR-6727-5p, miR-6088 is hsa-miR-6088, miR-4674 is hsa-miR-4674, miR-8073 is hsa-miR-8073, miR-4787-5p is hsa-miR-4787-5p, miR-1469 is hsa-miR-1469, miR-125a-3p is hsa-miR-125a-3p, miR-1233 is hsa-miR-1233 -5p is hsa-miR-1233-5p, miR-885-3p is hsa-miR-885-3p, miR-6802-5p is hsa-miR-6802-5p, miR-328-5p is hsa-miR-328-5p, miR-6787-5p is hsa-miR-6787-5p, miR-8069 is hsa-miR-8069, miR-6875-5p is hsa-miR-6875-5p, miR-1246 is hsa-miR-1246, miR-4734 is hsa-miR-4734, and miR-6757-5p is hsa-miR-6757 -5p, miR-6756-5p is hsa-miR-6756-5p, miR-3665 is hsa-miR-3665, miR-6836-3p is hsa-miR-6836-3p, miR-6821-5p is hsa-miR-6821-5p, miR-6805-5p is hsa-miR-6805-5p, miR-4728-5p is hsa-miR-4728-5p, miR-6726-5p is hsa-miR-6726-5p, miR-197-5p is hsa-miR-197-5p, miR-149-3p is hsa-miR-149-3p,miR-6850-5p is hsa-miR-6850-5p, miR-4476 is hsa-miR-4476, miR-6858-5p is hsa-miR-6858-5p, miR-564 is hsa-miR-564, miR-4763-3p is hsa-miR-4763-3p, miR-575 is hsa-miR-575, miR-6771-5p is hsa-miR-6771-5p, miR-1231 is hsa-miR-1231, miR-1908-3p is hsa-miR-1908-3p, and miR-150-3p is hsa-miR-150-3p. p, miR-3937 is hsa-miR-3937, miR-887-3p is hsa-miR-887-3p, miR-3940-5p is hsa-miR-3940-5p, miR-4741 is hsa-miR-4741, miR-6808-5p is hsa-miR-6808-5p, miR-6869-5p is hsa-miR-6869-5p, miR-5090 is hsa-miR-5090, miR-615-5p is hsa-miR-615-5p, miR-8072 is hsa-miR-8072, and miR-128-1-5p is hsa-miR-128-1. 28-1-5p, miR-1238-5p is hsa-miR-1238-5p, miR-365a-5p is hsa-miR-365a-5p, miR-204-3p is hsa-miR-204-3p, miR-4492 is hsa-miR-4492, miR-6785-5p is hsa-miR-6785-5p, miR-6511a-5p is hsa-miR-6511a-5p, miR-4525 is hsa-miR-4525, miR-1915-5p is hsa-miR-1915-5p, miR-3180 is hsa-miR-3180, miR-68 79-5p is hsa-miR-6879-5p, miR-1199-5p is hsa-miR-1199-5p, miR-6746-5p is hsa-miR-6746-5p, miR-711 is hsa-miR-711, miR-663b is hsa-miR-663b, miR-4707-3p is hsa-miR-4707-3p, miR-6893-5p is hsa-miR-6893-5p, miR-4675 is hsa-miR-4675, miR-4638-5p is hsa-miR-4638-5p, miR-4651 is hsa-miR-4651,miR-6087 is hsa-miR-6087, miR-4665-5p is hsa-miR-4665-5p, miR-4758-5p is hsa-miR-4758-5p, miR-6887-5p is hsa-miR-6887-5p, miR-3620-5p is hsa-miR-3620-5p, miR-1909-3p is hsa-miR-1909-3p, miR-7641 is hsa-miR-7641, miR-6724-5p is hsa-miR-6724-5p, miR-1343-3p is hsa-miR-1343-3p, miR-678 0b-5p is hsa-miR-6780b-5p, miR-4484 is hsa-miR-4484, miR-4690-5p is hsa-miR-4690-5p, miR-4429 is hsa-miR-4429, miR-1227-5p is hsa-miR-1227-5p, miR-4725-3p is hsa-miR-4725-3p, miR-6861-5p is hsa-miR-6861-5p, miR-6812-5p is hsa-miR-6812-5p, miR-3197 is hsa-miR-3197, and miR-8059 is hsa-miR-8061. 59, miR-3185 is hsa-miR-3185, miR-4706 is hsa-miR-4706, miR-4497 is hsa-miR-4497, miR-3131 is hsa-miR-3131, miR-6806-5p is hsa-miR-6806-5p, miR-187-5p is hsa-miR-187-5p, miR-3180-3p is hsa-miR-3180-3p, miR-6848-5p is hsa-miR-6848-5p, miR-6820-5p is hsa-miR-6820-5p, and miR-6800-5p is hsa-miR-6800-5p. R-6800-5p, miR-6717-5p is hsa-miR-6717-5p, miR-6795-5p is hsa-miR-6795-5p, miR-4632-5p is hsa-miR-4632-5p, miR-665 is hsa-miR-665, miR-6778-5p is hsa-miR-6778-5p, miR-3663-3p is hsa-miR-3663-3p, miR-4689 is hsa-miR-4689, miR-211-3p is hsa-miR-211-3p, miR-6511b-5p is hsa-miR-6511b-5p,miR-4750-5p is hsa-miR-4750-5p, miR-6126 is hsa-miR-6126, miR-614 is hsa-miR-614, miR-7110-5p is hsa-miR-7110-5p, miR-744-5p is hsa-miR-744-5p, miR-6769a-5p is hsa-miR-6769a-5p, miR-4792 is hsa-miR-4792, miR-5787 is hsa-miR-5787, miR-6798-5p is hsa-miR-6798-5p, and miR-6781-5p is hsa-miR-6781-5p. 81-5p, miR-4419b is hsa-miR-4419b, miR-4446-3p is hsa-miR-4446-3p, miR-4259 is hsa-miR-4259, miR-5572 is hsa-miR-5572, miR-6075 is hsa-miR-6075, miR-296-3p is hsa-miR-296-3p, miR-6891-5p is hsa-miR-6891-5p, miR-4745-5p is hsa-miR-4745-5p, miR-6775-5p is hsa-miR-6775-5p, and miR-6870-5p is hsa-miR-6870-5p. a-miR-6870-5p, miR-920 is hsa-miR-920, miR-4530 is hsa-miR-4530, miR-6819-5p is hsa-miR-6819-5p, miR-6825-5p is hsa-miR-6825-5p, miR-7847-3p is hsa-miR-7847-3p, miR-6131 is hsa-miR-6131, miR-4433-3p is hsa-miR-4433-3p, miR-1228-5p is hsa-miR-1228-5p, miR-6743-5p is hsa-miR-6743-5p, miR- R-1268a is hsa-miR-1268a, miR-3917 is hsa-miR-3917, miR-6786-5p is hsa-miR-6786-5p, miR-3154 is hsa-miR-3154, miR-638 is hsa-miR-638, miR-6741-5p is hsa-miR-6741-5p, miR-6889-5p is hsa-miR-6889-5p, miR-6840-3p is hsa-miR-6840-3p, miR-6510-5p is hsa-miR-6510-5p, miR-3188 is hsa-miR-3188,miR-551b-5p is hsa-miR-551b-5p, miR-5001-5p is hsa-miR-5001-5p, miR-1268b is hsa-miR-1268b, miR-7107-5p is hsa-miR-7107-5p, miR-6824-5p is hsa-miR-6824-5p, miR-6732-5p is hsa-miR-6732-5p, miR-371a-5p is hsa-miR-371a-5p, miR-6794-5p is hsa-miR-6794-5p, and miR-6779-5p is hsa-miR-6779-5p. , miR-4271 is hsa-miR-4271, miR-5195-3p is hsa-miR-5195-3p, miR-6762-5p is hsa-miR-6762-5p, miR-939-5p is hsa-miR-939-5p, miR-1247-3p is hsa-miR-1247-3p, miR-6777-5p is hsa-miR-6777-5p, miR-6722-3p is hsa-miR-6722-3p, miR-3656 is hsa-miR-3656, miR-4688 is hsa-miR-4688, and miR-3195 is hsa-miR-3195. iR-3195, miR-6766-5p is hsa-miR-6766-5p, miR-4447 is hsa-miR-4447, miR-4656 is hsa-miR-4656, miR-7108-5p is hsa-miR-7108-5p, miR-3191-3p is hsa-miR-3191-3p, miR-1273g-3p is hsa-miR-1273g-3p, miR-4463 is hsa-miR-4463, miR-2861 is hsa-miR-2861, miR-3196 is hsa-miR-3196, miR-6877-5p is hsa -miR-6877-5p, miR-3679-5p is hsa-miR-3679-5p, miR-4442 is hsa-miR-4442, miR-6789-5p is hsa-miR-6789-5p, miR-6782-5p is hsa-miR-6782-5p, miR-486-3p is hsa-miR-486-3p, miR-6085 is hsa-miR-6085, miR-4746-3p is hsa-miR-4746-3p, miR-619-5p is hsa-miR-619-5p, miR-937-5p is hsa-miR-937-5p,miR-6803-5p is hsa-miR-6803-5p, miR-4298 is hsa-miR-4298, miR-4454 is hsa-miR-4454, miR-4459 is hsa-miR-4459, miR-7150 is hsa-miR-7150, miR-6880-5p is hsa-miR-6880-5p, miR-4449 is hsa-miR-4449, miR-8063 is hsa-miR-8063, miR-4695-5p is hsa-miR-4695-5p, miR-6132 is hsa-miR-6132, and miR-682 9-5p is hsa-miR-6829-5p, miR-4486 is hsa-miR-4486, miR-6805-3p is hsa-miR-6805-3p, miR-6826-5p is hsa-miR-6826-5p, miR-4508 is hsa-miR-4508, miR-1343-5p is hsa-miR-1343-5p, miR-7114-5p is hsa-miR-7114-5p, miR-3622a-5p is hsa-miR-3622a-5p, miR-6765-5p is hsa-miR-6765-5p, miR-7845-5p is hsa-miR-7845-5p p is hsa-miR-7845-5p, miR-3960 is hsa-miR-3960, miR-6749-5p is hsa-miR-6749-5p, miR-1260b is hsa-miR-1260b, miR-6799-5p is hsa-miR-6799-5p, miR-4723-5p is hsa-miR-4723-5p, miR-6784-5p is hsa-miR-6784-5p, miR-5100 is hsa-miR-5100, miR-6769b-5p is hsa-miR-6769b-5p, and miR-1207-5p is hsa-miR-1207-5p. iR-1207-5p, miR-642a-3p is hsa-miR-642a-3p, miR-4505 is hsa-miR-4505, miR-4270 is hsa-miR-4270, miR-6721-5p is hsa-miR-6721-5p, miR-7111-5p is hsa-miR-7111-5p, miR-6791-5p is hsa-miR-6791-5p, miR-7109-5p is hsa-miR-7109-5p, miR-4258 is hsa-miR-4258, miR-6515-3p is hsa-miR-6515-3p,miR-6851-5p is hsa-miR-6851-5p, miR-6125 is hsa-miR-6125, miR-4749-5p is hsa-miR-4749-5p, miR-4726-5p is hsa-miR-4726-5p, miR-4513 is hsa-miR-4513, miR-6089 is hsa-miR-6089, miR-6816-5p is hsa-miR-6816-5p, miR-4466 is hsa-miR-4466, miR-4488 is hsa-miR-4488, miR-6752-5p is hsa-miR-6752-5p, and miR-4739 is hsa-miR-4739.

[0051] (3) The kit according to (1) or (2), wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (a) to (e),

[0052] (a) a polynucleotide consisting of the base sequence represented by any of SEQ ID NOs: 1 to 235 and 851 to 856, or a base sequence in which u is t in the base sequence, a mutant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0053] (b) a polynucleotide comprising the base sequence represented by any one of SEQ ID NOs: 1 to 235 and 851 to 856, or a base sequence in which u is t,

[0054] (c) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 1 to 235 and 851 to 856, or a base sequence in which u is t in the base sequence, a mutant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0055] (d) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 1 to 235 and 851 to 856, or a base sequence in which u is t in the base sequence, and

[0056] (e) A polynucleotide that hybridizes to any one of the polynucleotides (a) to (d) above under stringent conditions.

[0057] (4) The kit according to any one of (1) to (3), further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-760, miR-602, miR-423-5p, miR-92a-2-5p, miR-16-5p, miR-451a, miR-135a-3p, miR-486-5p, miR-4257, miR-92b-5p, miR-1915-3p, miR-718, miR-940, miR-296-5p, miR-23b-3p, and miR-92a-3p, which are other breast cancer markers.

[0058] (5) The kit according to (4), wherein miR-760 is hsa-miR-760, miR-602 is hsa-miR-602, miR-423-5p is hsa-miR-423-5p, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-16-5p is hsa-miR-16-5p, miR-451a is hsa-miR-451a, miR-135a-3p is hsa-miR-135a-3p, and miR-486-5p is hsa-miR-5p. iR-486-5p, miR-4257 is hsa-miR-4257, miR-92b-5p is hsa-miR-92b-5p, miR-1915-3p is hsa-miR-1915-3p, miR-718 is hsa-miR-718, miR-940 is hsa-miR-940, miR-296-5p is hsa-miR-296-5p, miR-23b-3p is hsa-miR-23b-3p and miR-92a-3p is hsa-miR-92a-3p.

[0059] (6) The kit according to (4) or (5), wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (f) to (j),

[0060] (f) a polynucleotide consisting of the base sequence represented by any of SEQ ID NOs: 236 to 251, or a base sequence in which u is t in the base sequence, a mutant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0061] (g) a polynucleotide comprising the base sequence represented by any one of SEQ ID NOs: 236 to 251,

[0062] (h) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 236 to 251, or a base sequence in which u is t in the base sequence, a variant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0063] (i) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 236 to 251, or a base sequence in which u is t in the base sequence, and

[0064] (j) A polynucleotide that hybridizes to any one of the polynucleotides (f) to (i) above under stringent conditions.

[0065] (7) The kit according to any one of (1) to (6), further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-658, miR-6842-5p, miR-6124, miR-6765-3p, miR-7106-5p, miR-4534, miR-92b-3p, miR-3135b, miR-4687-3p, miR-762, miR-3619-3p, miR-4467, miR-557, miR-1237-5p, miR-1908-5p, miR-4286, miR-6885-5p, and miR-6763-5p, which are other breast cancer markers.

[0066] (8) The kit according to (7), wherein miR-658 is hsa-miR-658, miR-6842-5p is hsa-miR-6842-5p, miR-6124 is hsa-miR-6124, miR-6765-3p is hsa-miR-6765-3p, miR-7106-5p is hsa-miR-7106-5p, miR-4534 is hsa-miR-4534, miR-92b-3p is hsa-miR-92b-3p, miR-3135b is hsa-miR-3135b, and miR-4687-3p is hsa-miR-4687-3p. R-4687-3p, miR-762 was hsa-miR-762, miR-3619-3p was hsa-miR-3619-3p, miR-4467 was hsa-miR-4467, miR-557 was hsa-miR-557, miR-1237-5p was hsa-miR-1237-5p, miR-1908-5p was hsa-miR-1908-5p, miR-4286 was hsa-miR-4286, miR-6885-5p was hsa-miR-6885-5p and miR-6763-5p was hsa-miR-6763-5p.

[0067] (9) The kit according to (7) or (8), wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (k) to (o),

[0068] (k) a polynucleotide consisting of the base sequence represented by any of SEQ ID NOs: 252 to 269, or a base sequence in which u is t in the base sequence, a mutant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0069] (1) a polynucleotide comprising the base sequence represented by any one of SEQ ID NOs: 252 to 269,

[0070] (m) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 252 to 269, or a base sequence in which u is t in the base sequence, a variant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0071] (n) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 252 to 269, or a base sequence in which u is t in the base sequence, and

[0072] (o) A polynucleotide that hybridizes to any one of the polynucleotides (k) to (n) above under stringent conditions.

[0073] (10) The kit according to any one of (1) to (9), comprising at least two nucleic acids capable of specifically binding to at least two polynucleotides selected from all breast cancer markers described in (1) or (2).

[0074] (11). p、miR-4634、miR-663a、miR-4532、miR-7704、miR-3178、miR-6729-5p、miR- 6090, miR-4732-5p, miR-3184-5p, miR-6727-5p, miR-6088, miR-4674, miR-8073, miR-4787-5p, miR-1469, miR-125a-3p, miR-1233-5p, miR-885-3p, m iR-6802-5p, miR-328-5p, miR-6787-5p, miR-8069, miR-6875-5p, miR-1246, miR-4734, miR-6757-5p, miR-6756-5p, miR-3665, miR-6836-3p, miR-682 1-5p、miR-6805-5p、miR-4728-5p、miR-6726-5p、miR-197-5p、miR-149-3p、miR-6850-5p、miR-4476、miR-6858-5p、miR-564、miR-4763-3p、miR-575、m iR-6771-5p、miR-1231、miR-1908-3p、miR-150-3p、miR-3937、miR-887-3p、miR-3940-5p、miR-4741、miR-6808-5p、miR-6869-5p、miR-5090、miR-615- 5p、miR-8072、miR-128-1-5p、miR-1238-5p、miR-365a-5p、miR-204-3p、miR-4492、miR-6785-5p、miR-6511a-5p、miR-4525、miR-1915-5p、miR-3180、m iR-6879-5p, miR-1199-5p, miR-6746-5p, miR-711, miR-663b, miR-4707-3p, miR-6893-5p, miR-4675, miR-4638-5p, miR-4651, miR-6087, miR-4665-5 p、miR-4758-5p、miR-6887-5p、miR-3620-5p、miR-1909-3p、miR-7641、miR-6724-5p、miR-1343-3p、miR-6780b-5p、miR-4484、miR-4690-5p、miR-4429、miR-1227-5p, miR-4725-3p, miR-6861-5p, miR-6812-5p, miR-3197, miR-8059, miR-3185, miR-4706, miR-4497, miR-3131, miR-6806-5p, miR-187-5p miR-3180-3p, miR-6848-5p, miR-6820-5p, miR-6800-5p, miR-6717-5p, miR-6795-5p, miR-4632-5p, miR-665, miR-6778-5p, miR-3663-3p, miR-4689 miR-211-3p, miR-6511b-5p, miR-4750-5p, miR-6126, miR-614, miR-7110-5p, miR-744-5p, miR-6769a-5p, miR-4792, miR-5787, miR-6798-5p, miR-6 781-5p、miR-4419b、miR-4446-3p、miR-4259、miR-5572、miR-6075、miR-296-3p、miR-6891-5p、miR-4745-5p、miR-6775-5p、miR-6870-5p、miR-920、mi R-4530, miR-6819-5p, miR-6825-5p, miR-7847-3p, miR-6131, miR-4433-3p, miR-1228-5p, miR-6743-5p, miR-1268a, miR-3917, miR-6786-5p, miR-31 54, miR-638, miR-6741-5p, miR-6889-5p, miR-6840-3p, miR-6510-5p, miR-3188, miR-551b-5p, miR-5001-5p, miR-1268b, miR-7107-5p, miR-6824-5p miR-6732-5p, miR-371a-5p, miR-6794-5p, miR-6779-5p, miR-4271, miR-5195-3p, miR-6762-5p, miR-939-5p, miR-1247-3p, miR-6777-5p, miR-6722 -3p、miR-3656、miR-4688、miR-3195、miR-6766-5p、miR-4447、miR-4656、miR-7108-5p、miR-3191-3p、miR-1273g-3p、miR-4463、miR-2861、miR-3196、A nucleic acid that specifically binds to at least one polynucleotide selected from miR-6877-5p, miR-3679-5p, miR-4442, miR-6789-5p, miR-6782-5p, miR-486-3p, miR-6085, miR-4746-3p, miR-619-5p, miR-937-5p, miR-6803-5p, miR-4298, miR-4454, miR-4459, miR-7150, miR-6880-5p, miR-4449, miR-8063, miR-4695-5p, miR-6132, miR-6829-5p, miR-4486, miR-6805-3p, miR-6826-5p, miR-4508, miR-1343-5p, miR-7114-5p, miR-3622a-5p, miR-6765-5p, miR-7845-5p, miR-3960, miR-6749-5p, miR-1260b, miR-6799-5p, miR-4723-5p, miR-6784-5p, miR-5100, miR-6769b-5p, miR-1207-5p, miR-642a-3p, miR-4505, miR-4270, miR-6721-5p, miR-7111-5p, miR-6791-5p, miR-7109-5p, miR-4258, miR-6515-3p, miR-6851-5p, miR-6125, miR-4749-5p, miR-4726-5p, miR-4513, miR-6089, miR-6816-5p, miR-4466, miR-4488, miR-6752-5p, and miR-4739.

[0075] (12) The device according to (11), wherein miR-4783-3p is hsa-miR-4783-3p, miR-4730 is hsa-miR-4730, miR-1307-3p is hsa-miR-1307-3p, miR-4634 is hsa-miR-4634, miR-663a is hsa-miR-663a, miR-4532 is hsa-miR-4532, miR-7704 is hsa-miR-7704, miR-3178 is hsa-miR-3178, miR-6729-5p is hsa-miR-6729-5p, and miR-6090 is hsa -miR-6090, miR-4732-5p is hsa-miR-4732-5p, miR-3184-5p is hsa-miR-3184-5p, miR-6727-5p is hsa-miR-6727-5p, miR-6088 is hsa-miR-6088, miR-4674 is hsa-miR-4674, miR-8073 is hsa-miR-8073, miR-4787-5p is hsa-miR-4787-5p, miR-1469 is hsa-miR-1469, miR-125a-3p is hsa-miR-125a-3p, miR-1233 is hsa-miR-1233 -5p is hsa-miR-1233-5p, miR-885-3p is hsa-miR-885-3p, miR-6802-5p is hsa-miR-6802-5p, miR-328-5p is hsa-miR-328-5p, miR-6787-5p is hsa-miR-6787-5p, miR-8069 is hsa-miR-8069, miR-6875-5p is hsa-miR-6875-5p, miR-1246 is hsa-miR-1246, miR-4734 is hsa-miR-4734, and miR-6757-5p is hsa-miR-6757 -5p, miR-6756-5p is hsa-miR-6756-5p, miR-3665 is hsa-miR-3665, miR-6836-3p is hsa-miR-6836-3p, miR-6821-5p is hsa-miR-6821-5p, miR-6805-5p is hsa-miR-6805-5p, miR-4728-5p is hsa-miR-4728-5p, miR-6726-5p is hsa-miR-6726-5p, miR-197-5p is hsa-miR-197-5p, miR-149-3p is hsa-miR-149-3p,miR-6850-5p is hsa-miR-6850-5p, miR-4476 is hsa-miR-4476, miR-6858-5p is hsa-miR-6858-5p, miR-564 is hsa-miR-564, miR-4763-3p is hsa-miR-4763-3p, miR-575 is hsa-miR-575, miR-6771-5p is hsa-miR-6771-5p, miR-1231 is hsa-miR-1231, miR-1908-3p is hsa-miR-1908-3p, and miR-150-3p is hsa-miR-150-3p. p, miR-3937 is hsa-miR-3937, miR-887-3p is hsa-miR-887-3p, miR-3940-5p is hsa-miR-3940-5p, miR-4741 is hsa-miR-4741, miR-6808-5p is hsa-miR-6808-5p, miR-6869-5p is hsa-miR-6869-5p, miR-5090 is hsa-miR-5090, miR-615-5p is hsa-miR-615-5p, miR-8072 is hsa-miR-8072, and miR-128-1-5p is hsa-miR-128-1. 28-1-5p, miR-1238-5p is hsa-miR-1238-5p, miR-365a-5p is hsa-miR-365a-5p, miR-204-3p is hsa-miR-204-3p, miR-4492 is hsa-miR-4492, miR-6785-5p is hsa-miR-6785-5p, miR-6511a-5p is hsa-miR-6511a-5p, miR-4525 is hsa-miR-4525, miR-1915-5p is hsa-miR-1915-5p, miR-3180 is hsa-miR-3180, miR-68 79-5p is hsa-miR-6879-5p, miR-1199-5p is hsa-miR-1199-5p, miR-6746-5p is hsa-miR-6746-5p, miR-711 is hsa-miR-711, miR-663b is hsa-miR-663b, miR-4707-3p is hsa-miR-4707-3p, miR-6893-5p is hsa-miR-6893-5p, miR-4675 is hsa-miR-4675, miR-4638-5p is hsa-miR-4638-5p, miR-4651 is hsa-miR-4651,miR-6087 is hsa-miR-6087, miR-4665-5p is hsa-miR-4665-5p, miR-4758-5p is hsa-miR-4758-5p, miR-6887-5p is hsa-miR-6887-5p, miR-3620-5p is hsa-miR-3620-5p, miR-1909-3p is hsa-miR-1909-3p, miR-7641 is hsa-miR-7641, miR-6724-5p is hsa-miR-6724-5p, miR-1343-3p is hsa-miR-1343-3p, miR-678 0b-5p is hsa-miR-6780b-5p, miR-4484 is hsa-miR-4484, miR-4690-5p is hsa-miR-4690-5p, miR-4429 is hsa-miR-4429, miR-1227-5p is hsa-miR-1227-5p, miR-4725-3p is hsa-miR-4725-3p, miR-6861-5p is hsa-miR-6861-5p, miR-6812-5p is hsa-miR-6812-5p, miR-3197 is hsa-miR-3197, and miR-8059 is hsa-miR-8061. 59, miR-3185 is hsa-miR-3185, miR-4706 is hsa-miR-4706, miR-4497 is hsa-miR-4497, miR-3131 is hsa-miR-3131, miR-6806-5p is hsa-miR-6806-5p, miR-187-5p is hsa-miR-187-5p, miR-3180-3p is hsa-miR-3180-3p, miR-6848-5p is hsa-miR-6848-5p, miR-6820-5p is hsa-miR-6820-5p, and miR-6800-5p is hsa-miR-6800-5p. R-6800-5p, miR-6717-5p is hsa-miR-6717-5p, miR-6795-5p is hsa-miR-6795-5p, miR-4632-5p is hsa-miR-4632-5p, miR-665 is hsa-miR-665, miR-6778-5p is hsa-miR-6778-5p, miR-3663-3p is hsa-miR-3663-3p, miR-4689 is hsa-miR-4689, miR-211-3p is hsa-miR-211-3p, miR-6511b-5p is hsa-miR-6511b-5p,miR-4750-5p is hsa-miR-4750-5p, miR-6126 is hsa-miR-6126, miR-614 is hsa-miR-614, miR-7110-5p is hsa-miR-7110-5p, miR-744-5p is hsa-miR-744-5p, miR-6769a-5p is hsa-miR-6769a-5p, miR-4792 is hsa-miR-4792, miR-5787 is hsa-miR-5787, miR-6798-5p is hsa-miR-6798-5p, and miR-6781-5p is hsa-miR-6781-5p. 81-5p, miR-4419b is hsa-miR-4419b, miR-4446-3p is hsa-miR-4446-3p, miR-4259 is hsa-miR-4259, miR-5572 is hsa-miR-5572, miR-6075 is hsa-miR-6075, miR-296-3p is hsa-miR-296-3p, miR-6891-5p is hsa-miR-6891-5p, miR-4745-5p is hsa-miR-4745-5p, miR-6775-5p is hsa-miR-6775-5p, and miR-6870-5p is hsa-miR-6870-5p. a-miR-6870-5p, miR-920 is hsa-miR-920, miR-4530 is hsa-miR-4530, miR-6819-5p is hsa-miR-6819-5p, miR-6825-5p is hsa-miR-6825-5p, miR-7847-3p is hsa-miR-7847-3p, miR-6131 is hsa-miR-6131, miR-4433-3p is hsa-miR-4433-3p, miR-1228-5p is hsa-miR-1228-5p, miR-6743-5p is hsa-miR-6743-5p, miR- R-1268a is hsa-miR-1268a, miR-3917 is hsa-miR-3917, miR-6786-5p is hsa-miR-6786-5p, miR-3154 is hsa-miR-3154, miR-638 is hsa-miR-638, miR-6741-5p is hsa-miR-6741-5p, miR-6889-5p is hsa-miR-6889-5p, miR-6840-3p is hsa-miR-6840-3p, miR-6510-5p is hsa-miR-6510-5p, miR-3188 is hsa-miR-3188,miR-551b-5p is hsa-miR-551b-5p, miR-5001-5p is hsa-miR-5001-5p, miR-1268b is hsa-miR-1268b, miR-7107-5p is hsa-miR-7107-5p, miR-6824-5p is hsa-miR-6824-5p, miR-6732-5p is hsa-miR-6732-5p, miR-371a-5p is hsa-miR-371a-5p, miR-6794-5p is hsa-miR-6794-5p, and miR-6779-5p is hsa-miR-6779-5p. , miR-4271 is hsa-miR-4271, miR-5195-3p is hsa-miR-5195-3p, miR-6762-5p is hsa-miR-6762-5p, miR-939-5p is hsa-miR-939-5p, miR-1247-3p is hsa-miR-1247-3p, miR-6777-5p is hsa-miR-6777-5p, miR-6722-3p is hsa-miR-6722-3p, miR-3656 is hsa-miR-3656, miR-4688 is hsa-miR-4688, and miR-3195 is hsa-miR-3195. iR-3195, miR-6766-5p is hsa-miR-6766-5p, miR-4447 is hsa-miR-4447, miR-4656 is hsa-miR-4656, miR-7108-5p is hsa-miR-7108-5p, miR-3191-3p is hsa-miR-3191-3p, miR-1273g-3p is hsa-miR-1273g-3p, miR-4463 is hsa-miR-4463, miR-2861 is hsa-miR-2861, miR-3196 is hsa-miR-3196, miR-6877-5p is hsa -miR-6877-5p, miR-3679-5p is hsa-miR-3679-5p, miR-4442 is hsa-miR-4442, miR-6789-5p is hsa-miR-6789-5p, miR-6782-5p is hsa-miR-6782-5p, miR-486-3p is hsa-miR-486-3p, miR-6085 is hsa-miR-6085, miR-4746-3p is hsa-miR-4746-3p, miR-619-5p is hsa-miR-619-5p, miR-937-5p is hsa-miR-937-5p,miR-6803-5p is hsa-miR-6803-5p, miR-4298 is hsa-miR-4298, miR-4454 is hsa-miR-4454, miR-4459 is hsa-miR-4459, miR-7150 is hsa-miR-7150, miR-6880-5p is hsa-miR-6880-5p, miR-4449 is hsa-miR-4449, miR-8063 is hsa-miR-8063, miR-4695-5p is hsa-miR-4695-5p, miR-6132 is hsa-miR-6132, and miR-682 9-5p is hsa-miR-6829-5p, miR-4486 is hsa-miR-4486, miR-6805-3p is hsa-miR-6805-3p, miR-6826-5p is hsa-miR-6826-5p, miR-4508 is hsa-miR-4508, miR-1343-5p is hsa-miR-1343-5p, miR-7114-5p is hsa-miR-7114-5p, miR-3622a-5p is hsa-miR-3622a-5p, miR-6765-5p is hsa-miR-6765-5p, miR-7845-5p is hsa-miR-7845-5p p is hsa-miR-7845-5p, miR-3960 is hsa-miR-3960, miR-6749-5p is hsa-miR-6749-5p, miR-1260b is hsa-miR-1260b, miR-6799-5p is hsa-miR-6799-5p, miR-4723-5p is hsa-miR-4723-5p, miR-6784-5p is hsa-miR-6784-5p, miR-5100 is hsa-miR-5100, miR-6769b-5p is hsa-miR-6769b-5p, and miR-1207-5p is hsa-miR-1207-5p. iR-1207-5p, miR-642a-3p is hsa-miR-642a-3p, miR-4505 is hsa-miR-4505, miR-4270 is hsa-miR-4270, miR-6721-5p is hsa-miR-6721-5p, miR-7111-5p is hsa-miR-7111-5p, miR-6791-5p is hsa-miR-6791-5p, miR-7109-5p is hsa-miR-7109-5p, miR-4258 is hsa-miR-4258, miR-6515-3p is hsa-miR-6515-3p,miR-6851-5p is hsa-miR-6851-5p, miR-6125 is hsa-miR-6125, miR-4749-5p is hsa-miR-4749-5p, miR-4726-5p is hsa-miR-4726-5p, miR-4513 is hsa-miR-4513, miR-6089 is hsa-miR-6089, miR-6816-5p is hsa-miR-6816-5p, miR-4466 is hsa-miR-4466, miR-4488 is hsa-miR-4488, miR-6752-5p is hsa-miR-6752-5p, and miR-4739 is hsa-miR-4739.

[0076] (13) The device according to (11) or (12), wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (a) to (e),

[0077] (a) a polynucleotide consisting of the base sequence represented by any of SEQ ID NOs: 1 to 235 and 851 to 856, or a base sequence in which u is t in the base sequence, a mutant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0078] (b) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 1 to 235 and 851 to 856, or a base sequence in which u is t in the base sequence,

[0079] (c) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 1 to 235 and 851 to 856, or a base sequence in which u is t in the base sequence, a mutant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0080] (d) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 1 to 235 and 851 to 856, or a base sequence in which u is t in the base sequence, and

[0081] (e) A polynucleotide that hybridizes to any one of the polynucleotides (a) to (d) above under stringent conditions.

[0082] (14) The device according to any one of (11) to (13), further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-760, miR-602, miR-423-5p, miR-92a-2-5p, miR-16-5p, miR-451a, miR-135a-3p, miR-486-5p, miR-4257, miR-92b-5p, miR-1915-3p, miR-718, miR-940, miR-296-5p, miR-23b-3p, and miR-92a-3p, which are other breast cancer markers.

[0083] (15) The device according to (14), wherein miR-760 is hsa-miR-760, miR-602 is hsa-miR-602, miR-423-5p is hsa-miR-423-5p, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-16-5p is hsa-miR-16-5p, miR-451a is hsa-miR-451a, miR-135a-3p is hsa-miR-135a-3p, and miR-486-5p is hsa-miR-5p. iR-486-5p, miR-4257 is hsa-miR-4257, miR-92b-5p is hsa-miR-92b-5p, miR-1915-3p is hsa-miR-1915-3p, miR-718 is hsa-miR-718, miR-940 is hsa-miR-940, miR-296-5p is hsa-miR-296-5p, miR-23b-3p is hsa-miR-23b-3p and miR-92a-3p is hsa-miR-92a-3p.

[0084] (16) The device according to (14) or (15), wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (f) to (j),

[0085] (f) a polynucleotide consisting of the base sequence represented by any of SEQ ID NOs: 236 to 251, or a base sequence in which u is t in the base sequence, a mutant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0086] (g) a polynucleotide comprising the base sequence represented by any one of SEQ ID NOs: 236 to 251,

[0087] (h) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 236 to 251, or a base sequence in which u is t in the base sequence, a variant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0088] (i) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 236 to 251, or a base sequence in which u is t in the base sequence, and

[0089] (j) A polynucleotide that hybridizes to any one of the polynucleotides (f) to (i) above under stringent conditions.

[0090] (17) The device according to any one of (11) to (16), further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-658, miR-6842-5p, miR-6124, miR-6765-3p, miR-7106-5p, miR-4534, miR-92b-3p, miR-3135b, miR-4687-3p, miR-762, miR-3619-3p, miR-4467, miR-557, miR-1237-5p, miR-1908-5p, miR-4286, miR-6885-5p, and miR-6763-5p, which are other breast cancer markers.

[0091] (18) The device according to (17), wherein miR-658 is hsa-miR-658, miR-6842-5p is hsa-miR-6842-5p, miR-6124 is hsa-miR-6124, miR-6765-3p is hsa-miR-6765-3p, miR-7106-5p is hsa-miR-7106-5p, miR-4534 is hsa-miR-4534, miR-92b-3p is hsa-miR-92b-3p, miR-3135b is hsa-miR-3135b, and miR-4687-3p is hsa-miR-4687-3p. R-4687-3p, miR-762 was hsa-miR-762, miR-3619-3p was hsa-miR-3619-3p, miR-4467 was hsa-miR-4467, miR-557 was hsa-miR-557, miR-1237-5p was hsa-miR-1237-5p, miR-1908-5p was hsa-miR-1908-5p, miR-4286 was hsa-miR-4286, miR-6885-5p was hsa-miR-6885-5p and miR-6763-5p was hsa-miR-6763-5p.

[0092] (19) The device according to (17) or (18), wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (k) to (o),

[0093] (k) a polynucleotide consisting of the base sequence represented by any of SEQ ID NOs: 252 to 269, or a base sequence in which u is t in the base sequence, a mutant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0094] (1) a polynucleotide comprising the base sequence represented by any one of SEQ ID NOs: 252 to 269,

[0095] (m) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 252 to 269, or a base sequence in which u is t in the base sequence, a variant of the polynucleotide, a derivative of the polynucleotide, or a fragment of the polynucleotide comprising 15 or more consecutive bases,

[0096] (n) a polynucleotide comprising a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 252 to 269, or a base sequence in which u is t in the base sequence, and

[0097] (o) A polynucleotide that hybridizes to any one of the polynucleotides (k) to (n) above under stringent conditions.

[0098] (20) The device according to any one of (11) to (19), wherein the device is for determination by hybridization technology.

[0099] (21) The device according to (20), wherein the hybridization technology is nucleic acid array technology.

[0100] (22) The device according to any one of (11) to (21), wherein the device comprises at least two nucleic acids capable of specifically binding to at least two polynucleotides selected from all breast cancer markers described in (11) or (12) respectively.

[0101] (23) A method for detecting breast cancer, comprising: using the kit according to any one of (1) to (10) or the device according to any one of (11) to (22) to determine the expression level of a target nucleic acid in a specimen of a subject, and using the measured expression level and the control expression level of a healthy subject measured in the same way to perform an in vitro evaluation on whether the subject has breast cancer or not.

[0102] (24) The method according to (23), wherein the subject is a human.

[0103] (25) The method according to (23) or (24), wherein the specimen is blood, serum or plasma.

[0104] <Definition of terms>

[0105] The terms used in this specification have the following definitions.

[0106] The display of abbreviations such as nucleotide, polynucleotide, DNA, RNA, etc. follows the "Guidelines for the Preparation of Specifications Containing Base Sequences or Amino Acid Sequences" (compiled by the Japan Patent Office) and the common practice in this technical field.

[0107] In this specification, the term "polynucleotide" refers to nucleic acids including any one of RNA, DNA, and RNA / DNA (chimera). In addition, the above-mentioned DNA includes any one of cDNA, genomic DNA, and synthetic DNA. In addition, the above-mentioned RNA includes any one of total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. In this specification, "synthetic DNA" and "synthetic RNA" refer to DNA and RNA artificially produced based on a specified base sequence (which can be any one of a natural sequence or a non-natural sequence) using, for example, an automatic nucleic acid synthesizer. In this specification, "non-natural sequence" is intended to be used in a broad sense, including sequences that differ from natural sequences, such as sequences that include substitutions, deletions, insertions, and / or additions of one or more nucleotides (i.e., mutant sequences), sequences that include one or more modified nucleotides (i.e., modified sequences), etc. In addition, in this specification, polynucleotides and nucleic acids are used interchangeably.

[0108] In this specification, a "fragment" is a polynucleotide (including an oligonucleotide) having a continuous base sequence of a portion of a polynucleotide, and desirably has a length of 15 bases or more, preferably 17 bases or more, and more preferably 19 bases or more.

[0109] In this specification, "gene" is intended to include not only RNA and double-stranded DNA, but also each single-stranded DNA such as the positive chain (or sense chain) or complementary chain (or antisense chain) constituting them. In addition, its length is not particularly limited. Therefore, in this specification, "gene", unless otherwise specified, includes: double-stranded DNA comprising human genomic DNA, single-stranded DNA (positive chain) comprising cDNA, single-stranded DNA (complementary chain) with a sequence complementary to the positive chain, microRNA (miRNA), and any of their fragments and their transcription products. In addition, the "gene" is not only the "gene" shown in a specific base sequence (or sequence number), but also an RNA having the same biological function as the RNA encoded by the gene, such as a "nucleic acid" encoding a homologue (i.e., a homologue or a straight homologue (or ortholog)), a mutant of a gene polymorphism, and a derivative. Specific examples of such "nucleic acids" encoding homologs, mutants, or derivatives include "nucleic acids" having a base sequence that hybridizes under the stringent conditions described below with the base sequence set forth in any of SEQ ID NOs: 1 to 871, or with the complement of a base sequence in which u is t in such a base sequence. Furthermore, a "gene" may include, for example, an expression control region, a coding region, exons, or introns, regardless of functional regions. Furthermore, a "gene" may be contained within a cell, released outside the cell and exist independently, or encapsulated in vesicles called exosomes.

[0110] As used herein, "exosomes" are small vesicles surrounded by a lipid bilayer secreted by cells. Exosomes originate from multivesicular endosomes and, when released into the extracellular environment, may contain biological substances such as "genes" such as RNA and DNA, as well as proteins. Exosomes are known to be present in body fluids such as blood, serum, plasma, serum, and lymph.

[0111] As used herein, "transcript" refers to RNA synthesized using the DNA sequence of a gene as a template. RNA polymerase binds to a region upstream of the gene called the promoter, synthesizing RNA in a manner complementary to the base sequence of the DNA, with ribonucleotides attached to the 3' end. This RNA contains not only the gene itself but also the entire sequence from the transcription start point to the end of the poly A sequence, represented by expression control regions, coding regions, exons, or introns.

[0112] In addition, as used herein, "microRNA (miRNA)" is intended to be used as a 15-25 base non-coding RNA that is transcribed as a hairpin-like RNA precursor, cleaved by a dsRNA cleavage enzyme with RNase III cleavage activity, and incorporated into a protein complex called RISC, thereby participating in the translational repression of mRNA, unless otherwise specified. Furthermore, the "miRNA" used herein includes not only "miRNAs" represented by specific base sequences (or sequence numbers), but also precursors (pre-miRNA, pri-miRNA) of such "miRNAs," miRNAs with equivalent biological functions, such as homologs (i.e., homologs or orthologs), mutants resulting from genetic polymorphisms, and derivatives. Specifically, examples of such precursors, homologs, mutants, or derivatives include "miRNAs" that can be identified by miRBase version 20 (http: / / www.mirbase.org / ) and that hybridize under stringent conditions described below to the complementary sequence of any of the specific base sequences represented by any of SEQ ID NOs. 1 to 871. In addition, the "miRNA" used in this specification can be a gene product of a miR gene, such a gene product comprising a mature miRNA (for example, a non-coding RNA of 15 to 25 bases or 19 to 25 bases involved in translational inhibition of mRNA as described above) or a miRNA precursor (for example, a pre-miRNA or pri-miRNA as described above).

[0113] The term "probe" herein includes a polynucleotide for specifically detecting RNA produced by gene expression or a polynucleotide derived from the RNA and / or a polynucleotide complementary thereto.

[0114] In this specification, "primer" includes a polynucleotide that specifically recognizes and amplifies RNA produced by gene expression or a polynucleotide derived from the RNA and / or a polynucleotide complementary thereto. Here, "complementary polynucleotide (complementary chain, negative chain)" refers to a full-length sequence of a polynucleotide consisting of a base sequence defined by any one of sequence numbers 1 to 871, or a base sequence in which u is t in the base sequence, or a partial sequence thereof (herein, for convenience, referred to as a positive chain), based on a base pair relationship such as A:T (U) and G:C and a polynucleotide that is in a complementary relationship on the base. However, such a complementary chain is not limited to the case where the base sequence of the positive chain that becomes the object completely forms a complementary sequence, and can also have a complementary relationship to the extent that it can hybridize with the positive chain that becomes the object under stringent conditions.

[0115] As used herein, "stringent conditions" refer to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater degree (e.g., the average of the background values ​​+ the standard error of the background values ​​× 2 or greater) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the hybridization environment. By controlling the stringency of hybridization and / or washing conditions, target sequences that are 100% complementary to the nucleic acid probe can be identified. Specific examples of "stringent conditions" are described below.

[0116] The "Tm value" herein refers to the temperature at which the double-stranded portion of a polynucleotide denatures into a single strand and the double strands and single strands exist in a 1:1 ratio.

[0117] As used herein, "mutant" refers to a natural mutant caused by polymorphism, mutation, etc. in the case of nucleic acids, or a mutant comprising a deletion, substitution, addition or insertion of one or more bases in any of the base sequences of SEQ ID NOs. 1 to 871, or a base sequence in which u is t in the base sequence, or a partial sequence thereof, or a mutant showing an identity of about 90% or more, about 95% or more, about 97% or more, about 98% or more, or about 99% or more with the respective base sequences or partial sequences thereof, or a nucleic acid that hybridizes with a polynucleotide or oligonucleotide comprising the base sequence or a partial sequence thereof under the stringent conditions defined above.

[0118] In this specification, "a plurality of" refers to an integer of about 10, 9, 8, 7, 6, 5, 4, 3 or 2.

[0119] The "mutant" herein can be produced using known techniques such as site-directed mutagenesis and mutation introduction using PCR.

[0120] As used herein, "% identity" can be determined using the above-mentioned protein or gene search systems utilizing BLAST or FASTA, with or without introducing gaps (Zheng Zhang et al., 2000, J. Comput. Biol., Vol. 7, pp. 203-214; Altschul, SF et al., 1990, Journal of Molecular Biology, Vol. 215, pp. 403-410; Pearson, WR et al., 1988, Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 2444-2448).

[0121] In this specification, "derivative" refers to modified nucleic acids, and includes, but is not limited to, derivatives labeled with fluorophores, etc., derivatives containing modified nucleotides (for example, nucleotides containing groups such as halogens, alkyl groups such as methyl groups, alkoxy groups such as methoxy groups, thio groups, carboxymethyl groups, and nucleotides that have undergone base reconstruction, double bond saturation, deamination, replacement of oxygen molecules with sulfur molecules, etc.), PNA (peptide nucleic acid; Nielsen, PE et al., 1991, Science, Vol. 254, p1497-500), LNA (locked nucleic acid; Obika, S. et al., 1998, Tetrahedron Lett., Vol. 39, p5401-5404), etc.

[0122] As used herein, "nucleic acids" capable of specifically binding to polynucleotides selected from the aforementioned miRNAs as breast cancer markers are synthetic or prepared nucleic acids, specifically including "nucleic acid probes" or "primers," and are used directly or indirectly to detect the presence of breast cancer in a subject, diagnose the presence, extent, improvement, or degree of improvement of breast cancer, or sensitivity to breast cancer treatment, or screen for candidate substances useful for the prevention, improvement, or treatment of breast cancer. These include nucleotides, oligonucleotides, and polynucleotides that can specifically recognize and bind to a transcript represented by any of SEQ ID NOs: 1 to 871, or a cDNA synthesized nucleic acid thereof, in a living body sample, particularly blood, urine, or other body fluid, that is associated with breast cancer. These nucleotides, oligonucleotides, and polynucleotides, based on the aforementioned properties, can be effectively used as probes for detecting the aforementioned genes expressed in vivo, in tissues, or in cells, and as primers for amplifying the aforementioned genes expressed in vivo.

[0123] The term "detection" used in this specification can be replaced with the term "inspection," "measurement," "detection," or "determination support." Furthermore, the term "evaluation" used in this specification includes supporting diagnosis or evaluation based on the results of an inspection or measurement.

[0124] As used herein, the term "subject" refers to mammals, including humans, primates such as chimpanzees, pets such as dogs and cats, livestock such as cattle, horses, sheep, and goats, and rodents such as mice and rats. Furthermore, the term "healthy subject" refers to a mammal that does not have the cancer being tested.

[0125] As used herein, "P" or "P-value" indicates the probability of observing a statistically significant difference compared to the statistic calculated from the data under the null hypothesis in a statistical test. Therefore, a smaller "P" or "P-value" indicates a significant difference between the comparison subjects.

[0126] In this specification, "sensitivity" refers to the value of (number of true positives) / (number of true positives + number of false negatives). A high sensitivity allows for early detection of breast cancer, leading to complete resection of the cancerous area and a reduction in the recurrence rate.

[0127] As used herein, "specificity" refers to (number of true negatives) / (number of true negatives + number of false positives). High specificity prevents unnecessary additional testing due to misidentification of healthy individuals as breast cancer patients, reducing the burden on patients and medical expenses.

[0128] In this specification, "accuracy" refers to the value of (number of true positives + number of true negatives) / (total number of cases). Accuracy indicates the proportion of correct discrimination results for all samples and is the primary indicator for evaluating detection performance.

[0129] As used herein, "specimens" as the subject of assessment, detection, or diagnosis refer to tissues and biological materials in which the expression of the genes of the present invention changes as breast cancer develops, progresses, and as treatments for breast cancer are effective. Specifically, these include breast tissue and surrounding blood vessels, lymph nodes, and organs. Furthermore, these include organs suspected of metastasis, skin, and body fluids such as blood, urine, saliva, sweat, and tissue extracts; serum and plasma prepared from blood; feces; and hair. Furthermore, these include biological samples extracted from these materials, specifically genes such as RNA and miRNA.

[0130] As used herein, the term "hsa-miR-4783-3p gene" or "hsa-miR-4783-3p" includes the hsa-miR-4783-3p gene described in SEQ ID NO: 1 (miRBase Accession No. MIMAT0019947) and homologs or orthologs in other species. The hsa-miR-4783-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4783-3p", "hsa-mir-4783" (miRBase Accession No. MI0017428, SEQ ID NO: 270) is known to have a hairpin-like structure.

[0131] As used herein, the term "hsa-miR-4730 gene" or "hsa-miR-4730" includes the hsa-miR-4730 gene described in SEQ ID NO: 2 (miRBase Accession No. MIMAT0019852) and homologs or orthologs in other species. The hsa-miR-4730 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4730", "hsa-mir-4730" (miRBase Accession No. MI0017367, SEQ ID NO: 271) is known to have a hairpin-like structure.

[0132] As used herein, the term “hsa-miR-1307-3p gene” or “hsa-miR-1307-3p” includes the hsa-miR-1307-3p gene described in SEQ ID NO: 3 (miRBase Accession No. MIMAT0005951) and homologs or orthologs in other biological species. The hsa-miR-1307-3p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, as a precursor of “hsa-miR-1307-3p”, “hsa-mir-1307” (miRBase Accession No. MI0006444, SEQ ID NO: 272) is known to have a hairpin-like structure.

[0133] As used herein, the term "hsa-miR-4634 gene" or "hsa-miR-4634" includes the hsa-miR-4634 gene described in SEQ ID NO: 4 (miRBase Accession No. MIMAT0019691) and homologs or orthologs in other species. The hsa-miR-4634 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4634," "hsa-mir-4634" (miRBase Accession No. MI0017261, SEQ ID NO: 273) is known to have a hairpin-like structure.

[0134] As used herein, the term "hsa-miR-663a gene" or "hsa-miR-663a" includes the hsa-miR-663a gene described in SEQ ID NO: 5 (miRBase Accession No. MIMAT0003326) and homologs or orthologs in other species. The hsa-miR-663a gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Furthermore, as a precursor of "hsa-miR-663a", "hsa-mir-663a" (miRBase Accession No. MI0003672, SEQ ID NO: 274) is known to have a hairpin-like structure.

[0135] As used herein, the term "hsa-miR-4532 gene" or "hsa-miR-4532" includes the hsa-miR-4532 gene described in SEQ ID NO: 6 (miRBase Accession No. MIMAT0019071) and homologs or orthologs in other species. The hsa-miR-4532 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4532," "hsa-mir-4532" (miRBase Accession No. MI0016899, SEQ ID NO: 275) is known to have a hairpin-like structure.

[0136] As used herein, the term “hsa-miR-7704 gene” or “hsa-miR-7704” includes the hsa-miR-7704 gene described in SEQ ID NO: 7 (miRBase Accession No. MIMAT0030019) and homologs or orthologs in other biological species. The hsa-miR-7704 gene can be obtained by the method described in Swaminathan S et al., 2013, Biochem Biophys Res Commun, Vol. 434, pp. 228-234. In addition, as a precursor of “hsa-miR-7704”, “hsa-mir-7704” (miRBase Accession No. MI0025240, SEQ ID NO: 276) is known to have a hairpin-like structure.

[0137] As used herein, the term “hsa-miR-3178 gene” or “hsa-miR-3178” includes the hsa-miR-3178 gene described in SEQ ID NO: 8 (miRBase Accession No. MIMAT0015055) and homologs or orthologs in other species. The hsa-miR-3178 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, as a precursor of “hsa-miR-3178”, “hsa-mir-3178” (miRBase Accession No. MI0014212, SEQ ID NO: 277) is known to have a hairpin-like structure.

[0138] As used herein, the term "hsa-miR-6729-5p gene" or "hsa-miR-6729-5p" includes the hsa-miR-6729-5p gene described in SEQ ID NO: 9 (miRBase Accession No. MIMAT0027359) and homologs or orthologs in other species. The hsa-miR-6729-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6729-5p", "hsa-mir-6729" (miRBase Accession No. MI0022574, SEQ ID NO: 278) is known to have a hairpin-like structure.

[0139] As used herein, the term "hsa-miR-6090 gene" or "hsa-miR-6090" includes the hsa-miR-6090 gene described in SEQ ID NO: 10 (miRBase Accession No. MIMAT0023715) and homologs or orthologs in other species. The hsa-miR-6090 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. Furthermore, as a precursor of "hsa-miR-6090," "hsa-mir-6090" (miRBase Accession No. MI0020367, SEQ ID NO: 279) is known to have a hairpin-like structure.

[0140] As used herein, the term "hsa-miR-4732-5p gene" or "hsa-miR-4732-5p" includes the hsa-miR-4732-5p gene described in SEQ ID NO: 11 (miRBase Accession No. MIMAT0019855) and homologs or orthologs in other species. The hsa-miR-4732-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4732-5p", "hsa-mir-4732" (miRBase Accession No. MI0017369, SEQ ID NO: 280) is known to have a hairpin-like structure.

[0141] As used herein, the term “hsa-miR-3184-5p gene” or “hsa-miR-3184-5p” includes the hsa-miR-3184-5p gene described in SEQ ID NO: 12 (miRBase Accession No. MIMAT0015064) and homologs or orthologs in other species. The hsa-miR-3184-5p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Furthermore, as a precursor of “hsa-miR-3184-5p,” “hsa-mir-3184” (miRBase Accession No. MI0014226, SEQ ID NO: 281) is known to have a hairpin-like structure.

[0142] As used herein, the term “hsa-miR-6727-5p gene” or “hsa-miR-6727-5p” includes the hsa-miR-6727-5p gene described in SEQ ID NO: 13 (miRBase Accession No. MIMAT0027355) and homologs or orthologs in other species. The hsa-miR-6727-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6727-5p,” “hsa-mir-6727” (miRBase Accession No. MI0022572, SEQ ID NO: 282) is known to have a hairpin-like structure.

[0143] As used herein, the term "hsa-miR-6088 gene" or "hsa-miR-6088" includes the hsa-miR-6088 gene described in SEQ ID NO: 14 (miRBase Accession No. MIMAT0023713) and homologs or orthologs in other species. The hsa-miR-6088 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. Furthermore, as a precursor of "hsa-miR-6088," "hsa-mir-6088" (miRBase Accession No. MI0020365, SEQ ID NO: 283) is known to have a hairpin-like structure.

[0144] As used herein, the term "hsa-miR-4674 gene" or "hsa-miR-4674" includes the hsa-miR-4674 gene described in SEQ ID NO: 15 (miRBase Accession No. MIMAT0019756) and homologs or orthologs in other species. The hsa-miR-4674 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4674," "hsa-mir-4674" (miRBase Accession No. MI0017305, SEQ ID NO: 284) is known to have a hairpin-like structure.

[0145] As used herein, the term “hsa-miR-8073 gene” or “hsa-miR-8073” includes the hsa-miR-8073 gene described in SEQ ID NO: 16 (miRBase Accession No. MIMAT0031000) and homologs or orthologs in other biological species. The hsa-miR-8073 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, as a precursor of “hsa-miR-8073”, “hsa-mir-8073” (miRBase Accession No. MI0025909, SEQ ID NO: 285) is known to form a hairpin-like structure.

[0146] As used herein, the term "hsa-miR-4787-5p gene" or "hsa-miR-4787-5p" includes the hsa-miR-4787-5p gene described in SEQ ID NO: 17 (miRBase Accession No. MIMAT0019956) and homologs or orthologs in other species. The hsa-miR-4787-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4787-5p," "hsa-mir-4787" (miRBase Accession No. MI0017434, SEQ ID NO: 286) is known to have a hairpin-like structure.

[0147] As used herein, the term “hsa-miR-1469 gene” or “hsa-miR-1469” includes the hsa-miR-1469 gene described in SEQ ID NO: 18 (miRBase Accession No. MIMAT0007347) and homologs or orthologs in other biological species. The hsa-miR-1469 gene can be obtained by the method described in Kawaji H et al., 2008, BMC Genomics, Vol. 9, p157. In addition, as a precursor of “hsa-miR-1469”, “hsa-mir-1469” (miRBase Accession No. MI0007074, SEQ ID NO: 287) that forms a hairpin-like structure is known.

[0148] As used herein, the term "hsa-miR-125a-3p gene" or "hsa-miR-125a-3p" includes the hsa-miR-125a-3p gene described in SEQ ID NO: 19 (miRBase Accession No. MIMAT0004602) and homologs or orthologs in other species. The hsa-miR-125a-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. Furthermore, as a precursor of "hsa-miR-125a-3p", "hsa-mir-125a" (miRBase Accession No. MI0000469, SEQ ID NO: 288) is known to have a hairpin-like structure.

[0149] As used herein, the term "hsa-miR-1233-5p gene" or "hsa-miR-1233-5p" includes the hsa-miR-1233-5p gene described in SEQ ID NO: 20 (miRBase Accession No. MIMAT0022943) and homologs or orthologs in other biological species. The hsa-miR-1233-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Furthermore, as precursors of "hsa-miR-1233-5p," "hsa-mir-1233-1 and hsa-mir-1233-2" (miRBase Accession Nos. MI0006323 and MI0015973, SEQ ID NOs: 289 and 290) are known to form hairpin-like structures.

[0150] As used herein, the term "hsa-miR-885-3p gene" or "hsa-miR-885-3p" includes the hsa-miR-885-3p gene described in SEQ ID NO: 21 (miRBase Accession No. MIMAT0004948) and homologs or orthologs in other species. The hsa-miR-885-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. Furthermore, as a precursor of "hsa-miR-885-3p", "hsa-mir-885" (miRBase Accession No. MI0005560, SEQ ID NO: 291) is known to have a hairpin-like structure.

[0151] As used herein, the term "hsa-miR-6802-5p gene" or "hsa-miR-6802-5p" includes the hsa-miR-6802-5p gene described in SEQ ID NO: 22 (miRBase Accession No. MIMAT0027504) and homologs or orthologs in other species. The hsa-miR-6802-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6802-5p", "hsa-mir-6802" (miRBase Accession No. MI0022647, SEQ ID NO: 292) is known to have a hairpin-like structure.

[0152] As used herein, the term "hsa-miR-328-5p gene" or "hsa-miR-328-5p" includes the hsa-miR-328-5p gene described in SEQ ID NO: 23 (miRBase Accession No. MIMAT0026486) and homologs or orthologs in other species. The hsa-miR-328-5p gene can be obtained by the method described in Kim J et al., 2004, Proc Natl Acad Sci U SA, Vol. 101, pp. 360-365. Furthermore, as a precursor of "hsa-miR-328-5p", "hsa-mir-328" (miRBase Accession No. MI0000804, SEQ ID NO: 293) is known to have a hairpin-like structure.

[0153] As used herein, the term “hsa-miR-6787-5p gene” or “hsa-miR-6787-5p” includes the hsa-miR-6787-5p gene described in SEQ ID NO: 24 (miRBase Accession No. MIMAT0027474) and homologs or orthologs in other species. The hsa-miR-6787-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6787-5p,” “hsa-mir-6787” (miRBase Accession No. MI0022632, SEQ ID NO: 294) is known to have a hairpin-like structure.

[0154] As used herein, the term “hsa-miR-8069 gene” or “hsa-miR-8069” includes the hsa-miR-8069 gene described in SEQ ID NO: 25 (miRBase Accession No. MIMAT0030996) and homologs or orthologs in other species. The hsa-miR-8069 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, as a precursor of “hsa-miR-8069,” “hsa-mir-8069” (miRBase Accession No. MI0025905, SEQ ID NO: 295) is known to have a hairpin-like structure.

[0155] As used herein, the term “hsa-miR-6875-5p gene” or “hsa-miR-6875-5p” includes the hsa-miR-6875-5p gene described in SEQ ID NO: 26 (miRBase Accession No. MIMAT0027650) and homologs or orthologs in other species. The hsa-miR-6875-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6875-5p,” “hsa-mir-6875” (miRBase Accession No. MI0022722, SEQ ID NO: 296) is known to have a hairpin-like structure.

[0156] As used herein, the term “hsa-miR-1246 gene” or “hsa-miR-1246” includes the hsa-miR-1246 gene described in SEQ ID NO: 27 (miRBase Accession No. MIMAT0005898) and homologs or orthologs in other biological species. The hsa-miR-1246 gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, as a precursor of “hsa-miR-1246”, “hsa-mir-1246” (miRBase Accession No. MI0006381, SEQ ID NO: 297) is known to have a hairpin-like structure.

[0157] As used herein, the term "hsa-miR-4734 gene" or "hsa-miR-4734" includes the hsa-miR-4734 gene described in SEQ ID NO: 28 (miRBase Accession No. MIMAT0019859) and homologs or orthologs in other species. The hsa-miR-4734 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4734," "hsa-mir-4734" (miRBase Accession No. MI0017371, SEQ ID NO: 298) is known to have a hairpin-like structure.

[0158] As used herein, the term "hsa-miR-6757-5p gene" or "hsa-miR-6757-5p" includes the hsa-miR-6757-5p gene described in SEQ ID NO: 29 (miRBase Accession No. MIMAT0027414) and homologs or orthologs in other species. The hsa-miR-6757-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6757-5p", "hsa-mir-6757" (miRBase Accession No. MI0022602, SEQ ID NO: 299) is known to have a hairpin-like structure.

[0159] As used herein, the term "hsa-miR-6756-5p gene" or "hsa-miR-6756-5p" includes the hsa-miR-6756-5p gene described in SEQ ID NO: 30 (miRBase Accession No. MIMAT0027412) and homologs or orthologs in other species. The hsa-miR-6756-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6756-5p," "hsa-mir-6756" (miRBase Accession No. MI0022601, SEQ ID NO: 300) is known to have a hairpin-like structure.

[0160] As used herein, the term "hsa-miR-3665 gene" or "hsa-miR-3665" includes the hsa-miR-3665 gene described in SEQ ID NO: 31 (miRBase Accession No. MIMAT0018087) and homologs or orthologs in other species. The hsa-miR-3665 gene can be obtained by the method described in Xie X et al., 2005, Nature, Vol. 434, pp. 338-345. Furthermore, as a precursor of "hsa-miR-3665," "hsa-mir-3665" (miRBase Accession No. MI0016066, SEQ ID NO: 301) is known to have a hairpin-like structure.

[0161] As used herein, the term "hsa-miR-6836-3p gene" or "hsa-miR-6836-3p" includes the hsa-miR-6836-3p gene described in SEQ ID NO: 32 (miRBase Accession No. MIMAT0027575) and homologs or orthologs in other species. The hsa-miR-6836-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6836-3p", "hsa-mir-6836" (miRBase Accession No. MI0022682, SEQ ID NO: 302) is known to have a hairpin-like structure.

[0162] As used herein, the term "hsa-miR-6821-5p gene" or "hsa-miR-6821-5p" includes the hsa-miR-6821-5p gene described in SEQ ID NO: 33 (miRBase Accession No. MIMAT0027542) and homologs or orthologs in other species. The hsa-miR-6821-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6821-5p", "hsa-mir-6821" (miRBase Accession No. MI0022666, SEQ ID NO: 303) is known to have a hairpin-like structure.

[0163] As used herein, the term "hsa-miR-6805-5p gene" or "hsa-miR-6805-5p" includes the hsa-miR-6805-5p gene described in SEQ ID NO: 34 (miRBase Accession No. MIMAT0027510) and homologs or orthologs in other species. The hsa-miR-6805-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6805-5p", "hsa-mir-6805" (miRBase Accession No. MI0022650, SEQ ID NO: 304) is known to have a hairpin-like structure.

[0164] As used herein, the term "hsa-miR-4728-5p gene" or "hsa-miR-4728-5p" includes the hsa-miR-4728-5p gene described in SEQ ID NO: 35 (miRBase Accession No. MIMAT0019849) and homologs or orthologs in other species. The hsa-miR-4728-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4728-5p", "hsa-mir-4728" (miRBase Accession No. MI0017365, SEQ ID NO: 305) is known to have a hairpin-like structure.

[0165] As used herein, the term "hsa-miR-6726-5p gene" or "hsa-miR-6726-5p" includes the hsa-miR-6726-5p gene described in SEQ ID NO: 36 (miRBase Accession No. MIMAT0027353) and homologs or orthologs in other species. The hsa-miR-6726-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6726-5p", "hsa-mir-6726" (miRBase Accession No. MI0022571, SEQ ID NO: 306) is known to have a hairpin-like structure.

[0166] As used herein, the term “hsa-miR-197-5p gene” or “hsa-miR-197-5p” includes the hsa-miR-197-5p gene described in SEQ ID NO: 37 (miRBase Accession No. MIMAT0022691) and homologs or orthologs in other species. The hsa-miR-197-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2003, RNA, Vol. 9, pp. 175-179. Furthermore, as a precursor of “hsa-miR-197-5p,” “hsa-mir-197” (miRBase Accession No. MI0000239, SEQ ID NO: 307) is known to have a hairpin-like structure.

[0167] As used herein, the term "hsa-miR-149-3p gene" or "hsa-miR-149-3p" includes the hsa-miR-149-3p gene described in SEQ ID NO: 38 (miRBase Accession No. MIMAT0004609) and homologs or orthologs in other species. The hsa-miR-149-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. Furthermore, as a precursor of "hsa-miR-149-3p", "hsa-mir-149" (miRBase Accession No. MI0000478, SEQ ID NO: 308) is known to have a hairpin-like structure.

[0168] As used herein, the term "hsa-miR-6850-5p gene" or "hsa-miR-6850-5p" includes the hsa-miR-6850-5p gene described in SEQ ID NO: 39 (miRBase Accession No. MIMAT0027600) and homologs or orthologs in other species. The hsa-miR-6850-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6850-5p", "hsa-mir-6850" (miRBase Accession No. MI0022696, SEQ ID NO: 309) is known to have a hairpin-like structure.

[0169] As used herein, the term "hsa-miR-4476 gene" or "hsa-miR-4476" includes the hsa-miR-4476 gene described in SEQ ID NO: 40 (miRBase Accession No. MIMAT0019003) and homologs or orthologs in other species. The hsa-miR-4476 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4476", "hsa-mir-4476" (miRBase Accession No. MI0016828, SEQ ID NO: 310) is known to have a hairpin-like structure.

[0170] As used herein, the term “hsa-miR-6858-5p gene” or “hsa-miR-6858-5p” includes the hsa-miR-6858-5p gene described in SEQ ID NO: 41 (miRBase Accession No. MIMAT0027616) and homologs or orthologs in other species. The hsa-miR-6858-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6858-5p,” “hsa-mir-6858” (miRBase Accession No. MI0022704, SEQ ID NO: 311) is known to have a hairpin-like structure.

[0171] As used herein, the term "hsa-miR-564 gene" or "hsa-miR-564" includes the hsa-miR-564 gene described in SEQ ID NO: 42 (miRBase Accession No. MIMAT0003228) and homologs or orthologs in other species. The hsa-miR-564 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, as a precursor of "hsa-miR-564", "hsa-mir-564" (miRBase Accession No. MI0003570, SEQ ID NO: 312) is known to have a hairpin-like structure.

[0172] As used herein, the term "hsa-miR-4763-3p gene" or "hsa-miR-4763-3p" includes the hsa-miR-4763-3p gene described in SEQ ID NO: 43 (miRBase Accession No. MIMAT0019913) and homologs or orthologs in other species. The hsa-miR-4763-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4763-3p", "hsa-mir-4763" (miRBase Accession No. MI0017404, SEQ ID NO: 313) is known to have a hairpin-like structure.

[0173] As used herein, the term "hsa-miR-575 gene" or "hsa-miR-575" includes the hsa-miR-575 gene described in SEQ ID NO: 44 (miRBase Accession No. MIMAT0003240) and homologs or orthologs in other species. The hsa-miR-575 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Furthermore, as a precursor of "hsa-miR-575," "hsa-mir-575" (miRBase Accession No. MI0003582, SEQ ID NO: 314) is known to have a hairpin-like structure.

[0174] As used herein, the term "hsa-miR-6771-5p gene" or "hsa-miR-6771-5p" includes the hsa-miR-6771-5p gene described in SEQ ID NO: 45 (miRBase Accession No. MIMAT0027442) and homologs or orthologs in other species. The hsa-miR-6771-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6771-5p", "hsa-mir-6771" (miRBase Accession No. MI0022616, SEQ ID NO: 315) is known to have a hairpin-like structure.

[0175] As used herein, the term "hsa-miR-1231 gene" or "hsa-miR-1231" includes the hsa-miR-1231 gene described in SEQ ID NO: 46 (miRBase Accession No. MIMAT0005586) and homologs or orthologs in other species. The hsa-miR-1231 gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Furthermore, as a precursor of "hsa-miR-1231," "hsa-mir-1231" (miRBase Accession No. MI0006321, SEQ ID NO: 316) is known to form a hairpin-like structure.

[0176] As used herein, the term “hsa-miR-1908-3p gene” or “hsa-miR-1908-3p” includes the hsa-miR-1908-3p gene described in SEQ ID NO: 47 (miRBase Accession No. MIMAT0026916) and homologs or orthologs in other biological species. The hsa-miR-1908-3p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. In addition, as a precursor of “hsa-miR-1908-3p”, “hsa-mir-1908” (miRBase Accession No. MI0008329, SEQ ID NO: 317) is known to have a hairpin-like structure.

[0177] As used herein, the term "hsa-miR-150-3p gene" or "hsa-miR-150-3p" includes the hsa-miR-150-3p gene described in SEQ ID NO: 48 (miRBase Accession No. MIMAT0004610) and homologs or orthologs in other species. The hsa-miR-150-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. Furthermore, as a precursor of "hsa-miR-150-3p", "hsa-mir-150" (miRBase Accession No. MI0000479, SEQ ID NO: 318) is known to have a hairpin-like structure.

[0178] As used herein, the term "hsa-miR-3937 gene" or "hsa-miR-3937" includes the hsa-miR-3937 gene described in SEQ ID NO: 49 (miRBase Accession No. MIMAT0018352) and homologs or orthologs in other species. The hsa-miR-3937 gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, Vol. 5, e10563. Furthermore, as a precursor of "hsa-miR-3937," "hsa-mir-3937" (miRBase Accession No. MI0016593, SEQ ID NO: 319) is known to have a hairpin-like structure.

[0179] As used herein, the term "hsa-miR-887-3p gene" or "hsa-miR-887-3p" includes the hsa-miR-887-3p gene described in SEQ ID NO: 50 (miRBase Accession No. MIMAT0004951) and homologs or orthologs in other species. The hsa-miR-887-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, as a precursor of "hsa-miR-887-3p", "hsa-mir-887" (miRBase Accession No. MI0005562, SEQ ID NO: 320) is known to have a hairpin-like structure.

[0180] As used herein, the term "hsa-miR-3940-5p gene" or "hsa-miR-3940-5p" includes the hsa-miR-3940-5p gene described in SEQ ID NO: 51 (miRBase Accession No. MIMAT0019229) and homologs or orthologs in other species. The hsa-miR-3940-5p gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, Vol. 5, e10563. Furthermore, as a precursor of "hsa-miR-3940-5p," "hsa-mir-3940" (miRBase Accession No. MI0016597, SEQ ID NO: 321) is known to have a hairpin-like structure.

[0181] As used herein, the term "hsa-miR-4741 gene" or "hsa-miR-4741" includes the hsa-miR-4741 gene described in SEQ ID NO: 52 (miRBase Accession No. MIMAT0019871) and homologs or orthologs in other species. The hsa-miR-4741 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4741," "hsa-mir-4741" (miRBase Accession No. MI0017379, SEQ ID NO: 322) is known to have a hairpin-like structure.

[0182] As used herein, the term “hsa-miR-6808-5p gene” or “hsa-miR-6808-5p” includes the hsa-miR-6808-5p gene described in SEQ ID NO: 53 (miRBase Accession No. MIMAT0027516) and homologs or orthologs in other species. The hsa-miR-6808-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6808-5p,” “hsa-mir-6808” (miRBase Accession No. MI0022653, SEQ ID NO: 323) is known to have a hairpin-like structure.

[0183] As used herein, the term “hsa-miR-6869-5p gene” or “hsa-miR-6869-5p” includes the hsa-miR-6869-5p gene described in SEQ ID NO: 54 (miRBase Accession No. MIMAT0027638) and homologs or orthologs in other species. The hsa-miR-6869-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6869-5p,” “hsa-mir-6869” (miRBase Accession No. MI0022716, SEQ ID NO: 324) is known to have a hairpin-like structure.

[0184] As used herein, the term "hsa-miR-5090 gene" or "hsa-miR-5090" includes the hsa-miR-5090 gene described in SEQ ID NO: 55 (miRBase Accession No. MIMAT0021082) and homologs or orthologs in other species. The hsa-miR-5090 gene can be obtained by the method described in Ding N et al., 2011, J Radiat Res, Vol. 52, pp. 425-432. Furthermore, as a precursor of "hsa-miR-5090", "hsa-mir-5090" (miRBase Accession No. MI0017979, SEQ ID NO: 325) is known to have a hairpin-like structure.

[0185] As used herein, the term "hsa-miR-615-5p gene" or "hsa-miR-615-5p" includes the hsa-miR-615-5p gene described in SEQ ID NO: 56 (miRBase Accession No. MIMAT0004804) and homologs or orthologs in other species. The hsa-miR-615-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Furthermore, as a precursor of "hsa-miR-615-5p", "hsa-mir-615" (miRBase Accession No. MI0003628, SEQ ID NO: 326) is known to have a hairpin-like structure.

[0186] As used herein, the term “hsa-miR-8072 gene” or “hsa-miR-8072” includes the hsa-miR-8072 gene described in SEQ ID NO: 57 (miRBase Accession No. MIMAT0030999) and homologs or orthologs in other species. The hsa-miR-8072 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, as a precursor of “hsa-miR-8072”, “hsa-mir-8072” (miRBase Accession No. MI0025908, SEQ ID NO: 327) is known to have a hairpin-like structure.

[0187] As used herein, the term "hsa-miR-128-1-5p gene" or "hsa-miR-128-1-5p" includes the hsa-miR-128-1-5p gene described in SEQ ID NO: 58 (miRBase Accession No. MIMAT0026477) and homologs or orthologs in other species. The hsa-miR-128-1-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. Furthermore, as a precursor of "hsa-miR-128-1-5p," "hsa-mir-128-1" (miRBase Accession No. MI0000447, SEQ ID NO: 328) is known to have a hairpin-like structure.

[0188] As used herein, the term "hsa-miR-1238-5p gene" or "hsa-miR-1238-5p" includes the hsa-miR-1238-5p gene described in SEQ ID NO: 59 (miRBase Accession No. MIMAT0022947) and homologs or orthologs in other species. The hsa-miR-1238-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Furthermore, as a precursor of "hsa-miR-1238-5p", "hsa-mir-1238" (miRBase Accession No. MI0006328, SEQ ID NO: 329) is known to have a hairpin-like structure.

[0189] As used herein, the term "hsa-miR-365a-5p gene" or "hsa-miR-365a-5p" includes the hsa-miR-365a-5p gene described in SEQ ID NO: 60 (miRBase Accession No. MIMAT0009199) and homologs or orthologs in other species. The hsa-miR-365a-5p gene can be obtained by the method described in Xie X et al., 2005, Nature, Vol. 434, pp. 338-345. Furthermore, as a precursor of "hsa-miR-365a-5p," "hsa-mir-365a" (miRBase Accession No. MI0000767, SEQ ID NO: 330) is known to have a hairpin-like structure.

[0190] As used herein, the term "hsa-miR-204-3p gene" or "hsa-miR-204-3p" includes the hsa-miR-204-3p gene described in SEQ ID NO: 61 (miRBase Accession No. MIMAT0022693) and homologs or orthologs in other species. The hsa-miR-204-3p gene can be obtained by the method described in Lim LP et al., 2003, Science, Vol. 299, p1540. Furthermore, as a precursor of "hsa-miR-204-3p", "hsa-mir-204" (miRBase Accession No. MI0000284, SEQ ID NO: 331) is known to have a hairpin-like structure.

[0191] As used herein, the term "hsa-miR-4492 gene" or "hsa-miR-4492" includes the hsa-miR-4492 gene described in SEQ ID NO: 62 (miRBase Accession No. MIMAT0019027) and homologs or orthologs in other species. The hsa-miR-4492 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4492", "hsa-mir-4492" (miRBase Accession No. MI0016854, SEQ ID NO: 332) is known to have a hairpin-like structure.

[0192] As used herein, the term “hsa-miR-6785-5p gene” or “hsa-miR-6785-5p” includes the hsa-miR-6785-5p gene described in SEQ ID NO: 63 (miRBase Accession No. MIMAT0027470) and homologs or orthologs in other species. The hsa-miR-6785-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6785-5p,” “hsa-mir-6785” (miRBase Accession No. MI0022630, SEQ ID NO: 333) is known to have a hairpin-like structure.

[0193] As used herein, the term "hsa-miR-6511a-5p gene" or "hsa-miR-6511a-5p" includes the hsa-miR-6511a-5p gene described in SEQ ID NO: 64 (miRBase Accession No. MIMAT0025478) and homologs or orthologs in other species. The hsa-miR-6511a-5p gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet, Vol. 20, pp. 4025-4040. In addition, as precursors of "hsa-miR-6511a-5p", "hsa-mir-6511a-1, hsa-mir-6511a-2, hsa-mir-6511a-3, hsa-mir-6511a-4" (miRBase accession numbers MI0022223, MI0023564, MI0023565, MI0023566, sequence numbers 334, 335, 336, 337) are known to form hairpin-like structures.

[0194] As used herein, the term "hsa-miR-4525 gene" or "hsa-miR-4525" includes the hsa-miR-4525 gene described in SEQ ID NO: 65 (miRBase Accession No. MIMAT0019064) and homologs or orthologs in other species. The hsa-miR-4525 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4525," "hsa-mir-4525" (miRBase Accession No. MI0016892, SEQ ID NO: 338) is known to have a hairpin-like structure.

[0195] As used herein, the term "hsa-miR-1915-5p gene" or "hsa-miR-1915-5p" includes the hsa-miR-1915-5p gene described in SEQ ID NO: 66 (miRBase Accession No. MIMAT0007891) and homologs or orthologs in other biological species. The hsa-miR-1915-5p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. Furthermore, as a precursor of "hsa-miR-1915-5p", "hsa-mir-1915" (miRBase Accession No. MI0008336, SEQ ID NO: 339) is known to have a hairpin-like structure.

[0196] As used herein, the term “hsa-miR-3180 gene” or “hsa-miR-3180” includes the hsa-miR-3180 gene described in SEQ ID NO: 67 (miRBase Accession No. MIMAT0018178) and homologs or orthologs in other biological species. The hsa-miR-3180 gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, as precursors of “hsa-miR-3180”, “hsa-mir-3180-4 and hsa-mir-3180-5” (miRBase Accession Nos. MI0016408 and MI0016409, SEQ ID NOs: 340 and 341) are known.

[0197] As used herein, the term “hsa-miR-6879-5p gene” or “hsa-miR-6879-5p” includes the hsa-miR-6879-5p gene described in SEQ ID NO: 68 (miRBase Accession No. MIMAT0027658) and homologs or orthologs in other species. The hsa-miR-6879-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6879-5p,” “hsa-mir-6879” (miRBase Accession No. MI0022726, SEQ ID NO: 342) is known to have a hairpin-like structure.

[0198] As used herein, the term “hsa-miR-1199-5p gene” or “hsa-miR-1199-5p” includes the hsa-miR-1199-5p gene described in SEQ ID NO: 69 (miRBase Accession No. MIMAT0031119) and homologs or orthologs in other biological species. The hsa-miR-1199-5p gene can be obtained by the method described in Salvi A et al., 2013, Int J Oncol, Vol. 42, pp. 391-402. In addition, as a precursor of “hsa-miR-1199-5p”, “hsa-mir-1199” (miRBase Accession No. MI0020340, SEQ ID NO: 343) is known to have a hairpin-like structure.

[0199] As used herein, the term "hsa-miR-6746-5p gene" or "hsa-miR-6746-5p" includes the hsa-miR-6746-5p gene described in SEQ ID NO: 70 (miRBase Accession No. MIMAT0027392) and homologs or orthologs in other species. The hsa-miR-6746-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6746-5p", "hsa-mir-6746" (miRBase Accession No. MI0022591, SEQ ID NO: 344) is known to have a hairpin-like structure.

[0200] As used herein, the term “hsa-miR-711 gene” or “hsa-miR-711” includes the hsa-miR-711 gene described in SEQ ID NO: 71 (miRBase Accession No. MIMAT0012734) and homologs or orthologs in other biological species. The hsa-miR-711 gene can be obtained by the method described in Artzi S et al., 2008, BMC Bioinformatics, Vol. 9, p39. In addition, as a precursor of “hsa-miR-711”, “hsa-mir-711” (miRBase Accession No. MI0012488, SEQ ID NO: 345) is known to have a hairpin-like structure.

[0201] As used herein, the term "hsa-miR-663b gene" or "hsa-miR-663b" includes the hsa-miR-663b gene described in SEQ ID NO: 72 (miRBase Accession No. MIMAT0005867) and homologs or orthologs in other species. The hsa-miR-663b gene can be obtained by the method described in Takada S et al., 2008, Leukemia, Vol. 22, pp. 1274-1278. Furthermore, as a precursor of "hsa-miR-663b," "hsa-mir-663b" (miRBase Accession No. MI0006336, SEQ ID NO: 346) is known to have a hairpin-like structure.

[0202] As used herein, the term "hsa-miR-4707-3p gene" or "hsa-miR-4707-3p" includes the hsa-miR-4707-3p gene described in SEQ ID NO: 73 (miRBase Accession No. MIMAT0019808) and homologs or orthologs in other species. The hsa-miR-4707-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4707-3p", "hsa-mir-4707" (miRBase Accession No. MI0017340, SEQ ID NO: 347) is known to have a hairpin-like structure.

[0203] As used herein, the term "hsa-miR-6893-5p gene" or "hsa-miR-6893-5p" includes the hsa-miR-6893-5p gene described in SEQ ID NO: 74 (miRBase Accession No. MIMAT0027686) and homologs or orthologs in other species. The hsa-miR-6893-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6893-5p", "hsa-mir-6893" (miRBase Accession No. MI0022740, SEQ ID NO: 348) is known to have a hairpin-like structure.

[0204] As used herein, the term "hsa-miR-4675 gene" or "hsa-miR-4675" includes the hsa-miR-4675 gene described in SEQ ID NO: 75 (miRBase Accession No. MIMAT0019757) and homologs or orthologs in other species. The hsa-miR-4675 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4675," "hsa-mir-4675" (miRBase Accession No. MI0017306, SEQ ID NO: 349) is known to have a hairpin-like structure.

[0205] As used herein, the term "hsa-miR-4638-5p gene" or "hsa-miR-4638-5p" includes the hsa-miR-4638-5p gene described in SEQ ID NO: 76 (miRBase Accession No. MIMAT0019695) and homologs or orthologs in other species. The hsa-miR-4638-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4638-5p", "hsa-mir-4638" (miRBase Accession No. MI0017265, SEQ ID NO: 350) is known to have a hairpin-like structure.

[0206] As used herein, the term “hsa-miR-4651 gene” or “hsa-miR-4651” includes the hsa-miR-4651 gene described in SEQ ID NO: 77 (miRBase Accession No. MIMAT0019715) and homologs or orthologs in other species. The hsa-miR-4651 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of “hsa-miR-4651,” “hsa-mir-4651” (miRBase Accession No. MI0017279, SEQ ID NO: 351) is known to have a hairpin-like structure.

[0207] As used herein, the term "hsa-miR-6087 gene" or "hsa-miR-6087" includes the hsa-miR-6087 gene described in SEQ ID NO: 78 (miRBase Accession No. MIMAT0023712) and homologs or orthologs in other species. The hsa-miR-6087 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. Furthermore, as a precursor of "hsa-miR-6087," "hsa-mir-6087" (miRBase Accession No. MI0020364, SEQ ID NO: 352) is known to form a hairpin-like structure.

[0208] As used herein, the term "hsa-miR-4665-5p gene" or "hsa-miR-4665-5p" includes the hsa-miR-4665-5p gene described in SEQ ID NO: 79 (miRBase Accession No. MIMAT0019739) and homologs or orthologs in other species. The hsa-miR-4665-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4665-5p," "hsa-mir-4665" (miRBase Accession No. MI0017295, SEQ ID NO: 353) is known to have a hairpin-like structure.

[0209] As used herein, the term "hsa-miR-4758-5p gene" or "hsa-miR-4758-5p" includes the hsa-miR-4758-5p gene described in SEQ ID NO: 80 (miRBase Accession No. MIMAT0019903) and homologs or orthologs in other species. The hsa-miR-4758-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4758-5p", "hsa-mir-4758" (miRBase Accession No. MI0017399, SEQ ID NO: 354) is known to have a hairpin-like structure.

[0210] As used herein, the term “hsa-miR-6887-5p gene” or “hsa-miR-6887-5p” includes the hsa-miR-6887-5p gene described in SEQ ID NO: 81 (miRBase Accession No. MIMAT0027674) and homologs or orthologs in other species. The hsa-miR-6887-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6887-5p,” “hsa-mir-6887” (miRBase Accession No. MI0022734, SEQ ID NO: 355) is known to have a hairpin-like structure.

[0211] As used herein, the term "hsa-miR-3620-5p gene" or "hsa-miR-3620-5p" includes the hsa-miR-3620-5p gene described in SEQ ID NO: 82 (miRBase Accession No. MIMAT0022967) and homologs or orthologs in other biological species. The hsa-miR-3620-5p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p58. Furthermore, as a precursor of "hsa-miR-3620-5p", "hsa-mir-3620" (miRBase Accession No. MI0016011, SEQ ID NO: 356) is known to have a hairpin-like structure.

[0212] As used herein, the term “hsa-miR-1909-3p gene” or “hsa-miR-1909-3p” includes the hsa-miR-1909-3p gene described in SEQ ID NO: 83 (miRBase Accession No. MIMAT0007883) and homologs or orthologs in other biological species. The hsa-miR-1909-3p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. In addition, as a precursor of “hsa-miR-1909-3p”, “hsa-mir-1909” (miRBase Accession No. MI0008330, SEQ ID NO: 357) is known to have a hairpin-like structure.

[0213] As used herein, the term “hsa-miR-7641 gene” or “hsa-miR-7641” includes the hsa-miR-7641 gene described in SEQ ID NO: 84 (miRBase Accession No. MIMAT0029782) and homologs or orthologs in other biological species. The hsa-miR-7641 gene can be obtained by the method described in Yoo JK et al., 2013, Arch Pharm Res, Vol. 36, pp. 353-358. In addition, as precursors of “hsa-miR-7641”, “hsa-mir-7641-1, hsa-mir-7641-2” (miRBase Accession Nos. MI0024975 and MI0024976, SEQ ID NOs: 358 and 359) are known as hairpin-like structure forming precursors of “hsa-miR-7641”.

[0214] As used herein, the term "hsa-miR-6724-5p gene" or "hsa-miR-6724-5p" includes the hsa-miR-6724-5p gene described in SEQ ID NO: 85 (miRBase Accession No. MIMAT0025856) and homologs or orthologs in other species. The hsa-miR-6724-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. Furthermore, as a precursor of "hsa-miR-6724-5p," "hsa-mir-6724" (miRBase Accession No. MI0022559, SEQ ID NO: 360) is known to have a hairpin-like structure.

[0215] As used herein, the term "hsa-miR-1343-3p gene" or "hsa-miR-1343-3p" includes the hsa-miR-1343-3p gene described in SEQ ID NO: 86 (miRBase Accession No. MIMAT0019776) and homologs or orthologs in other species. The hsa-miR-1343-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-1343-3p", "hsa-mir-1343" (miRBase Accession No. MI0017320, SEQ ID NO: 361) is known to have a hairpin-like structure.

[0216] As used herein, the term “hsa-miR-6780b-5p gene” or “hsa-miR-6780b-5p” includes the hsa-miR-6780b-5p gene described in SEQ ID NO: 87 (miRBase Accession No. MIMAT0027572) and homologs or orthologs in other species. The hsa-miR-6780b-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6780b-5p,” “hsa-mir-6780b” (miRBase Accession No. MI0022681, SEQ ID NO: 362) is known to have a hairpin-like structure.

[0217] As used herein, the term "hsa-miR-4484 gene" or "hsa-miR-4484" includes the hsa-miR-4484 gene described in SEQ ID NO: 88 (miRBase Accession No. MIMAT0019018) and homologs or orthologs in other species. The hsa-miR-4484 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4484", "hsa-mir-4484" (miRBase Accession No. MI0016845, SEQ ID NO: 363) is known to have a hairpin-like structure.

[0218] As used herein, the term "hsa-miR-4690-5p gene" or "hsa-miR-4690-5p" includes the hsa-miR-4690-5p gene described in SEQ ID NO: 89 (miRBase Accession No. MIMAT0019779) and homologs or orthologs in other species. The hsa-miR-4690-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4690-5p," "hsa-mir-4690" (miRBase Accession No. MI0017323, SEQ ID NO: 364) is known to have a hairpin-like structure.

[0219] As used herein, the term "hsa-miR-4429 gene" or "hsa-miR-4429" includes the hsa-miR-4429 gene described in SEQ ID NO: 90 (miRBase Accession No. MIMAT0018944) and homologs or orthologs in other species. The hsa-miR-4429 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4429", "hsa-mir-4429" (miRBase Accession No. MI0016768, SEQ ID NO: 365) is known to have a hairpin-like structure.

[0220] As used herein, the term "hsa-miR-1227-5p gene" or "hsa-miR-1227-5p" includes the hsa-miR-1227-5p gene described in SEQ ID NO: 91 (miRBase Accession No. MIMAT0022941) and homologs or orthologs in other species. The hsa-miR-1227-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Furthermore, as a precursor of "hsa-miR-1227-5p", "hsa-mir-1227" (miRBase Accession No. MI0006316, SEQ ID NO: 366) is known to have a hairpin-like structure.

[0221] As used herein, the term "hsa-miR-4725-3p gene" or "hsa-miR-4725-3p" includes the hsa-miR-4725-3p gene described in SEQ ID NO: 92 (miRBase Accession No. MIMAT0019844) and homologs or orthologs in other species. The hsa-miR-4725-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4725-3p", "hsa-mir-4725" (miRBase Accession No. MI0017362, SEQ ID NO: 367) is known to have a hairpin-like structure.

[0222] As used herein, the term “hsa-miR-6861-5p gene” or “hsa-miR-6861-5p” includes the hsa-miR-6861-5p gene described in SEQ ID NO: 93 (miRBase Accession No. MIMAT0027623) and homologs or orthologs in other species. The hsa-miR-6861-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6861-5p,” “hsa-mir-6861” (miRBase Accession No. MI0022708, SEQ ID NO: 368) is known to have a hairpin-like structure.

[0223] As used herein, the term "hsa-miR-6812-5p gene" or "hsa-miR-6812-5p" includes the hsa-miR-6812-5p gene described in SEQ ID NO: 94 (miRBase Accession No. MIMAT0027524) and homologs or orthologs in other species. The hsa-miR-6812-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6812-5p", "hsa-mir-6812" (miRBase Accession No. MI0022657, SEQ ID NO: 369) is known to have a hairpin-like structure.

[0224] As used herein, the term “hsa-miR-3197 gene” or “hsa-miR-3197” includes the hsa-miR-3197 gene described in SEQ ID NO: 95 (miRBase Accession No. MIMAT0015082) and homologs or orthologs in other species. The hsa-miR-3197 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Furthermore, as a precursor of “hsa-miR-3197,” “hsa-mir-3197” (miRBase Accession No. MI0014245, SEQ ID NO: 370) is known to have a hairpin-like structure.

[0225] As used herein, the term “hsa-miR-8059 gene” or “hsa-miR-8059” includes the hsa-miR-8059 gene described in SEQ ID NO: 96 (miRBase Accession No. MIMAT0030986) and homologs or orthologs in other species. The hsa-miR-8059 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, as a precursor of “hsa-miR-8059”, “hsa-mir-8059” (miRBase Accession No. MI0025895, SEQ ID NO: 371) is known to have a hairpin-like structure.

[0226] As used herein, the term “hsa-miR-3185 gene” or “hsa-miR-3185” includes the hsa-miR-3185 gene described in SEQ ID NO: 97 (miRBase Accession No. MIMAT0015065) and homologs or orthologs in other species. The hsa-miR-3185 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Furthermore, as a precursor of “hsa-miR-3185,” “hsa-mir-3185” (miRBase Accession No. MI0014227, SEQ ID NO: 372) is known to have a hairpin-like structure.

[0227] As used herein, the term "hsa-miR-4706 gene" or "hsa-miR-4706" includes the hsa-miR-4706 gene described in SEQ ID NO: 98 (miRBase Accession No. MIMAT0019806) and homologs or orthologs in other species. The hsa-miR-4706 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4706", "hsa-mir-4706" (miRBase Accession No. MI0017339, SEQ ID NO: 373) is known to have a hairpin-like structure.

[0228] As used herein, the term "hsa-miR-4497 gene" or "hsa-miR-4497" includes the hsa-miR-4497 gene described in SEQ ID NO: 99 (miRBase Accession No. MIMAT0019032) and homologs or orthologs in other species. The hsa-miR-4497 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4497", "hsa-mir-4497" (miRBase Accession No. MI0016859, SEQ ID NO: 374) is known to have a hairpin-like structure.

[0229] As used herein, the term “hsa-miR-3131 gene” or “hsa-miR-3131” includes the hsa-miR-3131 gene described in SEQ ID NO: 100 (miRBase Accession No. MIMAT0014996) and homologs or orthologs in other species. The hsa-miR-3131 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Furthermore, as a precursor of “hsa-miR-3131,” “hsa-mir-3131” (miRBase Accession No. MI0014151, SEQ ID NO: 375) is known to have a hairpin-like structure.

[0230] As used herein, the term "hsa-miR-6806-5p gene" or "hsa-miR-6806-5p" includes the hsa-miR-6806-5p gene described in SEQ ID NO: 101 (miRBase Accession No. MIMAT0027512) and homologs or orthologs in other species. The hsa-miR-6806-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6806-5p," "hsa-mir-6806" (miRBase Accession No. MI0022651, SEQ ID NO: 376) is known to have a hairpin-like structure.

[0231] As used herein, the term "hsa-miR-187-5p gene" or "hsa-miR-187-5p" includes the hsa-miR-187-5p gene described in SEQ ID NO: 102 (miRBase Accession No. MIMAT0004561) and homologs or orthologs in other species. The hsa-miR-187-5p gene can be obtained by the method described in Lim LP et al., 2003, Science, Vol. 299, p1540. Furthermore, as a precursor of "hsa-miR-187-5p", "hsa-mir-187" (miRBase Accession No. MI0000274, SEQ ID NO: 377) is known to have a hairpin-like structure.

[0232] As used herein, the term “hsa-miR-3180-3p gene” or “hsa-miR-3180-3p” includes the hsa-miR-3180-3p gene described in SEQ ID NO: 103 (miRBase Accession No. MIMAT0015058) and homologs or orthologs in other species. The hsa-miR-3180-3p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, as precursors of "hsa-miR-3180-3p", "hsa-mir-3180-1, hsa-mir-3180-2, hsa-mir-3180-3" (miRBase accession numbers MI0014214, MI0014215, MI0014217, sequence numbers 378, 379, 380) are known to form hairpin-like structures.

[0233] As used herein, the term "hsa-miR-6848-5p gene" or "hsa-miR-6848-5p" includes the hsa-miR-6848-5p gene described in SEQ ID NO: 104 (miRBase Accession No. MIMAT0027596) and homologs or orthologs in other species. The hsa-miR-6848-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6848-5p," "hsa-mir-6848" (miRBase Accession No. MI0022694, SEQ ID NO: 381) is known to have a hairpin-like structure.

[0234] As used herein, the term "hsa-miR-6820-5p gene" or "hsa-miR-6820-5p" includes the hsa-miR-6820-5p gene described in SEQ ID NO: 105 (miRBase Accession No. MIMAT0027540) and homologs or orthologs in other species. The hsa-miR-6820-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6820-5p," "hsa-mir-6820" (miRBase Accession No. MI0022665, SEQ ID NO: 382) is known to have a hairpin-like structure.

[0235] As used herein, the term "hsa-miR-6800-5p gene" or "hsa-miR-6800-5p" includes the hsa-miR-6800-5p gene described in SEQ ID NO: 106 (miRBase Accession No. MIMAT0027500) and homologs or orthologs in other species. The hsa-miR-6800-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6800-5p", "hsa-mir-6800" (miRBase Accession No. MI0022645, SEQ ID NO: 383) is known to have a hairpin-like structure.

[0236] As used herein, the term "hsa-miR-6717-5p gene" or "hsa-miR-6717-5p" includes the hsa-miR-6717-5p gene described in SEQ ID NO: 107 (miRBase Accession No. MIMAT0025846) and homologs or orthologs in other species. The hsa-miR-6717-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. Furthermore, as a precursor of "hsa-miR-6717-5p," "hsa-mir-6717" (miRBase Accession No. MI0022551, SEQ ID NO: 384) is known to have a hairpin-like structure.

[0237] As used herein, the term "hsa-miR-6795-5p gene" or "hsa-miR-6795-5p" includes the hsa-miR-6795-5p gene described in SEQ ID NO: 108 (miRBase Accession No. MIMAT0027490) and homologs or orthologs in other species. The hsa-miR-6795-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6795-5p", "hsa-mir-6795" (miRBase Accession No. MI0022640, SEQ ID NO: 385) is known to have a hairpin-like structure.

[0238] As used herein, the term "hsa-miR-4632-5p gene" or "hsa-miR-4632-5p" includes the hsa-miR-4632-5p gene described in SEQ ID NO: 109 (miRBase Accession No. MIMAT0022977) and homologs or orthologs in other species. The hsa-miR-4632-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4632-5p", "hsa-mir-4632" (miRBase Accession No. MI0017259, SEQ ID NO: 386) is known to have a hairpin-like structure.

[0239] As used herein, the term "hsa-miR-665 gene" or "hsa-miR-665" includes the hsa-miR-665 gene described in SEQ ID NO: 110 (miRBase Accession No. MIMAT0004952) and homologs or orthologs in other species. The hsa-miR-665 gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, as a precursor of "hsa-miR-665", "hsa-mir-665" (miRBase Accession No. MI0005563, SEQ ID NO: 387) is known to have a hairpin-like structure.

[0240] As used herein, the term "hsa-miR-6778-5p gene" or "hsa-miR-6778-5p" includes the hsa-miR-6778-5p gene described in SEQ ID NO: 111 (miRBase Accession No. MIMAT0027456) and homologs or orthologs in other species. The hsa-miR-6778-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6778-5p", "hsa-mir-6778" (miRBase Accession No. MI0022623, SEQ ID NO: 388) is known to have a hairpin-like structure.

[0241] As used herein, the term "hsa-miR-3663-3p gene" or "hsa-miR-3663-3p" includes the hsa-miR-3663-3p gene described in SEQ ID NO: 112 (miRBase Accession No. MIMAT0018085) and homologs or orthologs in other species. The hsa-miR-3663-3p gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, Vol. 5, e10563. Furthermore, as a precursor of "hsa-miR-3663-3p", "hsa-mir-3663" (miRBase Accession No. MI0016064, SEQ ID NO: 389) is known to have a hairpin-like structure.

[0242] As used herein, the term “hsa-miR-4689 gene” or “hsa-miR-4689” includes the hsa-miR-4689 gene described in SEQ ID NO: 113 (miRBase Accession No. MIMAT0019778) and homologs or orthologs in other species. The hsa-miR-4689 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of “hsa-miR-4689,” “hsa-mir-4689” (miRBase Accession No. MI0017322, SEQ ID NO: 390) is known to have a hairpin-like structure.

[0243] As used herein, the term "hsa-miR-211-3p gene" or "hsa-miR-211-3p" includes the hsa-miR-211-3p gene described in SEQ ID NO: 114 (miRBase Accession No. MIMAT0022694) and homologs or orthologs in other species. The hsa-miR-211-3p gene can be obtained by the method described in Lim LP et al., 2003, Science, Vol. 299, p1540. Furthermore, as a precursor of "hsa-miR-211-3p", "hsa-mir-211" (miRBase Accession No. MI0000287, SEQ ID NO: 391) is known to have a hairpin-like structure.

[0244] As used herein, the term “hsa-miR-6511b-5p gene” or “hsa-miR-6511b-5p” includes the hsa-miR-6511b-5p gene described in SEQ ID NO: 115 (miRBase Accession No. MIMAT0025847) and homologs or orthologs in other species. The hsa-miR-6511b-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. Furthermore, as precursors of “hsa-miR-6511b-5p,” “hsa-mir-6511b-1 and hsa-mir-6511b-2” (miRBase Accession Nos. MI0022552 and MI0023431, SEQ ID NOs. 392 and 393) are known to form hairpin-like structures.

[0245] As used herein, the term "hsa-miR-4750-5p gene" or "hsa-miR-4750-5p" includes the hsa-miR-4750-5p gene described in SEQ ID NO: 116 (miRBase Accession No. MIMAT0019887) and homologs or orthologs in other species. The hsa-miR-4750-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4750-5p", "hsa-mir-4750" (miRBase Accession No. MI0017389, SEQ ID NO: 394) is known to have a hairpin-like structure.

[0246] As used herein, the term “hsa-miR-6126 gene” or “hsa-miR-6126” includes the hsa-miR-6126 gene described in SEQ ID NO: 117 (miRBase Accession No. MIMAT0024599) and homologs or orthologs in other species. The hsa-miR-6126 gene can be obtained by the method described in Smith JL et al., 2012, J Virol, Vol. 86, pp. 5278-5287. Furthermore, as a precursor of “hsa-miR-6126,” “hsa-mir-6126” (miRBase Accession No. MI0021260, SEQ ID NO: 395) is known to have a hairpin-like structure.

[0247] As used herein, the term "hsa-miR-614 gene" or "hsa-miR-614" includes the hsa-miR-614 gene described in SEQ ID NO: 118 (miRBase Accession No. MIMAT0003282) and homologs or orthologs in other species. The hsa-miR-614 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, as a precursor of "hsa-miR-614", "hsa-mir-614" (miRBase Accession No. MI0003627, SEQ ID NO: 396) is known to have a hairpin-like structure.

[0248] As used herein, the term "hsa-miR-7110-5p gene" or "hsa-miR-7110-5p" includes the hsa-miR-7110-5p gene described in SEQ ID NO: 119 (miRBase Accession No. MIMAT0028117) and homologs or orthologs in other species. The hsa-miR-7110-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-7110-5p", "hsa-mir-7110" (miRBase Accession No. MI0022961, SEQ ID NO: 397) is known to have a hairpin-like structure.

[0249] As used herein, the term "hsa-miR-744-5p gene" or "hsa-miR-744-5p" includes the hsa-miR-744-5p gene described in SEQ ID NO: 120 (miRBase Accession No. MIMAT0004945) and homologs or orthologs in other biological species. The hsa-miR-744-5p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, as a precursor of "hsa-miR-744-5p", "hsa-mir-744" (miRBase Accession No. MI0005559, SEQ ID NO: 398) is known to have a hairpin-like structure.

[0250] As used herein, the term "hsa-miR-6769a-5p gene" or "hsa-miR-6769a-5p" includes the hsa-miR-6769a-5p gene described in SEQ ID NO: 121 (miRBase Accession No. MIMAT0027438) and homologs or orthologs in other species. The hsa-miR-6769a-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6769a-5p," "hsa-mir-6769a" (miRBase Accession No. MI0022614, SEQ ID NO: 399) is known to have a hairpin-like structure.

[0251] As used herein, the term "hsa-miR-4792 gene" or "hsa-miR-4792" includes the hsa-miR-4792 gene described in SEQ ID NO: 122 (miRBase Accession No. MIMAT0019964) and homologs or orthologs in other species. The hsa-miR-4792 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4792," "hsa-mir-4792" (miRBase Accession No. MI0017439, SEQ ID NO: 400) is known to have a hairpin-like structure.

[0252] As used herein, the term “hsa-miR-5787 gene” or “hsa-miR-5787” includes the hsa-miR-5787 gene described in SEQ ID NO: 123 (miRBase Accession No. MIMAT0023252) and homologs or orthologs in other species. The hsa-miR-5787 gene can be obtained by the method described in Yoo H et al., 2011, Biochem Biophys Res Commun, Vol. 415, pp. 567-572. Furthermore, as a precursor of “hsa-miR-5787,” “hsa-mir-5787” (miRBase Accession No. MI0019797, SEQ ID NO: 401) is known to have a hairpin-like structure.

[0253] As used herein, the term "hsa-miR-6798-5p gene" or "hsa-miR-6798-5p" includes the hsa-miR-6798-5p gene described in SEQ ID NO: 124 (miRBase Accession No. MIMAT0027496) and homologs or orthologs in other species. The hsa-miR-6798-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6798-5p", "hsa-mir-6798" (miRBase Accession No. MI0022643, SEQ ID NO: 402) is known to have a hairpin-like structure.

[0254] As used herein, the term "hsa-miR-6781-5p gene" or "hsa-miR-6781-5p" includes the hsa-miR-6781-5p gene described in SEQ ID NO: 125 (miRBase Accession No. MIMAT0027462) and homologs or orthologs in other species. The hsa-miR-6781-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6781-5p", "hsa-mir-6781" (miRBase Accession No. MI0022626, SEQ ID NO: 403) is known to have a hairpin-like structure.

[0255] As used herein, the term "hsa-miR-4419b gene" or "hsa-miR-4419b" includes the hsa-miR-4419b gene described in SEQ ID NO: 126 (miRBase Accession No. MIMAT0019034) and homologs or orthologs in other species. The hsa-miR-4419b gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4419b", "hsa-mir-4419b" (miRBase Accession No. MI0016861, SEQ ID NO: 404) is known to have a hairpin-like structure.

[0256] As used herein, the term "hsa-miR-4446-3p gene" or "hsa-miR-4446-3p" includes the hsa-miR-4446-3p gene described in SEQ ID NO: 127 (miRBase Accession No. MIMAT0018965) and homologs or orthologs in other species. The hsa-miR-4446-3p gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4446-3p", "hsa-mir-4446" (miRBase Accession No. MI0016789, SEQ ID NO: 405) is known to have a hairpin-like structure.

[0257] As used herein, the term “hsa-miR-4259 gene” or “hsa-miR-4259” includes the hsa-miR-4259 gene described in SEQ ID NO: 128 (miRBase Accession No. MIMAT0016880) and homologs or orthologs in other biological species. The hsa-miR-4259 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, as a precursor of “hsa-miR-4259”, “hsa-mir-4259” (miRBase Accession No. MI0015858, SEQ ID NO: 406) is known to have a hairpin-like structure.

[0258] As used herein, the term “hsa-miR-5572 gene” or “hsa-miR-5572” includes the hsa-miR-5572 gene described in SEQ ID NO: 129 (miRBase Accession No. MIMAT0022260) and homologs or orthologs in other species. The hsa-miR-5572 gene can be obtained by the method described in Tandon M et al., 2012, Oral Dis, Vol. 18, pp. 127-131. Furthermore, as a precursor of “hsa-miR-5572,” “hsa-mir-5572” (miRBase Accession No. MI0019117, SEQ ID NO: 407) is known to have a hairpin-like structure.

[0259] As used herein, the term "hsa-miR-6075 gene" or "hsa-miR-6075" includes the hsa-miR-6075 gene described in SEQ ID NO: 130 (miRBase Accession No. MIMAT0023700) and homologs or orthologs in other species. The hsa-miR-6075 gene can be obtained by the method described in Voellenkle C et al., 2012, RNA, Vol. 18, pp. 472-484. Furthermore, as a precursor of "hsa-miR-6075," "hsa-mir-6075" (miRBase Accession No. MI0020352, SEQ ID NO: 408) is known to have a hairpin-like structure.

[0260] As used herein, the term "hsa-miR-296-3p gene" or "hsa-miR-296-3p" includes the hsa-miR-296-3p gene described in SEQ ID NO: 131 (miRBase Accession No. MIMAT0004679) and homologs or orthologs in other species. The hsa-miR-296-3p gene can be obtained by the method described in Houbaviy HB et al., 2003, Dev Cell, Vol. 5, pp. 351-358. Furthermore, as a precursor of "hsa-miR-296-3p", "hsa-mir-296" (miRBase Accession No. MI0000747, SEQ ID NO: 409) is known to have a hairpin-like structure.

[0261] As used herein, the term "hsa-miR-6891-5p gene" or "hsa-miR-6891-5p" includes the hsa-miR-6891-5p gene described in SEQ ID NO: 132 (miRBase Accession No. MIMAT0027682) and homologs or orthologs in other species. The hsa-miR-6891-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6891-5p," "hsa-mir-6891" (miRBase Accession No. MI0022738, SEQ ID NO: 410) is known to have a hairpin-like structure.

[0262] As used herein, the term "hsa-miR-4745-5p gene" or "hsa-miR-4745-5p" includes the hsa-miR-4745-5p gene described in SEQ ID NO: 133 (miRBase Accession No. MIMAT0019878) and homologs or orthologs in other species. The hsa-miR-4745-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4745-5p", "hsa-mir-4745" (miRBase Accession No. MI0017384, SEQ ID NO: 411) is known to have a hairpin-like structure.

[0263] As used herein, the term "hsa-miR-6775-5p gene" or "hsa-miR-6775-5p" includes the hsa-miR-6775-5p gene described in SEQ ID NO: 134 (miRBase Accession No. MIMAT0027450) and homologs or orthologs in other species. The hsa-miR-6775-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6775-5p," "hsa-mir-6775" (miRBase Accession No. MI0022620, SEQ ID NO: 412) is known to have a hairpin-like structure.

[0264] As used herein, the term "hsa-miR-6870-5p gene" or "hsa-miR-6870-5p" includes the hsa-miR-6870-5p gene described in SEQ ID NO: 135 (miRBase Accession No. MIMAT0027640) and homologs or orthologs in other species. The hsa-miR-6870-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6870-5p," "hsa-mir-6870" (miRBase Accession No. MI0022717, SEQ ID NO: 413) is known to have a hairpin-like structure.

[0265] As used herein, the term "hsa-miR-920 gene" or "hsa-miR-920" includes the hsa-miR-920 gene described in SEQ ID NO: 136 (miRBase Accession No. MIMAT0004970) and homologs or orthologs in other species. The hsa-miR-920 gene can be obtained by the method described in Novotny GW et al., 2007, Int J Androl, Vol. 30, pp. 316-326. Furthermore, as a precursor of "hsa-miR-920," "hsa-mir-920" (miRBase Accession No. MI0005712, SEQ ID NO: 414) is known to have a hairpin-like structure.

[0266] As used herein, the term "hsa-miR-4530 gene" or "hsa-miR-4530" includes the hsa-miR-4530 gene described in SEQ ID NO: 137 (miRBase Accession No. MIMAT0019069) and homologs or orthologs in other species. The hsa-miR-4530 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4530", "hsa-mir-4530" (miRBase Accession No. MI0016897, SEQ ID NO: 415) is known to have a hairpin-like structure.

[0267] As used herein, the term "hsa-miR-6819-5p gene" or "hsa-miR-6819-5p" includes the hsa-miR-6819-5p gene described in SEQ ID NO: 138 (miRBase Accession No. MIMAT0027538) and homologs or orthologs in other species. The hsa-miR-6819-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6819-5p," "hsa-mir-6819" (miRBase Accession No. MI0022664, SEQ ID NO: 416) is known to have a hairpin-like structure.

[0268] As used herein, the term "hsa-miR-6825-5p gene" or "hsa-miR-6825-5p" includes the hsa-miR-6825-5p gene described in SEQ ID NO: 139 (miRBase Accession No. MIMAT0027550) and homologs or orthologs in other species. The hsa-miR-6825-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6825-5p," "hsa-mir-6825" (miRBase Accession No. MI0022670, SEQ ID NO: 417) is known to have a hairpin-like structure.

[0269] As used herein, the term "hsa-miR-7847-3p gene" or "hsa-miR-7847-3p" includes the hsa-miR-7847-3p gene described in SEQ ID NO: 140 (miRBase Accession No. MIMAT0030422) and homologs or orthologs in other species. The hsa-miR-7847-3p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. Furthermore, as a precursor of "hsa-miR-7847-3p", "hsa-mir-7847" (miRBase Accession No. MI0025517, SEQ ID NO: 418) is known to have a hairpin-like structure.

[0270] As used herein, the term "hsa-miR-6131 gene" or "hsa-miR-6131" includes the hsa-miR-6131 gene described in SEQ ID NO: 141 (miRBase Accession No. MIMAT0024615) and homologs or orthologs in other species. The hsa-miR-6131 gene can be obtained by the method described in Dannemann M et al., 2012, Genome Biol Evol, 4, pp. 552-564. Furthermore, as a precursor of "hsa-miR-6131," "hsa-mir-6131" (miRBase Accession No. MI0021276, SEQ ID NO: 419) is known to have a hairpin-like structure.

[0271] As used herein, the term "hsa-miR-4433-3p gene" or "hsa-miR-4433-3p" includes the hsa-miR-4433-3p gene described in SEQ ID NO: 142 (miRBase Accession No. MIMAT0018949) and homologs or orthologs in other species. The hsa-miR-4433-3p gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4433-3p", "hsa-mir-4433" (miRBase Accession No. MI0016773, SEQ ID NO: 420) is known to have a hairpin-like structure.

[0272] As used herein, the term "hsa-miR-1228-5p gene" or "hsa-miR-1228-5p" includes the hsa-miR-1228-5p gene described in SEQ ID NO: 143 (miRBase Accession No. MIMAT0005582) and homologs or orthologs in other species. The hsa-miR-1228-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Furthermore, as a precursor of "hsa-miR-1228-5p", "hsa-mir-1228" (miRBase Accession No. MI0006318, SEQ ID NO: 421) is known to have a hairpin-like structure.

[0273] As used herein, the term "hsa-miR-6743-5p gene" or "hsa-miR-6743-5p" includes the hsa-miR-6743-5p gene described in SEQ ID NO: 144 (miRBase Accession No. MIMAT0027387) and homologs or orthologs in other species. The hsa-miR-6743-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6743-5p", "hsa-mir-6743" (miRBase Accession No. MI0022588, SEQ ID NO: 422) is known to have a hairpin-like structure.

[0274] As used herein, the term “hsa-miR-1268a gene” or “hsa-miR-1268a” includes the hsa-miR-1268a gene described in SEQ ID NO: 145 (miRBase Accession No. MIMAT0005922) and homologs or orthologs in other species. The hsa-miR-1268a gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, as a precursor of “hsa-miR-1268a”, “hsa-mir-1268a” (miRBase Accession No. MI0006405, SEQ ID NO: 423) is known to have a hairpin-like structure.

[0275] As used herein, the term “hsa-miR-3917 gene” or “hsa-miR-3917” includes the hsa-miR-3917 gene described in SEQ ID NO: 146 (miRBase Accession No. MIMAT0018191) and homologs or orthologs in other species. The hsa-miR-3917 gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. Furthermore, as a precursor of “hsa-miR-3917,” “hsa-mir-3917” (miRBase Accession No. MI0016423, SEQ ID NO: 424) is known to have a hairpin-like structure.

[0276] As used herein, the term "hsa-miR-6786-5p gene" or "hsa-miR-6786-5p" includes the hsa-miR-6786-5p gene described in SEQ ID NO: 147 (miRBase Accession No. MIMAT0027472) and homologs or orthologs in other species. The hsa-miR-6786-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6786-5p," "hsa-mir-6786" (miRBase Accession No. MI0022631, SEQ ID NO: 425) is known to have a hairpin-like structure.

[0277] As used herein, the term "hsa-miR-3154 gene" or "hsa-miR-3154" includes the hsa-miR-3154 gene described in SEQ ID NO: 148 (miRBase Accession No. MIMAT0015028) and homologs or orthologs in other species. The hsa-miR-3154 gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. Furthermore, as a precursor of "hsa-miR-3154," "hsa-mir-3154" (miRBase Accession No. MI0014182, SEQ ID NO: 426) is known to have a hairpin-like structure.

[0278] As used herein, the term "hsa-miR-638 gene" or "hsa-miR-638" includes the hsa-miR-638 gene described in SEQ ID NO: 149 (miRBase Accession No. MIMAT0003308) and homologs or orthologs in other species. The hsa-miR-638 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Furthermore, as a precursor of "hsa-miR-638", "hsa-mir-638" (miRBase Accession No. MI0003653, SEQ ID NO: 427) is known to have a hairpin-like structure.

[0279] As used herein, the term "hsa-miR-6741-5p gene" or "hsa-miR-6741-5p" includes the hsa-miR-6741-5p gene described in SEQ ID NO: 150 (miRBase Accession No. MIMAT0027383) and homologs or orthologs in other species. The hsa-miR-6741-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6741-5p", "hsa-mir-6741" (miRBase Accession No. MI0022586, SEQ ID NO: 428) is known to have a hairpin-like structure.

[0280] As used herein, the term “hsa-miR-6889-5p gene” or “hsa-miR-6889-5p” includes the hsa-miR-6889-5p gene described in SEQ ID NO: 151 (miRBase Accession No. MIMAT0027678) and homologs or orthologs in other species. The hsa-miR-6889-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6889-5p,” “hsa-mir-6889” (miRBase Accession No. MI0022736, SEQ ID NO: 429) is known to have a hairpin-like structure.

[0281] As used herein, the term "hsa-miR-6840-3p gene" or "hsa-miR-6840-3p" includes the hsa-miR-6840-3p gene described in SEQ ID NO: 152 (miRBase Accession No. MIMAT0027583) and homologs or orthologs in other species. The hsa-miR-6840-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6840-3p," "hsa-mir-6840" (miRBase Accession No. MI0022686, SEQ ID NO: 430) is known to have a hairpin-like structure.

[0282] As used herein, the term "hsa-miR-6510-5p gene" or "hsa-miR-6510-5p" includes the hsa-miR-6510-5p gene described in SEQ ID NO: 153 (miRBase Accession No. MIMAT0025476) and homologs or orthologs in other species. The hsa-miR-6510-5p gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet, Vol. 20, pp. 4025-4040. Furthermore, as a precursor of "hsa-miR-6510-5p", "hsa-mir-6510" (miRBase Accession No. MI0022222, SEQ ID NO: 431) is known to have a hairpin-like structure.

[0283] As used herein, the term “hsa-miR-3188 gene” or “hsa-miR-3188” includes the hsa-miR-3188 gene described in SEQ ID NO: 154 (miRBase Accession No. MIMAT0015070) and homologs or orthologs in other species. The hsa-miR-3188 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Furthermore, as a precursor of “hsa-miR-3188,” “hsa-mir-3188” (miRBase Accession No. MI0014232, SEQ ID NO: 432) is known to have a hairpin-like structure.

[0284] As used herein, the term "hsa-miR-551b-5p gene" or "hsa-miR-551b-5p" includes the hsa-miR-551b-5p gene described in SEQ ID NO: 155 (miRBase Accession No. MIMAT0004794) and homologs or orthologs in other species. The hsa-miR-551b-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, as a precursor of "hsa-miR-551b-5p", "hsa-mir-551b" (miRBase Accession No. MI0003575, SEQ ID NO: 433) is known to have a hairpin-like structure.

[0285] As used herein, the term "hsa-miR-5001-5p gene" or "hsa-miR-5001-5p" includes the hsa-miR-5001-5p gene described in SEQ ID NO: 156 (miRBase Accession No. MIMAT0021021) and homologs or orthologs in other biological species. The hsa-miR-5001-5p gene can be obtained by the method described in Hansen TB et al., 2011, RNA Biol, Vol. 8, pp. 378-383. Furthermore, as a precursor of "hsa-miR-5001-5p," "hsa-mir-5001" (miRBase Accession No. MI0017867, SEQ ID NO: 434) is known to have a hairpin-like structure.

[0286] As used herein, the term "hsa-miR-1268b gene" or "hsa-miR-1268b" includes the hsa-miR-1268b gene described in SEQ ID NO: 157 (miRBase Accession No. MIMAT0018925) and homologs or orthologs in other species. The hsa-miR-1268b gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-1268b", "hsa-mir-1268b" (miRBase Accession No. MI0016748, SEQ ID NO: 435) is known to have a hairpin-like structure.

[0287] As used herein, the term "hsa-miR-7107-5p gene" or "hsa-miR-7107-5p" includes the hsa-miR-7107-5p gene described in SEQ ID NO: 158 (miRBase Accession No. MIMAT0028111) and homologs or orthologs in other species. The hsa-miR-7107-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-7107-5p", "hsa-mir-7107" (miRBase Accession No. MI0022958, SEQ ID NO: 436) is known to have a hairpin-like structure.

[0288] As used herein, the term "hsa-miR-6824-5p gene" or "hsa-miR-6824-5p" includes the hsa-miR-6824-5p gene described in SEQ ID NO: 159 (miRBase Accession No. MIMAT0027548) and homologs or orthologs in other species. The hsa-miR-6824-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6824-5p," "hsa-mir-6824" (miRBase Accession No. MI0022669, SEQ ID NO: 437) is known to have a hairpin-like structure.

[0289] As used herein, the term "hsa-miR-6732-5p gene" or "hsa-miR-6732-5p" includes the hsa-miR-6732-5p gene described in SEQ ID NO: 160 (miRBase Accession No. MIMAT0027365) and homologs or orthologs in other species. The hsa-miR-6732-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6732-5p," "hsa-mir-6732" (miRBase Accession No. MI0022577, SEQ ID NO: 438) is known to have a hairpin-like structure.

[0290] As used herein, the term "hsa-miR-371a-5p gene" or "hsa-miR-371a-5p" includes the hsa-miR-371a-5p gene described in SEQ ID NO: 161 (miRBase Accession No. MIMAT0004687) and homologs or orthologs in other biological species. The hsa-miR-371a-5p gene can be obtained by the method described in Suh MR et al., 2004, Dev Biol, Vol. 270, pp. 488-498. Furthermore, as a precursor of "hsa-miR-371a-5p", "hsa-mir-371a" (miRBase Accession No. MI0000779, SEQ ID NO: 439) is known to have a hairpin-like structure.

[0291] As used herein, the term "hsa-miR-6794-5p gene" or "hsa-miR-6794-5p" includes the hsa-miR-6794-5p gene described in SEQ ID NO: 162 (miRBase Accession No. MIMAT0027488) and homologs or orthologs in other species. The hsa-miR-6794-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6794-5p," "hsa-mir-6794" (miRBase Accession No. MI0022639, SEQ ID NO: 440) is known to have a hairpin-like structure.

[0292] As used herein, the term “hsa-miR-6779-5p gene” or “hsa-miR-6779-5p” includes the hsa-miR-6779-5p gene described in SEQ ID NO: 163 (miRBase Accession No. MIMAT0027458) and homologs or orthologs in other species. The hsa-miR-6779-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6779-5p,” “hsa-mir-6779” (miRBase Accession No. MI0022624, SEQ ID NO: 441) is known to have a hairpin-like structure.

[0293] As used herein, the term “hsa-miR-4271 gene” or “hsa-miR-4271” includes the hsa-miR-4271 gene described in SEQ ID NO: 164 (miRBase Accession No. MIMAT0016901) and homologs or orthologs in other biological species. The hsa-miR-4271 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, as a precursor of “hsa-miR-4271”, “hsa-mir-4271” (miRBase Accession No. MI0015879, SEQ ID NO: 442) is known to form a hairpin-like structure.

[0294] As used herein, the term "hsa-miR-5195-3p gene" or "hsa-miR-5195-3p" includes the hsa-miR-5195-3p gene described in SEQ ID NO: 165 (miRBase Accession No. MIMAT0021127) and homologs or orthologs in other species. The hsa-miR-5195-3p gene can be obtained by the method described in Schotte D et al., 2011, Leukemia, Vol. 25, pp. 1389-1399. Furthermore, as a precursor of "hsa-miR-5195-3p," "hsa-mir-5195" (miRBase Accession No. MI0018174, SEQ ID NO: 443) is known to have a hairpin-like structure.

[0295] As used herein, the term "hsa-miR-6762-5p gene" or "hsa-miR-6762-5p" includes the hsa-miR-6762-5p gene described in SEQ ID NO: 166 (miRBase Accession No. MIMAT0027424) and homologs or orthologs in other species. The hsa-miR-6762-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6762-5p," "hsa-mir-6762" (miRBase Accession No. MI0022607, SEQ ID NO: 444) is known to have a hairpin-like structure.

[0296] As used herein, the term "hsa-miR-939-5p gene" or "hsa-miR-939-5p" includes the hsa-miR-939-5p gene described in SEQ ID NO: 167 (miRBase Accession No. MIMAT0004982) and homologs or orthologs in other species. The hsa-miR-939-5p gene can be obtained by the method described in Lui WO et al., 2007, Cancer Res, Vol. 67, pp. 6031-6043. Furthermore, as a precursor of "hsa-miR-939-5p," "hsa-mir-939" (miRBase Accession No. MI0005761, SEQ ID NO: 445) is known to have a hairpin-like structure.

[0297] As used herein, the term “hsa-miR-1247-3p gene” or “hsa-miR-1247-3p” includes the hsa-miR-1247-3p gene described in SEQ ID NO: 168 (miRBase Accession No. MIMAT0022721) and homologs or orthologs in other biological species. The hsa-miR-1247-3p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, as a precursor of “hsa-miR-1247-3p”, “hsa-mir-1247” (miRBase Accession No. MI0006382, SEQ ID NO: 446) is known to have a hairpin-like structure.

[0298] As used herein, the term “hsa-miR-6777-5p gene” or “hsa-miR-6777-5p” includes the hsa-miR-6777-5p gene described in SEQ ID NO: 169 (miRBase Accession No. MIMAT0027454) and homologs or orthologs in other species. The hsa-miR-6777-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6777-5p,” “hsa-mir-6777” (miRBase Accession No. MI0022622, SEQ ID NO: 447) is known to have a hairpin-like structure.

[0299] As used herein, the term "hsa-miR-6722-3p gene" or "hsa-miR-6722-3p" includes the hsa-miR-6722-3p gene described in SEQ ID NO: 170 (miRBase Accession No. MIMAT0025854) and homologs or orthologs in other species. The hsa-miR-6722-3p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. Furthermore, as a precursor of "hsa-miR-6722-3p," "hsa-mir-6722" (miRBase Accession No. MI0022557, SEQ ID NO: 448) is known to have a hairpin-like structure.

[0300] As used herein, the term "hsa-miR-3656 gene" or "hsa-miR-3656" includes the hsa-miR-3656 gene described in SEQ ID NO: 171 (miRBase Accession No. MIMAT0018076) and homologs or orthologs in other species. The hsa-miR-3656 gene can be obtained by the method described in Meiri E et al., 2010, Nucleic Acids Res, Vol. 38, pp. 6234-6246. Furthermore, as a precursor of "hsa-miR-3656", "hsa-mir-3656" (miRBase Accession No. MI0016056, SEQ ID NO: 449) is known to have a hairpin-like structure.

[0301] As used herein, the term “hsa-miR-4688 gene” or “hsa-miR-4688” includes the hsa-miR-4688 gene described in SEQ ID NO: 172 (miRBase Accession No. MIMAT0019777) and homologs or orthologs in other species. The hsa-miR-4688 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of “hsa-miR-4688,” “hsa-mir-4688” (miRBase Accession No. MI0017321, SEQ ID NO: 450) is known to have a hairpin-like structure.

[0302] As used herein, the term “hsa-miR-3195 gene” or “hsa-miR-3195” includes the hsa-miR-3195 gene described in SEQ ID NO: 173 (miRBase Accession No. MIMAT0015079) and homologs or orthologs in other species. The hsa-miR-3195 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Furthermore, as a precursor of “hsa-miR-3195,” “hsa-mir-3195” (miRBase Accession No. MI0014240, SEQ ID NO: 451) is known to have a hairpin-like structure.

[0303] As used herein, the term "hsa-miR-6766-5p gene" or "hsa-miR-6766-5p" includes the hsa-miR-6766-5p gene described in SEQ ID NO: 174 (miRBase Accession No. MIMAT0027432) and homologs or orthologs in other species. The hsa-miR-6766-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6766-5p," "hsa-mir-6766" (miRBase Accession No. MI0022611, SEQ ID NO: 452) is known to have a hairpin-like structure.

[0304] As used herein, the term "hsa-miR-4447 gene" or "hsa-miR-4447" includes the hsa-miR-4447 gene described in SEQ ID NO: 175 (miRBase Accession No. MIMAT0018966) and homologs or orthologs in other species. The hsa-miR-4447 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4447", "hsa-mir-4447" (miRBase Accession No. MI0016790, SEQ ID NO: 453) is known to have a hairpin-like structure.

[0305] As used herein, the term “hsa-miR-4656 gene” or “hsa-miR-4656” includes the hsa-miR-4656 gene described in SEQ ID NO: 176 (miRBase Accession No. MIMAT0019723) and homologs or orthologs in other species. The hsa-miR-4656 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of “hsa-miR-4656,” “hsa-mir-4656” (miRBase Accession No. MI0017284, SEQ ID NO: 454) that forms a hairpin-like structure is known.

[0306] As used herein, the term "hsa-miR-7108-5p gene" or "hsa-miR-7108-5p" includes the hsa-miR-7108-5p gene described in SEQ ID NO: 177 (miRBase Accession No. MIMAT0028113) and homologs or orthologs in other species. The hsa-miR-7108-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-7108-5p", "hsa-mir-7108" (miRBase Accession No. MI0022959, SEQ ID NO: 455) is known to have a hairpin-like structure.

[0307] As used herein, the term “hsa-miR-3191-3p gene” or “hsa-miR-3191-3p” includes the hsa-miR-3191-3p gene described in SEQ ID NO: 178 (miRBase Accession No. MIMAT0015075) and homologs or orthologs in other species. The hsa-miR-3191-3p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Furthermore, as a precursor of “hsa-miR-3191-3p,” “hsa-mir-3191” (miRBase Accession No. MI0014236, SEQ ID NO: 456) is known to have a hairpin-like structure.

[0308] As used herein, the term “hsa-miR-1273g-3p gene” or “hsa-miR-1273g-3p” includes the hsa-miR-1273g-3p gene described in SEQ ID NO: 179 (miRBase Accession No. MIMAT0022742) and homologs or orthologs in other biological species. The hsa-miR-1273g-3p gene can be obtained by the method described in Reshmi G et al., 2011, Genomics, Vol. 97, pp. 333-340. In addition, as a precursor of “hsa-miR-1273g-3p”, “hsa-mir-1273g” (miRBase Accession No. MI0018003, SEQ ID NO: 457) is known to have a hairpin-like structure.

[0309] As used herein, the term "hsa-miR-4463 gene" or "hsa-miR-4463" includes the hsa-miR-4463 gene described in SEQ ID NO: 180 (miRBase Accession No. MIMAT0018987) and homologs or orthologs in other species. The hsa-miR-4463 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4463", "hsa-mir-4463" (miRBase Accession No. MI0016811, SEQ ID NO: 458) is known to have a hairpin-like structure.

[0310] As used herein, the term “hsa-miR-2861 gene” or “hsa-miR-2861” includes the hsa-miR-2861 gene described in SEQ ID NO: 181 (miRBase Accession No. MIMAT0013802) and homologs or orthologs in other species. The hsa-miR-2861 gene can be obtained by the method described in Li H et al., 2009, J Clin Invest, Vol. 119, pp. 3666-3677. Furthermore, as a precursor of “hsa-miR-2861,” “hsa-mir-2861” (miRBase Accession No. MI0013006, SEQ ID NO: 459) is known to have a hairpin-like structure.

[0311] As used herein, the term “hsa-miR-3196 gene” or “hsa-miR-3196” includes the hsa-miR-3196 gene described in SEQ ID NO: 182 (miRBase Accession No. MIMAT0015080) and homologs or orthologs in other species. The hsa-miR-3196 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Furthermore, as a precursor of “hsa-miR-3196,” “hsa-mir-3196” (miRBase Accession No. MI0014241, SEQ ID NO: 460) is known to have a hairpin-like structure.

[0312] As used herein, the term "hsa-miR-6877-5p gene" or "hsa-miR-6877-5p" includes the hsa-miR-6877-5p gene described in SEQ ID NO: 183 (miRBase Accession No. MIMAT0027654) and homologs or orthologs in other species. The hsa-miR-6877-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6877-5p", "hsa-mir-6877" (miRBase Accession No. MI0022724, SEQ ID NO: 461) is known to have a hairpin-like structure.

[0313] As used herein, the term "hsa-miR-3679-5p gene" or "hsa-miR-3679-5p" includes the hsa-miR-3679-5p gene described in SEQ ID NO: 184 (miRBase Accession No. MIMAT0018104) and homologs or orthologs in other species. The hsa-miR-3679-5p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. Furthermore, as a precursor of "hsa-miR-3679-5p," "hsa-mir-3679" (miRBase Accession No. MI0016080, SEQ ID NO: 462) is known to have a hairpin-like structure.

[0314] As used herein, the term "hsa-miR-4442 gene" or "hsa-miR-4442" includes the hsa-miR-4442 gene described in SEQ ID NO: 185 (miRBase Accession No. MIMAT0018960) and homologs or orthologs in other species. The hsa-miR-4442 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4442", "hsa-mir-4442" (miRBase Accession No. MI0016785, SEQ ID NO: 463) is known to have a hairpin-like structure.

[0315] As used herein, the term “hsa-miR-6789-5p gene” or “hsa-miR-6789-5p” includes the hsa-miR-6789-5p gene described in SEQ ID NO: 186 (miRBase Accession No. MIMAT0027478) and homologs or orthologs in other species. The hsa-miR-6789-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of “hsa-miR-6789-5p,” “hsa-mir-6789” (miRBase Accession No. MI0022634, SEQ ID NO: 464) is known to have a hairpin-like structure.

[0316] As used herein, the term "hsa-miR-6782-5p gene" or "hsa-miR-6782-5p" includes the hsa-miR-6782-5p gene described in SEQ ID NO: 187 (miRBase Accession No. MIMAT0027464) and homologs or orthologs in other species. The hsa-miR-6782-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6782-5p", "hsa-mir-6782" (miRBase Accession No. MI0022627, SEQ ID NO: 465) is known to have a hairpin-like structure.

[0317] As used herein, the term “hsa-miR-486-3p gene” or “hsa-miR-486-3p” includes the hsa-miR-486-3p gene described in SEQ ID NO: 188 (miRBase Accession No. MIMAT0004762) and homologs or orthologs in other species. The hsa-miR-486-3p gene can be obtained by the method described in Fu H et al., 2005, FEBS Lett, Vol. 579, pp. 3849-3854. Furthermore, as precursors of “hsa-miR-486-3p,” “hsa-mir-486, hsa-mir-486-2” (miRBase Accession Nos. MI0002470 and MI0023622, SEQ ID NOs. 466 and 467) are known.

[0318] As used herein, the term “hsa-miR-6085 gene” or “hsa-miR-6085” includes the hsa-miR-6085 gene described in SEQ ID NO: 189 (miRBase Accession No. MIMAT0023710) and homologs or orthologs in other species. The hsa-miR-6085 gene can be obtained by the method described in Voellenkle C et al., 2012, RNA, Vol. 18, pp. 472-484. Furthermore, as a precursor of “hsa-miR-6085,” “hsa-mir-6085” (miRBase Accession No. MI0020362, SEQ ID NO: 468) is known to have a hairpin-like structure.

[0319] As used herein, the term "hsa-miR-4746-3p gene" or "hsa-miR-4746-3p" includes the hsa-miR-4746-3p gene described in SEQ ID NO: 190 (miRBase Accession No. MIMAT0019881) and homologs or orthologs in other species. The hsa-miR-4746-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4746-3p", "hsa-mir-4746" (miRBase Accession No. MI0017385, SEQ ID NO: 469) is known to have a hairpin-like structure.

[0320] As used herein, the term "hsa-miR-619-5p gene" or "hsa-miR-619-5p" includes the hsa-miR-619-5p gene described in SEQ ID NO: 191 (miRBase Accession No. MIMAT0026622) and homologs or orthologs in other species. The hsa-miR-619-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Furthermore, as a precursor of "hsa-miR-619-5p", "hsa-mir-619" (miRBase Accession No. MI0003633, SEQ ID NO: 470) is known to have a hairpin-like structure.

[0321] As used herein, the term "hsa-miR-937-5p gene" or "hsa-miR-937-5p" includes the hsa-miR-937-5p gene described in SEQ ID NO: 192 (miRBase Accession No. MIMAT0022938) and homologs or orthologs in other species. The hsa-miR-937-5p gene can be obtained by the method described in Lui WO et al., 2007, Cancer Res, Vol. 67, pp. 6031-6043. Furthermore, as a precursor of "hsa-miR-937-5p", "hsa-mir-937" (miRBase Accession No. MI0005759, SEQ ID NO: 471) is known to have a hairpin-like structure.

[0322] As used herein, the term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" includes the hsa-miR-6803-5p gene described in SEQ ID NO: 193 (miRBase Accession No. MIMAT0027506) and homologs or orthologs in other species. The hsa-miR-6803-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6803-5p", "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 472) is known to have a hairpin-like structure.

[0323] As used herein, the term “hsa-miR-4298 gene” or “hsa-miR-4298” includes the hsa-miR-4298 gene described in SEQ ID NO: 194 (miRBase Accession No. MIMAT0016852) and homologs or orthologs in other species. The hsa-miR-4298 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, as a precursor of “hsa-miR-4298”, “hsa-mir-4298” (miRBase Accession No. MI0015830, SEQ ID NO: 473) is known to have a hairpin-like structure.

[0324] As used herein, the term "hsa-miR-4454 gene" or "hsa-miR-4454" includes the hsa-miR-4454 gene described in SEQ ID NO: 195 (miRBase Accession No. MIMAT0018976) and homologs or orthologs in other species. The hsa-miR-4454 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4454," "hsa-mir-4454" (miRBase Accession No. MI0016800, SEQ ID NO: 474) is known to have a hairpin-like structure.

[0325] As used herein, the term "hsa-miR-4459 gene" or "hsa-miR-4459" includes the hsa-miR-4459 gene described in SEQ ID NO: 196 (miRBase Accession No. MIMAT0018981) and homologs or orthologs in other species. The hsa-miR-4459 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4459", "hsa-mir-4459" (miRBase Accession No. MI0016805, SEQ ID NO: 475) is known to have a hairpin-like structure.

[0326] As used herein, the term “hsa-miR-7150 gene” or “hsa-miR-7150” includes the hsa-miR-7150 gene described in SEQ ID NO: 197 (miRBase Accession No. MIMAT0028211) and homologs or orthologs in other species. The hsa-miR-7150 gene can be obtained by the method described in Oulas A et al., 2009, Nucleic Acids Res, Vol. 37, pp. 3276-3287. Furthermore, as a precursor of “hsa-miR-7150,” “hsa-mir-7150” (miRBase Accession No. MI0023610, SEQ ID NO: 476) is known to have a hairpin-like structure.

[0327] As used herein, the term "hsa-miR-6880-5p gene" or "hsa-miR-6880-5p" includes the hsa-miR-6880-5p gene described in SEQ ID NO: 198 (miRBase Accession No. MIMAT0027660) and homologs or orthologs in other species. The hsa-miR-6880-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6880-5p", "hsa-mir-6880" (miRBase Accession No. MI0022727, SEQ ID NO: 477) is known to have a hairpin-like structure.

[0328] As used herein, the term "hsa-miR-4449 gene" or "hsa-miR-4449" includes the hsa-miR-4449 gene described in SEQ ID NO: 199 (miRBase Accession No. MIMAT0018968) and homologs or orthologs in other species. The hsa-miR-4449 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4449", "hsa-mir-4449" (miRBase Accession No. MI0016792, SEQ ID NO: 478) is known to have a hairpin-like structure.

[0329] As used herein, the term “hsa-miR-8063 gene” or “hsa-miR-8063” includes the hsa-miR-8063 gene described in SEQ ID NO: 200 (miRBase Accession No. MIMAT0030990) and homologs or orthologs in other species. The hsa-miR-8063 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, as a precursor of “hsa-miR-8063,” “hsa-mir-8063” (miRBase Accession No. MI0025899, SEQ ID NO: 479) is known to form a hairpin-like structure.

[0330] As used herein, the term "hsa-miR-4695-5p gene" or "hsa-miR-4695-5p" includes the hsa-miR-4695-5p gene described in SEQ ID NO: 201 (miRBase Accession No. MIMAT0019788) and homologs or orthologs in other species. The hsa-miR-4695-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4695-5p", "hsa-mir-4695" (miRBase Accession No. MI0017328, SEQ ID NO: 480) is known to have a hairpin-like structure.

[0331] As used herein, the term "hsa-miR-6132 gene" or "hsa-miR-6132" includes the hsa-miR-6132 gene described in SEQ ID NO: 202 (miRBase Accession No. MIMAT0024616) and homologs or orthologs in other species. The hsa-miR-6132 gene can be obtained by the method described in Dannemann M et al., 2012, Genome Biol Evol, 4, pp. 552-564. Furthermore, as a precursor of "hsa-miR-6132," "hsa-mir-6132" (miRBase Accession No. MI0021277, SEQ ID NO: 481) is known to have a hairpin-like structure.

[0332] As used herein, the term "hsa-miR-6829-5p gene" or "hsa-miR-6829-5p" includes the hsa-miR-6829-5p gene described in SEQ ID NO: 203 (miRBase Accession No. MIMAT0027558) and homologs or orthologs in other species. The hsa-miR-6829-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6829-5p," "hsa-mir-6829" (miRBase Accession No. MI0022674, SEQ ID NO: 482) is known to have a hairpin-like structure.

[0333] As used herein, the term "hsa-miR-4486 gene" or "hsa-miR-4486" includes the hsa-miR-4486 gene described in SEQ ID NO: 204 (miRBase Accession No. MIMAT0019020) and homologs or orthologs in other species. The hsa-miR-4486 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4486", "hsa-mir-4486" (miRBase Accession No. MI0016847, SEQ ID NO: 483) is known to have a hairpin-like structure.

[0334] As used herein, the term "hsa-miR-6805-3p gene" or "hsa-miR-6805-3p" includes the hsa-miR-6805-3p gene described in SEQ ID NO: 205 (miRBase Accession No. MIMAT0027511) and homologs or orthologs in other species. The hsa-miR-6805-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6805-3p", "hsa-mir-6805" (miRBase Accession No. MI0022650, SEQ ID NO: 304) is known to have a hairpin-like structure.

[0335] As used herein, the term "hsa-miR-6826-5p gene" or "hsa-miR-6826-5p" includes the hsa-miR-6826-5p gene described in SEQ ID NO: 206 (miRBase Accession No. MIMAT0027552) and homologs or orthologs in other species. The hsa-miR-6826-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6826-5p," "hsa-mir-6826" (miRBase Accession No. MI0022671, SEQ ID NO: 484) is known to have a hairpin-like structure.

[0336] As used herein, the term "hsa-miR-4508 gene" or "hsa-miR-4508" includes the hsa-miR-4508 gene described in SEQ ID NO: 207 (miRBase Accession No. MIMAT0019045) and homologs or orthologs in other species. The hsa-miR-4508 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4508," "hsa-mir-4508" (miRBase Accession No. MI0016872, SEQ ID NO: 485) is known to have a hairpin-like structure.

[0337] As used herein, the term "hsa-miR-1343-5p gene" or "hsa-miR-1343-5p" includes the hsa-miR-1343-5p gene described in SEQ ID NO: 208 (miRBase Accession No. MIMAT0027038) and homologs or orthologs in other species. The hsa-miR-1343-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-1343-5p", "hsa-mir-1343" (miRBase Accession No. MI0017320, SEQ ID NO: 361) is known to have a hairpin-like structure.

[0338] As used herein, the term "hsa-miR-7114-5p gene" or "hsa-miR-7114-5p" includes the hsa-miR-7114-5p gene described in SEQ ID NO: 209 (miRBase Accession No. MIMAT0028125) and homologs or orthologs in other species. The hsa-miR-7114-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-7114-5p", "hsa-mir-7114" (miRBase Accession No. MI0022965, SEQ ID NO: 486) is known to have a hairpin-like structure.

[0339] As used herein, the term “hsa-miR-3622a-5p gene” or “hsa-miR-3622a-5p” includes the hsa-miR-3622a-5p gene described in SEQ ID NO: 210 (miRBase Accession No. MIMAT0018003) and homologs or orthologs in other biological species. The hsa-miR-3622a-5p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p58. Furthermore, as a precursor of “hsa-miR-3622a-5p,” “hsa-mir-3622a” (miRBase Accession No. MI0016013, SEQ ID NO: 487) is known to have a hairpin-like structure.

[0340] As used herein, the term "hsa-miR-6765-5p gene" or "hsa-miR-6765-5p" includes the hsa-miR-6765-5p gene described in SEQ ID NO: 211 (miRBase Accession No. MIMAT0027430) and homologs or orthologs in other species. The hsa-miR-6765-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6765-5p," "hsa-mir-6765" (miRBase Accession No. MI0022610, SEQ ID NO: 488) is known to have a hairpin-like structure.

[0341] As used herein, the term "hsa-miR-7845-5p gene" or "hsa-miR-7845-5p" includes the hsa-miR-7845-5p gene described in SEQ ID NO: 212 (miRBase Accession No. MIMAT0030420) and homologs or orthologs in other species. The hsa-miR-7845-5p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. Furthermore, as a precursor of "hsa-miR-7845-5p," "hsa-mir-7845" (miRBase Accession No. MI0025515, SEQ ID NO: 489) is known to have a hairpin-like structure.

[0342] As used herein, the term "hsa-miR-3960 gene" or "hsa-miR-3960" includes the hsa-miR-3960 gene described in SEQ ID NO: 213 (miRBase Accession No. MIMAT0019337) and homologs or orthologs in other species. The hsa-miR-3960 gene can be obtained by the method described in Hu R et al., 2011, J Biol Chem, Vol. 286, pp. 12328-12339. Furthermore, as a precursor of "hsa-miR-3960," "hsa-mir-3960" (miRBase Accession No. MI0016964, SEQ ID NO: 490) is known to have a hairpin-like structure.

[0343] As used herein, the term "hsa-miR-6749-5p gene" or "hsa-miR-6749-5p" includes the hsa-miR-6749-5p gene described in SEQ ID NO: 214 (miRBase Accession No. MIMAT0027398) and homologs or orthologs in other species. The hsa-miR-6749-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6749-5p," "hsa-mir-6749" (miRBase Accession No. MI0022594, SEQ ID NO: 491) is known to have a hairpin-like structure.

[0344] As used herein, the term “hsa-miR-1260b gene” or “hsa-miR-1260b” includes the hsa-miR-1260b gene described in SEQ ID NO: 215 (miRBase Accession No. MIMAT0015041) and homologs or orthologs in other species. The hsa-miR-1260b gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, as a precursor of “hsa-miR-1260b”, “hsa-mir-1260b” (miRBase Accession No. MI0014197, SEQ ID NO: 492) is known to have a hairpin-like structure.

[0345] As used herein, the term "hsa-miR-6799-5p gene" or "hsa-miR-6799-5p" includes the hsa-miR-6799-5p gene described in SEQ ID NO: 216 (miRBase Accession No. MIMAT0027498) and homologs or orthologs in other species. The hsa-miR-6799-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6799-5p", "hsa-mir-6799" (miRBase Accession No. MI0022644, SEQ ID NO: 493) is known to have a hairpin-like structure.

[0346] As used herein, the term "hsa-miR-4723-5p gene" or "hsa-miR-4723-5p" includes the hsa-miR-4723-5p gene described in SEQ ID NO: 217 (miRBase Accession No. MIMAT0019838) and homologs or orthologs in other species. The hsa-miR-4723-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4723-5p", "hsa-mir-4723" (miRBase Accession No. MI0017359, SEQ ID NO: 494) is known to have a hairpin-like structure.

[0347] As used herein, the term "hsa-miR-6784-5p gene" or "hsa-miR-6784-5p" includes the hsa-miR-6784-5p gene described in SEQ ID NO: 218 (miRBase Accession No. MIMAT0027468) and homologs or orthologs in other species. The hsa-miR-6784-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6784-5p," "hsa-mir-6784" (miRBase Accession No. MI0022629, SEQ ID NO: 495) is known to have a hairpin-like structure.

[0348] As used herein, the term "hsa-miR-5100 gene" or "hsa-miR-5100" includes the hsa-miR-5100 gene described in SEQ ID NO: 219 (miRBase Accession No. MIMAT0022259) and homologs or orthologs in other species. The hsa-miR-5100 gene can be obtained by the method described in Tandon M et al., 2012, Oral Dis, Vol. 18, pp. 127-131. Furthermore, as a precursor of "hsa-miR-5100," "hsa-mir-5100" (miRBase Accession No. MI0019116, SEQ ID NO: 496) is known to have a hairpin-like structure.

[0349] As used herein, the term "hsa-miR-6769b-5p gene" or "hsa-miR-6769b-5p" includes the hsa-miR-6769b-5p gene described in SEQ ID NO: 220 (miRBase Accession No. MIMAT0027620) and homologs or orthologs in other species. The hsa-miR-6769b-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6769b-5p", "hsa-mir-6769b" (miRBase Accession No. MI0022706, SEQ ID NO: 497) is known to have a hairpin-like structure.

[0350] As used herein, the term “hsa-miR-1207-5p gene” or “hsa-miR-1207-5p” includes the hsa-miR-1207-5p gene described in SEQ ID NO: 221 (miRBase Accession No. MIMAT0005871) and homologs or orthologs in other biological species. The hsa-miR-1207-5p gene can be obtained by the method described in Huppi K et al., 2008, Mol Cancer Res, Vol. 6, pp. 212-221. In addition, as a precursor of “hsa-miR-1207-5p”, “hsa-mir-1207” (miRBase Accession No. MI0006340, SEQ ID NO: 498) is known to have a hairpin-like structure.

[0351] As used herein, the term "hsa-miR-642a-3p gene" or "hsa-miR-642a-3p" includes the hsa-miR-642a-3p gene described in SEQ ID NO: 222 (miRBase Accession No. MIMAT0020924) and homologs or orthologs in other species. The hsa-miR-642a-3p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Furthermore, as a precursor of "hsa-miR-642a-3p", "hsa-mir-642a" (miRBase Accession No. MI0003657, SEQ ID NO: 499) is known to have a hairpin-like structure.

[0352] As used herein, the term "hsa-miR-4505 gene" or "hsa-miR-4505" includes the hsa-miR-4505 gene described in SEQ ID NO: 223 (miRBase Accession No. MIMAT0019041) and homologs or orthologs in other species. The hsa-miR-4505 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4505," "hsa-mir-4505" (miRBase Accession No. MI0016868, SEQ ID NO: 500) is known to have a hairpin-like structure.

[0353] As used herein, the term “hsa-miR-4270 gene” or “hsa-miR-4270” includes the hsa-miR-4270 gene described in SEQ ID NO: 224 (miRBase Accession No. MIMAT0016900) and homologs or orthologs in other biological species. The hsa-miR-4270 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, as a precursor of “hsa-miR-4270”, “hsa-mir-4270” (miRBase Accession No. MI0015878, SEQ ID NO: 501) is known to have a hairpin-like structure.

[0354] As used herein, the term "hsa-miR-6721-5p gene" or "hsa-miR-6721-5p" includes the hsa-miR-6721-5p gene described in SEQ ID NO: 225 (miRBase Accession No. MIMAT0025852) and homologs or orthologs in other species. The hsa-miR-6721-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. Furthermore, as a precursor of "hsa-miR-6721-5p," "hsa-mir-6721" (miRBase Accession No. MI0022556, SEQ ID NO: 502) is known to have a hairpin-like structure.

[0355] As used herein, the term "hsa-miR-7111-5p gene" or "hsa-miR-7111-5p" includes the hsa-miR-7111-5p gene described in SEQ ID NO: 226 (miRBase Accession No. MIMAT0028119) and homologs or orthologs in other species. The hsa-miR-7111-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-7111-5p", "hsa-mir-7111" (miRBase Accession No. MI0022962, SEQ ID NO: 503) is known to have a hairpin-like structure.

[0356] As used herein, the term "hsa-miR-6791-5p gene" or "hsa-miR-6791-5p" includes the hsa-miR-6791-5p gene described in SEQ ID NO: 227 (miRBase Accession No. MIMAT0027482) and homologs or orthologs in other species. The hsa-miR-6791-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6791-5p," "hsa-mir-6791" (miRBase Accession No. MI0022636, SEQ ID NO: 504) is known to have a hairpin-like structure.

[0357] As used herein, the term "hsa-miR-7109-5p gene" or "hsa-miR-7109-5p" includes the hsa-miR-7109-5p gene described in SEQ ID NO: 228 (miRBase Accession No. MIMAT0028115) and homologs or orthologs in other species. The hsa-miR-7109-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-7109-5p", "hsa-mir-7109" (miRBase Accession No. MI0022960, SEQ ID NO: 505) is known to have a hairpin-like structure.

[0358] As used herein, the term “hsa-miR-4258 gene” or “hsa-miR-4258” includes the hsa-miR-4258 gene described in SEQ ID NO: 229 (miRBase Accession No. MIMAT0016879) and homologs or orthologs in other biological species. The hsa-miR-4258 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, as a precursor of “hsa-miR-4258”, “hsa-mir-4258” (miRBase Accession No. MI0015857, SEQ ID NO: 506) is known to have a hairpin-like structure.

[0359] As used herein, the term "hsa-miR-6515-3p gene" or "hsa-miR-6515-3p" includes the hsa-miR-6515-3p gene described in SEQ ID NO: 230 (miRBase Accession No. MIMAT0025487) and homologs or orthologs in other species. The hsa-miR-6515-3p gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet, Vol. 20, pp. 4025-4040. Furthermore, as a precursor of "hsa-miR-6515-3p", "hsa-mir-6515" (miRBase Accession No. MI0022227, SEQ ID NO: 507) is known to have a hairpin-like structure.

[0360] As used herein, the term "hsa-miR-6851-5p gene" or "hsa-miR-6851-5p" includes the hsa-miR-6851-5p gene described in SEQ ID NO: 231 (miRBase Accession No. MIMAT0027602) and homologs or orthologs in other species. The hsa-miR-6851-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6851-5p," "hsa-mir-6851" (miRBase Accession No. MI0022697, SEQ ID NO: 508) is known to have a hairpin-like structure.

[0361] As used herein, the term “hsa-miR-6125 gene” or “hsa-miR-6125” includes the hsa-miR-6125 gene described in SEQ ID NO: 232 (miRBase Accession No. MIMAT0024598) and homologs or orthologs in other species. The hsa-miR-6125 gene can be obtained by the method described in Smith JL et al., 2012, J Virol, Vol. 86, pp. 5278-5287. Furthermore, as a precursor of “hsa-miR-6125,” “hsa-mir-6125” (miRBase Accession No. MI0021259, SEQ ID NO: 509) is known to have a hairpin-like structure.

[0362] As used herein, the term "hsa-miR-4749-5p gene" or "hsa-miR-4749-5p" includes the hsa-miR-4749-5p gene described in SEQ ID NO: 233 (miRBase Accession No. MIMAT0019885) and homologs or orthologs in other species. The hsa-miR-4749-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4749-5p", "hsa-mir-4749" (miRBase Accession No. MI0017388, SEQ ID NO: 510) is known to have a hairpin-like structure.

[0363] As used herein, the term "hsa-miR-4726-5p gene" or "hsa-miR-4726-5p" includes the hsa-miR-4726-5p gene described in SEQ ID NO: 234 (miRBase Accession No. MIMAT0019845) and homologs or orthologs in other species. The hsa-miR-4726-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4726-5p", "hsa-mir-4726" (miRBase Accession No. MI0017363, SEQ ID NO: 511) is known to have a hairpin-like structure.

[0364] As used herein, the term "hsa-miR-4513 gene" or "hsa-miR-4513" includes the hsa-miR-4513 gene described in SEQ ID NO: 235 (miRBase Accession No. MIMAT0019050) and homologs or orthologs in other species. The hsa-miR-4513 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4513," "hsa-mir-4513" (miRBase Accession No. MI0016879, SEQ ID NO: 512) is known to have a hairpin-like structure.

[0365] As used herein, the term "hsa-miR-760 gene" or "hsa-miR-760" includes the hsa-miR-760 gene described in SEQ ID NO: 236 (miRBase Accession No. MIMAT0004957) and homologs or orthologs in other species. The hsa-miR-760 gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, as a precursor of "hsa-miR-760", "hsa-mir-760" (miRBase Accession No. MI0005567, SEQ ID NO: 513) is known to have a hairpin-like structure.

[0366] As used herein, the term "hsa-miR-602 gene" or "hsa-miR-602" includes the hsa-miR-602 gene described in SEQ ID NO: 237 (miRBase Accession No. MIMAT0003270) and homologs or orthologs in other species. The hsa-miR-602 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, p3687-3692. In addition, as a precursor of "hsa-miR-602", "hsa-mir-602" (miRBase Accession No. MI0003615, SEQ ID NO: 514) is known to have a hairpin-like structure.

[0367] As used herein, the term “hsa-miR-423-5p gene” or “hsa-miR-423-5p” includes the hsa-miR-423-5p gene described in SEQ ID NO: 238 (miRBase Accession No. MIMAT0004748) and homologs or orthologs in other biological species. The hsa-miR-423-5p gene can be obtained by the method described in Kasashima K et al., 2004, Biochem Biophys Res Commun, Vol. 322, pp. 403-410. In addition, as a precursor of “hsa-miR-423-5p”, “hsa-mir-423” (miRBase Accession No. MI0001445, SEQ ID NO: 515) is known to have a hairpin-like structure.

[0368] As used herein, the term "hsa-miR-92a-2-5p gene" or "hsa-miR-92a-2-5p" includes the hsa-miR-92a-2-5p gene described in SEQ ID NO: 239 (miRBase Accession No. MIMAT0004508) and homologs or orthologs in other biological species. The hsa-miR-92a-2-5p gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev, Vol. 16, pp. 720-728. In addition, as a precursor of "hsa-miR-92a-2-5p", "hsa-mir-92a-2" (miRBase Accession No. MI0000094, SEQ ID NO: 516) is known to have a hairpin-like structure.

[0369] As used herein, the term "hsa-miR-16-5p gene" or "hsa-miR-16-5p" includes the hsa-miR-16-5p gene described in SEQ ID NO: 240 (miRBase Accession No. MIMAT0000069) and homologs or orthologs in other species. The hsa-miR-16-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, Vol. 294, pp. 853-858. Furthermore, as precursors of "hsa-miR-16-5p," "hsa-mir-16-1 and hsa-mir-16-2" (miRBase Accession Nos. MI0000070 and MI0000115, SEQ ID NOs: 517 and 518) are known.

[0370] As used herein, the term "hsa-miR-451a gene" or "hsa-miR-451a" includes the hsa-miR-451a gene described in SEQ ID NO: 241 (miRBase Accession No. MIMAT0001631) and homologs or orthologs in other species. The hsa-miR-451a gene can be obtained by the method described in Altuvia Y et al., 2005, Nucleic Acids Res, Vol. 33, pp. 2697-2706. In addition, as a precursor of "hsa-miR-451a", "hsa-mir-451a" (miRBase Accession No. MI0001729, SEQ ID NO: 519) is known to have a hairpin-like structure.

[0371] As used herein, the term "hsa-miR-135a-3p gene" or "hsa-miR-135a-3p" includes the hsa-miR-135a-3p gene described in SEQ ID NO: 242 (miRBase Accession No. MIMAT0004595) and homologs or orthologs in other species. The hsa-miR-135a-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. Furthermore, as a precursor of "hsa-miR-135a-3p", "hsa-mir-135a" (miRBase Accession No. MI0000452, SEQ ID NO: 520) is known to have a hairpin-like structure.

[0372] As used herein, the term "hsa-miR-486-5p gene" or "hsa-miR-486-5p" includes the hsa-miR-486-5p gene described in SEQ ID NO: 243 (miRBase Accession No. MIMAT0002177) and homologs or orthologs in other species. The hsa-miR-486-5p gene can be obtained by the method described in Fu H et al., 2005, FEBS Lett, Vol. 579, pp. 3849-3854. Furthermore, as precursors of "hsa-miR-486-5p", "hsa-mir-486, hsa-mir-486-2" (miRBase Accession Nos. MI0002470, MI0023622, SEQ ID NOs. 466, 467) are known.

[0373] As used herein, the term “hsa-miR-4257 gene” or “hsa-miR-4257” includes the hsa-miR-4257 gene described in SEQ ID NO: 244 (miRBase Accession No. MIMAT0016878) and homologs or orthologs in other species. The hsa-miR-4257 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, as a precursor of “hsa-miR-4257”, “hsa-mir-4257” (miRBase Accession No. MI0015856, SEQ ID NO: 521) is known to have a hairpin-like structure.

[0374] As used herein, the term "hsa-miR-92b-5p gene" or "hsa-miR-92b-5p" includes the hsa-miR-92b-5p gene described in SEQ ID NO: 245 (miRBase Accession No. MIMAT0004792) and homologs or orthologs in other species. The hsa-miR-92b-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Furthermore, as a precursor of "hsa-miR-92b-5p", "hsa-mir-92b" (miRBase Accession No. MI0003560, SEQ ID NO: 522) is known to have a hairpin-like structure.

[0375] As used herein, the term "hsa-miR-1915-3p gene" or "hsa-miR-1915-3p" includes the hsa-miR-1915-3p gene described in SEQ ID NO: 246 (miRBase Accession No. MIMAT0007892) and homologs or orthologs in other biological species. The hsa-miR-1915-3p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. Furthermore, as a precursor of "hsa-miR-1915-3p", "hsa-mir-1915" (miRBase Accession No. MI0008336, SEQ ID NO: 339) is known to have a hairpin-like structure.

[0376] As used herein, the term “hsa-miR-718 gene” or “hsa-miR-718” includes the hsa-miR-718 gene described in SEQ ID NO: 247 (miRBase Accession No. MIMAT0012735) and homologs or orthologs in other biological species. The hsa-miR-718 gene can be obtained by the method described in Artzi S et al., 2008, BMC Bioinformatics, Vol. 9, p39. In addition, as a precursor of “hsa-miR-718”, “hsa-mir-718” (miRBase Accession No. MI0012489, SEQ ID NO: 523) is known to have a hairpin-like structure.

[0377] As used herein, the term "hsa-miR-940 gene" or "hsa-miR-940" includes the hsa-miR-940 gene described in SEQ ID NO: 248 (miRBase Accession No. MIMAT0004983) and homologs or orthologs in other species. The hsa-miR-940 gene can be obtained by the method described in Lui WO et al., 2007, Cancer Res, Vol. 67, pp. 6031-6043. Furthermore, as a precursor of "hsa-miR-940," "hsa-mir-940" (miRBase Accession No. MI0005762, SEQ ID NO: 524) is known to have a hairpin-like structure.

[0378] As used herein, the term "hsa-miR-296-5p gene" or "hsa-miR-296-5p" includes the hsa-miR-296-5p gene described in SEQ ID NO: 249 (miRBase Accession No. MIMAT0000690) and homologs or orthologs in other species. The hsa-miR-296-5p gene can be obtained by the method described in Houbaviy HB et al., 2003, Dev Cell, Vol. 5, pp. 351-358. Furthermore, as a precursor of "hsa-miR-296-5p," "hsa-mir-296" (miRBase Accession No. MI0000747, SEQ ID NO: 409) is known to have a hairpin-like structure.

[0379] As used herein, the term "hsa-miR-23b-3p gene" or "hsa-miR-23b-3p" includes the hsa-miR-23b-3p gene described in SEQ ID NO: 250 (miRBase Accession No. MIMAT0000418) and homologs or orthologs in other species. The hsa-miR-23b-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. Furthermore, as a precursor of "hsa-miR-23b-3p", "hsa-mir-23b" (miRBase Accession No. MI0000439, SEQ ID NO: 525) is known to have a hairpin-like structure.

[0380] As used herein, the term "hsa-miR-92a-3p gene" or "hsa-miR-92a-3p" includes the hsa-miR-92a-3p gene described in SEQ ID NO: 251 (miRBase Accession No. MIMAT0000092) and homologs or orthologs in other species. The hsa-miR-92a-3p gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev, Vol. 16, pp. 720-728. Furthermore, as precursors of "hsa-miR-92a-3p", "hsa-mir-92a-1, hsa-mir-92a-2" (miRBase Accession Nos. MI0000093, MI0000094, SEQ ID NOs: 526, 527) are known as hairpin-like structure precursors.

[0381] As used herein, the term "hsa-miR-658 gene" or "hsa-miR-658" includes the hsa-miR-658 gene described in SEQ ID NO: 252 (miRBase Accession No. MIMAT0003336) and homologs or orthologs in other species. The hsa-miR-658 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Furthermore, as a precursor of "hsa-miR-658", "hsa-mir-658" (miRBase Accession No. MI0003682, SEQ ID NO: 528) is known to have a hairpin-like structure.

[0382] As used herein, the term "hsa-miR-6842-5p gene" or "hsa-miR-6842-5p" includes the hsa-miR-6842-5p gene described in SEQ ID NO: 253 (miRBase Accession No. MIMAT0027586) and homologs or orthologs in other species. The hsa-miR-6842-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6842-5p", "hsa-mir-6842" (miRBase Accession No. MI0022688, SEQ ID NO: 529) is known to have a hairpin-like structure.

[0383] As used herein, the term "hsa-miR-6124 gene" or "hsa-miR-6124" includes the hsa-miR-6124 gene described in SEQ ID NO: 254 (miRBase Accession No. MIMAT0024597) and homologs or orthologs in other species. The hsa-miR-6124 gene can be obtained by the method described in Smith JL et al., 2012, J Virol, Vol. 86, pp. 5278-5287. Furthermore, as a precursor of "hsa-miR-6124," "hsa-mir-6124" (miRBase Accession No. MI0021258, SEQ ID NO: 530) is known to have a hairpin-like structure.

[0384] As used herein, the term "hsa-miR-6765-3p gene" or "hsa-miR-6765-3p" includes the hsa-miR-6765-3p gene described in SEQ ID NO: 255 (miRBase Accession No. MIMAT0027431) and homologs or orthologs in other species. The hsa-miR-6765-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6765-3p," "hsa-mir-6765" (miRBase Accession No. MI0022610, SEQ ID NO: 531) is known to have a hairpin-like structure.

[0385] As used herein, the term "hsa-miR-7106-5p gene" or "hsa-miR-7106-5p" includes the hsa-miR-7106-5p gene described in SEQ ID NO: 256 (miRBase Accession No. MIMAT0028109) and homologs or orthologs in other species. The hsa-miR-7106-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-7106-5p", "hsa-mir-7106" (miRBase Accession No. MI0022957, SEQ ID NO: 532) is known to have a hairpin-like structure.

[0386] As used herein, the term "hsa-miR-4534 gene" or "hsa-miR-4534" includes the hsa-miR-4534 gene described in SEQ ID NO: 257 (miRBase Accession No. MIMAT0019073) and homologs or orthologs in other species. The hsa-miR-4534 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4534," "hsa-mir-4534" (miRBase Accession No. MI0016901, SEQ ID NO: 533) is known to have a hairpin-like structure.

[0387] As used herein, the term "hsa-miR-92b-3p gene" or "hsa-miR-92b-3p" includes the hsa-miR-92b-3p gene described in SEQ ID NO: 258 (miRBase Accession No. MIMAT0003218) and homologs or orthologs in other species. The hsa-miR-92b-3p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Furthermore, as a precursor of "hsa-miR-92b-3p", "hsa-mir-92b" (miRBase Accession No. MI0003560, SEQ ID NO: 522) is known to have a hairpin-like structure.

[0388] As used herein, the term "hsa-miR-3135b gene" or "hsa-miR-3135b" includes the hsa-miR-3135b gene described in SEQ ID NO: 259 (miRBase Accession No. MIMAT0018985) and homologs or orthologs in other species. The hsa-miR-3135b gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-3135b", "hsa-mir-3135b" (miRBase Accession No. MI0016809, SEQ ID NO: 534) is known to have a hairpin-like structure.

[0389] As used herein, the term "hsa-miR-4687-3p gene" or "hsa-miR-4687-3p" includes the hsa-miR-4687-3p gene described in SEQ ID NO: 260 (miRBase Accession No. MIMAT0019775) and homologs or orthologs in other species. The hsa-miR-4687-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, as a precursor of "hsa-miR-4687-3p", "hsa-mir-4687" (miRBase Accession No. MI0017319, SEQ ID NO: 535) is known to have a hairpin-like structure.

[0390] As used herein, the term "hsa-miR-762 gene" or "hsa-miR-762" includes the hsa-miR-762 gene described in SEQ ID NO: 261 (miRBase Accession No. MIMAT0010313) and homologs or orthologs in other species. The hsa-miR-762 gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, as a precursor of "hsa-miR-762", "hsa-mir-762" (miRBase Accession No. MI0003892, SEQ ID NO: 536) is known to have a hairpin-like structure.

[0391] As used herein, the term "hsa-miR-3619-3p gene" or "hsa-miR-3619-3p" includes the hsa-miR-3619-3p gene described in SEQ ID NO: 262 (miRBase Accession No. MIMAT0019219) and homologs or orthologs in other biological species. The hsa-miR-3619-3p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p58. Furthermore, as a precursor of "hsa-miR-3619-3p", "hsa-mir-3619" (miRBase Accession No. MI0016009, SEQ ID NO: 537) is known to have a hairpin-like structure.

[0392] As used herein, the term "hsa-miR-4467 gene" or "hsa-miR-4467" includes the hsa-miR-4467 gene described in SEQ ID NO: 263 (miRBase Accession No. MIMAT0018994) and homologs or orthologs in other species. The hsa-miR-4467 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4467", "hsa-mir-4467" (miRBase Accession No. MI0016818, SEQ ID NO: 538) is known to have a hairpin-like structure.

[0393] As used herein, the term "hsa-miR-557 gene" or "hsa-miR-557" includes the hsa-miR-557 gene described in SEQ ID NO: 264 (miRBase Accession No. MIMAT0003221) and homologs or orthologs in other species. The hsa-miR-557 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Furthermore, as a precursor of "hsa-miR-557", "hsa-mir-557" (miRBase Accession No. MI0003563, SEQ ID NO: 539) is known to have a hairpin-like structure.

[0394] As used herein, the term "hsa-miR-1237-5p gene" or "hsa-miR-1237-5p" includes the hsa-miR-1237-5p gene described in SEQ ID NO: 265 (miRBase Accession No. MIMAT0022946) and homologs or orthologs in other species. The hsa-miR-1237-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Furthermore, as a precursor of "hsa-miR-1237-5p", "hsa-mir-1237" (miRBase Accession No. MI0006327, SEQ ID NO: 540) is known to have a hairpin-like structure.

[0395] As used herein, the term “hsa-miR-1908-5p gene” or “hsa-miR-1908-5p” includes the hsa-miR-1908-5p gene described in SEQ ID NO: 266 (miRBase Accession No. MIMAT0007881) and homologs or orthologs in other biological species. The hsa-miR-1908-5p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. In addition, as a precursor of “hsa-miR-1908-5p”, “hsa-mir-1908” (miRBase Accession No. MI0008329, SEQ ID NO: 541) is known to have a hairpin-like structure.

[0396] As used herein, the term “hsa-miR-4286 gene” or “hsa-miR-4286” includes the hsa-miR-4286 gene described in SEQ ID NO: 267 (miRBase Accession No. MIMAT0016916) and homologs or orthologs in other species. The hsa-miR-4286 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, as a precursor of “hsa-miR-4286”, “hsa-mir-4286” (miRBase Accession No. MI0015894, SEQ ID NO: 542) is known to have a hairpin-like structure.

[0397] As used herein, the term "hsa-miR-6885-5p gene" or "hsa-miR-6885-5p" includes the hsa-miR-6885-5p gene described in SEQ ID NO: 268 (miRBase Accession No. MIMAT0027670) and homologs or orthologs in other species. The hsa-miR-6885-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6885-5p," "hsa-mir-6885" (miRBase Accession No. MI0022732, SEQ ID NO: 543) is known to have a hairpin-like structure.

[0398] As used herein, the term "hsa-miR-6763-5p gene" or "hsa-miR-6763-5p" includes the hsa-miR-6763-5p gene described in SEQ ID NO: 269 (miRBase Accession No. MIMAT0027426) and homologs or orthologs in other species. The hsa-miR-6763-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6763-5p," "hsa-mir-6763" (miRBase Accession No. MI0022608, SEQ ID NO: 544) is known to have a hairpin-like structure.

[0399] As used herein, the term “hsa-miR-6089 gene” or “hsa-miR-6089” includes the hsa-miR-6089 gene described in SEQ ID NO: 851 (miRBase Accession No. MIMAT0023714) and homologs or orthologs in other biological species. The hsa-miR-6089 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. In addition, as precursors of “hsa-miR-6089”, “hsa-mir-6089-1, hsa-mir-6089-2” (miRBase Accession Nos. MI0020366, MI0023563, SEQ ID NOs: 857, 858) are known as hairpin-like structure forming precursors.

[0400] As used herein, the term "hsa-miR-6816-5p gene" or "hsa-miR-6816-5p" includes the hsa-miR-6816-5p gene described in SEQ ID NO: 852 (miRBase Accession No. MIMAT0027532) and homologs or orthologs in other species. The hsa-miR-6816-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6816-5p", "hsa-mir-6816" (miRBase Accession No. MI0022661, SEQ ID NO: 859) is known to have a hairpin-like structure.

[0401] As used herein, the term "hsa-miR-4466 gene" or "hsa-miR-4466" includes the hsa-miR-4466 gene described in SEQ ID NO: 853 (miRBase Accession No. MIMAT0018993) and homologs or orthologs in other species. The hsa-miR-4466 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4466", "hsa-mir-4466" (miRBase Accession No. MI0016817, SEQ ID NO: 860) is known to have a hairpin-like structure.

[0402] As used herein, the term "hsa-miR-4488 gene" or "hsa-miR-4488" includes the hsa-miR-4488 gene described in SEQ ID NO: 854 (miRBase Accession No. MIMAT0019022) and homologs or orthologs in other species. The hsa-miR-4488 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Furthermore, as a precursor of "hsa-miR-4488", "hsa-mir-4488" (miRBase Accession No. MI0016849, SEQ ID NO: 861) is known to have a hairpin-like structure.

[0403] As used herein, the term "hsa-miR-6752-5p gene" or "hsa-miR-6752-5p" includes the hsa-miR-6752-5p gene described in SEQ ID NO: 855 (miRBase Accession No. MIMAT0027404) and homologs or orthologs in other species. The hsa-miR-6752-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Furthermore, as a precursor of "hsa-miR-6752-5p," "hsa-mir-6752" (miRBase Accession No. MI0022597, SEQ ID NO: 862) is known to have a hairpin-like structure.

[0404] As used herein, the term "hsa-miR-4739 gene" or "hsa-miR-4739" includes the hsa-miR-4739 gene described in SEQ ID NO: 856 (miRBase Accession No. MIMAT0019868) and homologs or orthologs in other species. The hsa-miR-4739 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, as a precursor of "hsa-miR-4739", "hsa-mir-4739" (miRBase Accession No. MI0017377, SEQ ID NO: 863) is known to have a hairpin-like structure.

[0405] In addition, when a mature miRNA is cut out from an RNA precursor that forms a hairpin-like structure as a mature miRNA, sometimes one to several bases before and after the sequence are cut out short or long, and base substitution occurs to become a mutant, which is called isomiR (Morin RD. et al., 2008, Genome Res., Vol. 18, p. 610-621). In miRBase version 20, in addition to the base sequences shown in any one of sequence numbers 1 to 269 and 851 to 856, multiple mutants and fragments of the base sequences shown in any one of sequence numbers 545 to 850 and 864 to 871, which are called isomiR, are also shown. These mutants can also be obtained as miRNAs having the base sequences shown in any one of sequence numbers 1 to 269 and 851 to 856. That is, the sequence numbers 1, 2, 3, 4, 5, 6, 8, 11, 14, 15, 19, 20, 21, 23, 27, 28, 31, 35, 37, 38, 40, 42, 43, 47, 48, 50, 51, 52, 55, 56, 58, 60, 61, 62, 64, 65, 66, 67, 71, 72, 73, 76, 77, 78, 79, 80, 82, 83, 85, 86, 88, 89 of the present invention , 90, 92, 95, 97, 98, 99, 100, 102, 103, 107, 109, 110, 113, 114, 115, 116, 117, 118, 120, 122, 123, 126, 127, 129, 131, 133, 137, 141, 142, 143, 145, 146, 148, 149, 153, 154, 155, 156, 157, 161, 164, 165, 167, 168, 171, 172, 173, 178, 179, 180, 181, 182, 184, 185, 188, 191, 192, 194, 195, 196, 199, 201, 202, 204, 207, 210, 213, 215, 217, 219, 222, 223, 225, 230, 232, 233, 234, 235, 236, 238, 239 9, 240, 241, 242, 243, 245, 246, 247, 248, 249, 250, 251, 252, 254, 258, 259, 260, 263, 265, 266, 267, 851, 853, 854 and 856, or a polynucleotide consisting of a base sequence in which u is t in the base sequence, as the longest variant registered in, for example, miRBase version 20,Serial numbers 545, 547, 549, 551, 553, 555, 557, 559, 561, 563, 565, 567, 569, 571, 573, 575, 577, 579, 581, 583, 585, 587, 589, 591, 593, 595, 597, 599, 601, 603, 605, 607, 609, 611, 613, 615, 617, 619, 621, 623, 625, 627, 629, 631, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, 679, 681, 683, 685, 687, 689, 691, 693, 695, 697, 699, 7 01, 703, 705, 707, 709, 711, 713, 715, 717, 719, 721, 723, 725, 727, 729, 731, 733, 735, 737, 739, 741, 743, 745, 747, 749, 751, 753, 755, 757, 759, 761, 763, 765, 767, 769, 771, 773, 775, 777, 779, 78 1, 783, 785, 787, 789, 791, 793, 795, 797, 799, 801, 803, 805, 807, 809, 811, 813, 815, 817, 819, 821, 823, 825, 827, 829, 831, 833, 835, 837, 839, 841, 843, 845, 847, 849, 864, 866, 868, and 870. In addition,1, 2, 3, 4, 5, 6, 8, 11, 14, 15, 19, 20, 21, 23, 27, 28, 31, 35, 37, 38, 40, 42, 43, 47, 48, 50, 51, 52, 55, 56, 58, 60, 61, 62, 64, 65, 66, 67, 71, 72, 73, 76, 77, 78, 79, 80, 82, 83, 85, 86, 88, 89, 90 0, 92, 95, 97, 98, 99, 100, 102, 103, 107, 109, 110, 113, 114, 115, 116, 117, 118, 120, 122, 123, 126, 127, 129, 131, 133, 137, 141, 142, 143, 145, 146, 148, 149, 153, 154, 155, 156, 157, 161, 164, 1 65, 167, 168, 171, 172, 173, 178, 179, 180, 181, 182, 184, 185, 188, 191, 192, 194, 195, 196, 199, 201, 202, 204, 207, 210, 213, 215, 217, 219, 222, 223, 225, 230, 232, 233, 234, 235, 236, 238, 239 , 240, 241, 242, 243, 245, 246, 247, 248, 249, 250, 251, 252, 254, 258, 259, 260, 263, 265, 266, 267, 851, 853, 854 and 856, or a polynucleotide consisting of a base sequence in which u is t in the base sequence, as, for example, the shortest mutant registered in miRBase version 20,Serial numbers 546, 548, 550, 552, 554, 556, 558, 560, 562, 564, 566, 568, 570, 572, 574, 576, 578, 580, 582, 584, 586, 588, 590, 592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 621, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 22, 624, 626, 628, 630, 632, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, 680, 682, 684, 686, 688, 690, 692, 694, 696, 698, 700, 702 , 704, 706, 708, 710, 712, 714, 716, 718, 720, 722, 724, 726, 728, 730, 732, 734, 736, 738, 740, 742, 744, 746, 748, 750, 752, 754, 756, 758, 760, 762, 764, 766, 768, 770, 772, 774, 776, 778, 780, 782, Polynucleotides of the sequences shown in 784, 786, 788, 790, 792, 794, 796, 798, 800, 802, 804, 806, 808, 810, 812, 814, 816, 818, 820, 822, 824, 826, 828, 830, 832, 834, 836, 838, 840, 842, 844, 846, 848, 850, 865, 867, 869, and 871. In addition to these mutants and fragments, polynucleotides of multiple isomiRs with SEQ ID NOs: 1 to 269 and 851 to 856 registered in miRBase can also be mentioned. Furthermore, examples of polynucleotides comprising the base sequences represented by any one of SEQ ID NOs. 1 to 269 and 851 to 856 include the polynucleotides represented by any one of SEQ ID NOs. 270 to 544 and 857 to 863 as precursors, respectively.

[0406] Table 1 lists the names and miRBase accession numbers of the genes represented by SEQ ID NOs: 1 to 871.

[0407] In this specification, "capable of specifically binding" means that the nucleic acid probe or primer used in the present invention binds to a specific target nucleic acid and is substantially unable to bind to other nucleic acids.

[0408] [Table 1]

[0409]

[0410]

[0411]

[0412]

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420]

[0421]

[0422]

[0423]

[0424]

[0425]

[0426]

[0427]

[0428]

[0429]

[0430]

[0431]

[0432]

[0433]

[0434] This specification includes the contents described in the specifications and / or drawings of Japanese Patent Applications No. 2014-122672 and No. 2015-069321, which are the basis of priority of this application.

[0435] Effects of the Invention

[0436] The present invention makes it possible to easily and accurately detect breast cancer. For example, using the measured values ​​of several miRNAs in a patient's blood, serum, or plasma, which can be collected minimally invasively, as indicators, it is possible to easily detect whether a patient has breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0437] Figure 1 The relationship between the base sequences of hsa-miR-6805-5p shown in sequence number 34, which is generated from hsa-mir-6805 shown in sequence number 304 as a precursor, and hsa-miR-6805-3p shown in sequence number 205 is shown.

[0438] Figure 2 Middle left figure: A graph showing the expression levels of hsa-miR-4783-3p (SEQ ID NO. 1) in healthy subjects (100 people) and breast cancer patients (62 people) selected as the learning sample group, respectively, as the vertical axis. The horizontal line in the figure represents the threshold value (6.63) for distinguishing the two groups, optimized by Fisher's discriminant analysis. Right figure: A graph showing the expression levels of hsa-miR-4783-3p (SEQ ID NO. 1) in healthy subjects (50 people) and breast cancer patients (31 people) selected as the test sample group, respectively, as the vertical axis. The horizontal line in the figure represents the threshold value (6.63) for distinguishing the two groups, set by the learning sample group.

[0439] Figure 3 Middle left figure: A graph showing the expression level of hsa-miR-4783-3p (sequence number 1) in healthy subjects (100 people, circles) and breast cancer patients (62 people, triangles) selected as the learning sample group as the horizontal axis and the expression level of hsa-miR-4730 (sequence number 2) as the vertical axis. The line in the figure represents the discriminant function (0 = 1.41x + y + 0.77) that was optimized by Fisher's discriminant analysis to discriminate between the two groups. Right figure: A graph showing the expression level of hsa-miR-4783-3p (sequence number 1) in healthy subjects (50 people, circles) and breast cancer patients (31 people, triangles) selected as the test sample group as the horizontal axis and the expression level of hsa-miR-4730 (sequence number 2) as the vertical axis. The line in the figure represents the threshold value (0=1.41x+y+0.77) for distinguishing between the two groups, which was set based on the learning sample group.

[0440] Figure 4Middle A: Graph showing the discriminant score obtained from hsa-miR-602 (SEQ ID NO: 237) and hsa-miR-4730 (SEQ ID NO: 2) expression levels measured in 62 breast cancer patients, 102 healthy subjects, and 33 prostate cancer patients selected as a learning sample group using Fisher's discriminant analysis to create a discriminant equation (1.87 x hsa-miR-4730 + 0.42 x hsa-miR-602 - 18.58). The horizontal axis shows the discriminant score of the discriminant equation, with the sample group as the vertical axis. The dotted line in the figure indicates the discriminant boundary between the two groups, where the discriminant score is 0. B: Graph showing the expression levels of hsa-miR-602 (SEQ ID NO: 237) and hsa-miR-4730 (SEQ ID NO: 2) in 31 breast cancer patients, 48 ​​healthy subjects, and 19 prostate cancer patients selected as the test sample group, with the discriminant score obtained using the discriminant formula developed for the learning sample group on the vertical axis and the sample group on the horizontal axis. The dotted line in the figure indicates the discrimination boundary between the two groups, where the discrimination score is 0. DETAILED DESCRIPTION

[0441] The present invention will be described in further detail below.

[0442] 1. Target nucleic acid for breast cancer

[0443] Among the main target nucleic acids used as breast cancer markers for detecting the presence and / or absence of breast cancer or breast cancer cells using the above-defined nucleic acid probes or primers for detecting breast cancer of the present invention, hsa-miR-4783-3p, hsa-miR-4730, hsa-miR-1307-3p, hsa-miR-4634, hsa-miR-663a, hsa-miR-4532, hsa-miR-7704, hsa-miR-3178, hsa-miR-6729-5p, hsa-miR-6090, hsa-miR-4732-5p, hsa-miR-3184-5p, hsa-miR-663a, hsa-miR-4532 727-5p, hsa-miR-6088, hsa-miR-4674, hsa-miR-8073, hsa-miR-4787-5p, hsa-miR-1469, hsa-miR-125a-3p, hsa-miR-1233-5p, hsa-miR-885-3p, hs a-miR-6802-5p, hsa-miR-328-5p, hsa-miR-6787-5p, hsa-miR-8069, hsa-miR-6875-5p, hsa-miR-1246, hsa-miR-4734, hsa-miR-6757-5p, hsa-miR-6 756-5p, hsa-miR-3665, hsa-miR-6836-3p, hsa-miR-6821-5p, hsa-miR-6805-5p, hsa-miR-4728-5p, hsa-miR-6726-5p, hsa-miR-197-5p, hsa-miR-1 49-3p, hsa-miR-6850-5p, hsa-miR-4476, hsa-miR-6858-5p, hsa-miR-564, hsa-miR-4763-3p, hsa-miR-575, hsa-miR-6771-5p, hsa-miR-1231, hsa-m iR-1908-3p, hsa-miR-150-3p, hsa-miR-3937, hsa-miR-887-3p, hsa-miR-3940-5p, hsa-miR-4741, hsa-miR-6808-5p, hsa-miR-6869-5p, hsa-miR-5 090, hsa-miR-615-5p, hsa-miR-8072, hsa-miR-128-1-5p, hsa-miR-1238-5p, hsa-miR-365a-5p, hsa-miR-204-3p, hsa-miR-4492, hsa-miR-6785-5p,hsa-miR-6511a-5p, hsa-miR-4525, hsa-miR-1915-5p, hsa-miR-3180, hsa-miR-6879-5p, hsa-miR-1199-5p, hsa-miR-6746-5p, hsa-miR-711, hsa-m iR-663b、hsa-miR-4707-3p、hsa-miR-6893-5p、hsa-miR-4675、hsa-miR-4638-5p、hsa-miR-4651、hsa-miR-6087、hsa-miR-4665-5p、hsa-miR-4758- 5p, hsa-miR-6887-5p, hsa-miR-3620-5p, hsa-miR-1909-3p, hsa-miR-7641, hsa-miR-6724-5p, hsa-miR-1343-3p, hsa-miR-6780b-5p, hsa-miR-448 4、hsa-miR-4690-5p、hsa-miR-4429、hsa-miR-1227-5p、hsa-miR-4725-3p、hsa-miR-6861-5p、hsa-miR-6812-5p、hsa-miR-3197、hsa-miR-8059、hsa -miR-3185, hsa-miR-4706, hsa-miR-4497, hsa-miR-3131, hsa-miR-6806-5p, hsa-miR-187-5p, hsa-miR-3180-3p, hsa-miR-6848-5p, hsa-miR-6820 -5p、hsa-miR-6800-5p、hsa-miR-6717-5p、hsa-miR-6795-5p、hsa-miR-4632-5p、hsa-miR-665、hsa-miR-6778-5p、hsa-miR-3663-3p、hsa-miR-4689 hsa-miR-211-3p, hsa-miR-6511b-5p, hsa-miR-4750-5p, hsa-miR-6126, hsa-miR-614, hsa-miR-7110-5p, hsa-miR-744-5p, hsa-miR-6769a-5p, hs a-miR-4792, hsa-miR-5787, hsa-miR-6798-5p, hsa-miR-6781-5p, hsa-miR-4419b, hsa-miR-4446-3p, hsa-miR-4259, hsa-miR-5572, hsa-miR-6075hsa-miR-296-3p、hsa-miR-6891-5p、hsa-miR-4745-5p、hsa-miR-6775-5p、hsa-miR-6870-5p、hsa-miR-920、hsa-miR-4530、hsa-miR-6819-5p、hsa- miR-6825-5p, hsa-miR-7847-3p, hsa-miR-6131, hsa-miR-4433-3p, hsa-miR-1228-5p, hsa-miR-6743-5p, hsa-miR-1268a, hsa-miR-3917, hsa-miR-6 786-5p, hsa-miR-3154, hsa-miR-638, hsa-miR-6741-5p, hsa-miR-6889-5p, hsa-miR-6840-3p, hsa-miR-6510-5p, hsa-miR-3188, hsa-miR-551b-5p hsa-miR-5001-5p, hsa-miR-1268b, hsa-miR-7107-5p, hsa-miR-6824-5p, hsa-miR-6732-5p, hsa-miR-371a-5p, hsa-miR-6794-5p, hsa-miR-6779-5 p、hsa-miR-4271、hsa-miR-5195-3p、hsa-miR-6762-5p、hsa-miR-939-5p、hsa-miR-1247-3p、hsa-miR-6777-5p、hsa-miR-6722-3p、hsa-miR-3656、h sa-miR-4688, hsa-miR-3195, hsa-miR-6766-5p, hsa-miR-4447, hsa-miR-4656, hsa-miR-7108-5p, hsa-miR-3191-3p, hsa-miR-1273g-3p, hsa-miR-4 463, hsa-miR-2861, hsa-miR-3196, hsa-miR-6877-5p, hsa-miR-3679-5p, hsa-miR-4442, hsa-miR-6789-5p, hsa-miR-6782-5p, hsa-miR-486-3p, hs a-miR-6085, hsa-miR-4746-3p, hsa-miR-619-5p, hsa-miR-937-5p, hsa-miR-6803-5p, hsa-miR-4298, hsa-miR-4454, hsa-miR-4459, hsa-miR-7150hsa-miR-6880-5p, hsa-miR-4449, hsa-miR-8063, hsa-miR-4695-5p, hsa-miR-6132, hsa-miR-6829 -5p, hsa-miR-4486, hsa-miR-6805-3p, hsa-miR-6826-5p, hsa-miR-4508, hsa-miR-1343-5p, hsa-m iR-7114-5p, hsa-miR-3622a-5p, hsa-miR-6765-5p, hsa-miR-7845-5p, hsa-miR-3960, hsa-miR-67 49-5p, hsa-miR-1260b, hsa-miR-6799-5p, hsa-miR-4723-5p, hsa-miR-6784-5p, hsa-miR-5100, hsa -miR-6769b-5p, hsa-miR-1207-5p, hsa-miR-642a-3p, hsa-miR-4505, hsa-miR-4270, hsa-miR-672 1-5p, hsa-miR-7111-5p, hsa-miR-6791-5p, hsa-miR-7109-5p, hsa-miR-4258, hsa-miR-6515-3p, hs at least one miRNA selected from the group consisting of hsa-miR-6851-5p, hsa-miR-6125, hsa-miR-4749-5p, hsa-miR-4726-5p, hsa-miR-4513, hsa-miR-6089, hsa-miR-6816-5p, hsa-miR-4466, hsa-miR-4488, hsa-miR-6752-5p, and hsa-miR-4739. Furthermore, other breast cancer markers that can be combined with these miRNAs, i.e., at least one miRNA selected from the group consisting of hsa-miR-760, hsa-miR-602, hsa-miR-423-5p, hsa-miR-92a-2-5p, hsa-miR-16-5p, hsa-miR-451a, hsa-miR-135a-3p, hsa-miR-486-5p, hsa-miR-4257, hsa-miR-92b-5p, hsa-miR-1915-3p, hsa-miR-718, hsa-miR-940, hsa-miR-296-5p, hsa-miR-23b-3p and hsa-miR-92a-3p can also be preferably used as a target nucleic acid. Other breast cancer markers that can be combined with these miRNAs include hsa-miR-658, hsa-miR-6842-5p,At least one miRNA selected from the group consisting of hsa-miR-6124, hsa-miR-6765-3p, hsa-miR-7106-5p, hsa-miR-4534, hsa-miR-92b-3p, hsa-miR-3135b, hsa-miR-4687-3p, hsa-miR-762, hsa-miR-3619-3p, hsa-miR-4467, hsa-miR-557, hsa-miR-1237-5p, hsa-miR-1908-5p, hsa-miR-4286, hsa-miR-6885-5p, and hsa-miR-6763-5p can also be preferably used as the target nucleic acid.

[0444] Among the above-mentioned miRNAs, there are, for example, human genes containing the base sequences shown in any one of SEQ ID NOs: 1 to 269 and 851 to 856 (i.e., hsa-miR-4783-3p, hsa-miR-4730, hsa-miR-1307-3p, hsa-miR-4634, hsa-miR-663a, hsa-miR-4532, hsa-miR-7704, hsa-miR-3178, hsa-miR-6729-5p, hsa-miR-6090, hsa-miR-4732-5p, hsa-miR-3184-5p, hsa-miR-6727-5p, hsa-miR-6088, hsa-miR-4674, hsa-miR-8073, hsa-miR-4787-5p, hsa-miR-1469, hsa-miR-125a-3p, hsa-miR-1233-5p, hsa-miR-885-3p, hsa-miR-6802-5p, hsa-miR-328-5p, hsa-miR-6787-5p, hsa-miR-8069, hsa-miR-6875-5p, hsa-miR-1246, hsa-miR-4734, hsa-miR-6757-5p, hsa-miR-6756-5p, hsa-miR-3665, hsa-miR-6836-3p, hsa-miR-6821-5p, hsa-miR-6805-5p, hsa-miR-4728-5p, hsa-miR-6726-5p, hsa-miR-197-5p, hsa-miR-149-3p, hsa-miR-6850-5p, hsa-miR-4476, hsa-miR-6858-5p, hsa-miR-564, hsa-miR-4763-3p, hsa-miR-575, hsa-miR-6771-5p, hsa-miR-1231, hsa-miR-1908-3p, hsa-miR-150-3p, hsa-miR-3937, hsa-miR-887-3p, hsa-miR-3940-5p, hsa-miR-4741, hsa-miR-6808-5p, hsa-miR-6869-5p, hsa-miR-5090, hsa-miR-615-5p, hsa-miR-8072, hsa-miR-128-1-5p, hsa-miR-1238-5p, hsa-miR-365a-5p, hsa-miR-204-3p, hsa-miR-4492, hsa-miR-6785-5p, hsa-miR-6511a-5p,hsa-miR-4525, hsa-miR-1915-5p, hsa-miR-3180, hsa-miR-6879-5p, hsa-miR-1199-5p, hsa-miR-6746-5p, hsa-miR-711, hsa-miR-663b, hsa-miR- 4707-3p、hsa-miR-6893-5p、hsa-miR-4675、hsa-miR-4638-5p、hsa-miR-4651、hsa-miR-6087、hsa-miR-4665-5p、hsa-miR-4758-5p、hsa-miR-6887- 5p, hsa-miR-3620-5p, hsa-miR-1909-3p, hsa-miR-7641, hsa-miR-6724-5p, hsa-miR-1343-3p, hsa-miR-6780b-5p, hsa-miR-4484, hsa-miR-4690-5 p、hsa-miR-4429、hsa-miR-1227-5p、hsa-miR-4725-3p、hsa-miR-6861-5p、hsa-miR-6812-5p、hsa-miR-3197、hsa-miR-8059、hsa-miR-3185、hsa-mi R-4706, hsa-miR-4497, hsa-miR-3131, hsa-miR-6806-5p, hsa-miR-187-5p, hsa-miR-3180-3p, hsa-miR-6848-5p, hsa-miR-6820-5p, hsa-miR-6800 -5p、hsa-miR-6717-5p、hsa-miR-6795-5p、hsa-miR-4632-5p、hsa-miR-665、hsa-miR-6778-5p、hsa-miR-3663-3p、hsa-miR-4689、hsa-miR-211-3p、 hsa-miR-6511b-5p、hsa-miR-4750-5p、hsa-miR-6126、hsa-miR-614、hsa- miR-7110-5p、hsa-miR-744-5p、hsa-miR-6769a-5p、hsa-miR-4792、hsa-m iR-5787, hsa-miR-6798-5p, hsa-miR-6781-5p, hsa-miR-4419b, hsa-miR-4446-3p, hsa-miR-4259, hsa-miR-5572, hsa-miR-6075, hsa-miR-296-3phsa-miR-6891-5p, hsa-miR-4745-5p, hsa-miR-6775-5p, hsa-miR-6870-5p, hsa-miR-920, hsa-miR-4530, hsa-miR-6819-5p, hsa-miR-6825-5p, hsa -miR-7847-3p、hsa-miR-6131、hsa-miR-4433-3p、hsa-miR-1228-5p、hsa-miR-6743-5p、hsa-miR-1268a、hsa-miR-3917、hsa-miR-6786-5p、hsa-miR- 3154, hsa-miR-638, hsa-miR-6741-5p, hsa-miR-6889-5p, hsa-miR-6840-3p, hsa-miR-6510-5p, hsa-miR-3188, hsa-miR-551b-5p, hsa-miR-5001-5 p、hsa-miR-1268b、hsa-miR-7107-5p、hsa-miR-6824-5p、hsa-miR-6732-5 p、hsa-miR-371a-5p、hsa-miR-6794-5p、hsa-miR-6779-5p、hsa-miR-4271、 hsa-miR-5195-3p, hsa-miR-6762-5p, hsa-miR-939-5p, hsa-miR-1247-3p, hsa-miR-6777-5p, hsa-miR-6722-3p, hsa-miR-3656, hsa-miR-4688, hsa -miR-3195, hsa-miR-6766-5p, hsa-miR-4447, hsa-miR-4656, hsa-miR-7108-5p, hsa-miR-3191-3p, hsa-miR-1273g-3p, hsa-miR-4463, hsa-miR-286 1, hsa-miR-3196, hsa-miR-6877-5p, hsa-miR-3679-5p, hsa-miR-4442, hsa-miR-6789-5p, hsa-miR-6782-5p, hsa-miR-486-3p, hsa-miR-6085, hsa-m iR-4746-3p, hsa-miR-619-5p, hsa-miR-937-5p, hsa-miR-6803-5p, hsa-miR-4298, hsa-miR-4454, hsa-miR-4459, hsa-miR-7150, hsa-miR-6880-5phsa-miR-4449, hsa-miR-8063, hsa-miR-4695-5p, hsa-miR-6132, hsa-miR-6829-5p, hsa-miR-4486, hsa-miR-6805-3p, hsa-miR-6826-5p, hsa-miR- 4508, hsa-miR-1343-5p, hsa-miR-7114-5p, hsa-miR-3622a-5p, hsa-miR-6765-5p, hsa-miR-7845-5p, hsa-miR-3960, hsa-miR-6749-5p, hsa-miR-12 60b, hsa-miR-6799-5p, hsa-miR-4723-5p, hsa-miR-6784-5p, hsa-miR-5100, hsa-miR-6769b-5p, hsa-miR-1207-5p, hsa-miR-642a-3p, hsa-miR-450 5, hsa-miR-4270, hsa-miR-6721-5p, hsa-miR-7111-5p, hsa-miR-6791-5p, hsa-miR-7109-5p, hsa-miR-4258, hsa-miR-6515-3p, hsa-miR-6851-5p, h sa-miR-6125, hsa-miR-4749-5p, hsa-miR-4726-5p, hsa-miR-4513, hsa-miR-6089, hsa-miR-6816-5p, hsa-miR-4466, hsa-miR-4488, hsa-miR-6752 -5p、hsa-miR-4739、hsa-miR-760、hsa-miR-602、hsa-miR-423-5p、hsa-miR-92a-2-5p、hsa-miR-16-5p、hsa-miR-451a、hsa-miR-135a-3p、hsa-miR-4 86-5p、hsa-miR-4257、hsa-miR-92b-5p、hsa-miR-1915-3p、hsa-miR-718、hsa-miR-940、hsa-miR-296-5p、hsa-miR-23b-3p、hsa-miR-92a-3p、hsa-mi R-658, hsa-miR-6842-5p, hsa-miR-6124, hsa-miR-6765-3p, hsa-miR-7106-5p, hsa-miR-4534, hsa-miR-92b-3p, hsa-miR-3135b, hsa-miR-4687-3phsa-miR-762, hsa-miR-3619-3p, hsa-miR-4467, hsa-miR-557, hsa-miR-1237-5p, hsa-miR-1908-5p, hsa-miR-4286, hsa-miR-6885-5p, and hsa-miR-6763-5p), their homologs, their transcription products, and their mutants or derivatives. Here, genes, homologs, transcription products, mutants, and derivatives are as defined above.

[0445] A preferred target nucleic acid is a human gene comprising the base sequence shown in any one of SEQ ID NOs: 1 to 871, or a transcription product thereof, more preferably the transcription product, ie, miRNA, or its precursor RNA, pri-miRNA or pre-miRNA.

[0446] The first target gene is the hsa-miR-4783-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0447] The second target gene is the hsa-miR-4730 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0448] The third target gene is the hsa-miR-1307-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0449] The fourth target gene is the hsa-miR-4634 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0450] The fifth target gene is the hsa-miR-663a gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0451] The sixth target gene is the hsa-miR-4532 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0452] The seventh target gene is the hsa-miR-7704 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0453] The eighth target gene is the hsa-miR-3178 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0454] The ninth target gene is the hsa-miR-6729-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0455] The tenth target gene is the hsa-miR-6090 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0456] The eleventh target gene is the hsa-miR-4732-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0457] The twelfth target gene is the hsa-miR-3184-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0458] The 13th target gene is the hsa-miR-6727-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0459] The fourteenth target gene is the hsa-miR-6088 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0460] The fifteenth target gene is the hsa-miR-4674 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0461] The 16th target gene is the hsa-miR-8073 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0462] The 17th target gene is the hsa-miR-4787-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0463] The eighteenth target gene is the hsa-miR-1469 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0464] The 19th target gene is the hsa-miR-125a-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0465] The 20th target gene is the hsa-miR-1233-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0466] The 21st target gene is the hsa-miR-885-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0467] The 22nd target gene is the hsa-miR-6802-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0468] The 23rd target gene is the hsa-miR-328-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0469] The 24th target gene is the hsa-miR-6787-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0470] The 25th target gene is the hsa-miR-8069 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0471] The 26th target gene is the hsa-miR-6875-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0472] The 27th target gene is the hsa-miR-1246 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0473] The 28th target gene is the hsa-miR-4734 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0474] The 29th target gene is the hsa-miR-6757-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0475] The 30th target gene is the hsa-miR-6756-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0476] The 31st target gene is the hsa-miR-3665 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0477] The 32nd target gene is the hsa-miR-6836-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0478] The 33rd target gene is the hsa-miR-6821-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0479] The 34th target gene is the hsa-miR-6805-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0480] The 35th target gene is the hsa-miR-4728-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0481] The 36th target gene is the hsa-miR-6726-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0482] The 37th target gene is the hsa-miR-197-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0483] The 38th target gene is the hsa-miR-149-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0484] The 39th target gene is the hsa-miR-6850-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0485] The 40th target gene is the hsa-miR-4476 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0486] The 41st target gene is the hsa-miR-6858-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0487] The 42nd target gene is the hsa-miR-564 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0488] The 43rd target gene is the hsa-miR-4763-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0489] The 44th target gene is the hsa-miR-575 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0490] The 45th target gene is the hsa-miR-6771-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0491] The 46th target gene is the hsa-miR-1231 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0492] The 47th target gene is the hsa-miR-1908-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0493] The 48th target gene is the hsa-miR-150-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0494] The 49th target gene is the hsa-miR-3937 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0495] The 50th target gene is the hsa-miR-887-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0496] The 51st target gene is the hsa-miR-3940-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0497] The 52nd target gene is the hsa-miR-4741 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0498] The 53rd target gene is the hsa-miR-6808-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0499] The 54th target gene is the hsa-miR-6869-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0500] The 55th target gene is the hsa-miR-5090 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0501] The 56th target gene is the hsa-miR-615-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0502] The 57th target gene is the hsa-miR-8072 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0503] The 58th target gene is the hsa-miR-128-1-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0504] The 59th target gene is the hsa-miR-1238-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0505] The 60th target gene is the hsa-miR-365a-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0506] The 61st target gene is the hsa-miR-204-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0507] The 62nd target gene is the hsa-miR-4492 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0508] The 63rd target gene is the hsa-miR-6785-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0509] The 64th target gene is the hsa-miR-6511a-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0510] The 65th target gene is the hsa-miR-4525 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0511] The 66th target gene is the hsa-miR-1915-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0512] The 67th target gene is the hsa-miR-3180 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0513] The 68th target gene is the hsa-miR-6879-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0514] The 69th target gene is the hsa-miR-1199-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0515] The 70th target gene is the hsa-miR-6746-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0516] The 71st target gene is the hsa-miR-711 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0517] The 72nd target gene is the hsa-miR-663b gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0518] The 73rd target gene is the hsa-miR-4707-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0519] The 74th target gene is the hsa-miR-6893-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0520] The 75th target gene is the hsa-miR-4675 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0521] The 76th target gene is the hsa-miR-4638-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0522] The 77th target gene is the hsa-miR-4651 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0523] The 78th target gene is the hsa-miR-6087 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0524] The 79th target gene is the hsa-miR-4665-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0525] The 80th target gene is the hsa-miR-4758-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0526] The 81st target gene is the hsa-miR-6887-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0527] The 82nd target gene is the hsa-miR-3620-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0528] The 83rd target gene is the hsa-miR-1909-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0529] The 84th target gene is the hsa-miR-7641 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0530] The 85th target gene is the hsa-miR-6724-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0531] The 86th target gene is the hsa-miR-1343-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0532] The 87th target gene is the hsa-miR-6780b-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0533] The 88th target gene is the hsa-miR-4484 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0534] The 89th target gene is the hsa-miR-4690-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0535] The 90th target gene is the hsa-miR-4429 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0536] The 91st target gene is the hsa-miR-1227-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0537] The 92nd target gene is the hsa-miR-4725-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0538] The 93rd target gene is the hsa-miR-6861-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0539] The 94th target gene is the hsa-miR-6812-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0540] The 95th target gene is the hsa-miR-3197 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0541] The 96th target gene is the hsa-miR-8059 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0542] The 97th target gene is the hsa-miR-3185 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0543] The 98th target gene is the hsa-miR-4706 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0544] The 99th target gene is the hsa-miR-4497 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0545] The 100th target gene is the hsa-miR-3131 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0546] The 101st target gene is the hsa-miR-6806-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0547] The 102nd target gene is the hsa-miR-187-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0548] The 103rd target gene is the hsa-miR-3180-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0549] The 104th target gene is the hsa-miR-6848-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0550] The 105th target gene is the hsa-miR-6820-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0551] The 106th target gene is the hsa-miR-6800-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0552] The 107th target gene is the hsa-miR-6717-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0553] The 108th target gene is the hsa-miR-6795-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0554] The 109th target gene is the hsa-miR-4632-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0555] The 110th target gene is the hsa-miR-665 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0556] The 111th target gene is the hsa-miR-6778-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0557] The 112th target gene is the hsa-miR-3663-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0558] The 113th target gene is the hsa-miR-4689 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0559] The 114th target gene is the hsa-miR-211-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0560] The 115th target gene is the hsa-miR-6511b-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0561] The 116th target gene is the hsa-miR-4750-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0562] The 117th target gene is the hsa-miR-6126 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0563] The 118th target gene is the hsa-miR-614 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0564] The 119th target gene is the hsa-miR-7110-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0565] The 120th target gene is the hsa-miR-744-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0566] The 121st target gene is the hsa-miR-6769a-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0567] The 122nd target gene is the hsa-miR-4792 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0568] The 123rd target gene is the hsa-miR-5787 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0569] The 124th target gene is the hsa-miR-6798-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0570] The 125th target gene is the hsa-miR-6781-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0571] The 126th target gene is the hsa-miR-4419b gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0572] The 127th target gene is the hsa-miR-4446-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0573] The 128th target gene is the hsa-miR-4259 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0574] The 129th target gene is the hsa-miR-5572 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0575] The 130th target gene is the hsa-miR-6075 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0576] The 131st target gene is the hsa-miR-296-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0577] The 132nd target gene is the hsa-miR-6891-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0578] The 133rd target gene is the hsa-miR-4745-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0579] The 134th target gene is the hsa-miR-6775-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0580] The 135th target gene is the hsa-miR-6870-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0581] The 136th target gene is the hsa-miR-920 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0582] The 137th target gene is the hsa-miR-4530 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0583] The 138th target gene is the hsa-miR-6819-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0584] The 139th target gene is the hsa-miR-6825-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0585] The 140th target gene is the hsa-miR-7847-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0586] The 141st target gene is the hsa-miR-6131 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0587] The 142nd target gene is the hsa-miR-4433-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0588] The 143rd target gene is the hsa-miR-1228-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0589] The 144th target gene is the hsa-miR-6743-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0590] The 145th target gene is the hsa-miR-1268a gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0591] The 146th target gene is the hsa-miR-3917 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0592] The 147th target gene is the hsa-miR-6786-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0593] The 148th target gene is the hsa-miR-3154 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0594] The 149th target gene is the hsa-miR-638 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0595] The 150th target gene is the hsa-miR-6741-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0596] The 151st target gene is the hsa-miR-6889-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0597] The 152nd target gene is the hsa-miR-6840-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0598] The 153rd target gene is the hsa-miR-6510-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0599] The 154th target gene is the hsa-miR-3188 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0600] The 155th target gene is the hsa-miR-551b-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0601] The 156th target gene is the hsa-miR-5001-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0602] The 157th target gene is the hsa-miR-1268b gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0603] The 158th target gene is the hsa-miR-7107-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0604] The 159th target gene is the hsa-miR-6824-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0605] The 160th target gene is the hsa-miR-6732-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0606] The 161st target gene is the hsa-miR-371a-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0607] The 162nd target gene is the hsa-miR-6794-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0608] The 163rd target gene is the hsa-miR-6779-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0609] The 164th target gene is the hsa-miR-4271 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0610] The 165th target gene is the hsa-miR-5195-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0611] The 166th target gene is the hsa-miR-6762-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0612] The 167th target gene is the hsa-miR-939-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0613] The 168th target gene is the hsa-miR-1247-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0614] The 169th target gene is the hsa-miR-6777-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0615] The 170th target gene is the hsa-miR-6722-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0616] The 171st target gene is the hsa-miR-3656 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0617] The 172nd target gene is the hsa-miR-4688 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0618] The 173rd target gene is the hsa-miR-3195 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0619] The 174th target gene is the hsa-miR-6766-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0620] The 175th target gene is the hsa-miR-4447 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0621] The 176th target gene is the hsa-miR-4656 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0622] The 177th target gene is the hsa-miR-7108-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0623] The 178th target gene is the hsa-miR-3191-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0624] The 179th target gene is the hsa-miR-1273g-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0625] The 180th target gene is the hsa-miR-4463 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0626] The 181st target gene is the hsa-miR-2861 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0627] The 182nd target gene is the hsa-miR-3196 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0628] The 183rd target gene is the hsa-miR-6877-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0629] The 184th target gene is the hsa-miR-3679-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0630] The 185th target gene is the hsa-miR-4442 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0631] The 186th target gene is the hsa-miR-6789-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0632] The 187th target gene is the hsa-miR-6782-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0633] The 188th target gene is the hsa-miR-486-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0634] The 189th target gene is the hsa-miR-6085 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0635] The 190th target gene is the hsa-miR-4746-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0636] The 191st target gene is the hsa-miR-619-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0637] The 192nd target gene is the hsa-miR-937-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0638] The 193rd target gene is the hsa-miR-6803-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0639] The 194th target gene is the hsa-miR-4298 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0640] The 195th target gene is the hsa-miR-4454 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0641] The 196th target gene is the hsa-miR-4459 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0642] The 197th target gene is the hsa-miR-7150 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0643] The 198th target gene is the hsa-miR-6880-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0644] The 199th target gene is the hsa-miR-4449 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0645] The 200th target gene is the hsa-miR-8063 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0646] The 201st target gene is the hsa-miR-4695-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0647] The 202nd target gene is the hsa-miR-6132 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0648] The 203rd target gene is the hsa-miR-6829-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0649] The 204th target gene is the hsa-miR-4486 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0650] The 205th target gene is the hsa-miR-6805-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0651] The 206th target gene is the hsa-miR-6826-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0652] The 207th target gene is the hsa-miR-4508 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0653] The 208th target gene is the hsa-miR-1343-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0654] The 209th target gene is the hsa-miR-7114-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of genes or their transcripts can serve as markers for breast cancer.

[0655] The 210th target gene is the hsa-miR-3622a-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0656] The 211th target gene is the hsa-miR-6765-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0657] The 212th target gene is the hsa-miR-7845-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0658] The 213th target gene is the hsa-miR-3960 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0659] The 214th target gene is the hsa-miR-6749-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0660] The 215th target gene is the hsa-miR-1260b gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0661] The 216th target gene is the hsa-miR-6799-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0662] The 217th target gene is the hsa-miR-4723-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0663] The 218th target gene is the hsa-miR-6784-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0664] The 219th target gene is the hsa-miR-5100 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0665] The 220th target gene is the hsa-miR-6769b-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0666] The 221st target gene is the hsa-miR-1207-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0667] The 222nd target gene is the hsa-miR-642a-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0668] The 223rd target gene is the hsa-miR-4505 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0669] The 224th target gene is the hsa-miR-4270 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0670] The 225th target gene is the hsa-miR-6721-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0671] The 226th target gene is the hsa-miR-7111-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0672] The 227th target gene is the hsa-miR-6791-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there have been no reports that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0673] The 228th target gene is the hsa-miR-7109-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0674] The 229th target gene is the hsa-miR-4258 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0675] The 230th target gene is the hsa-miR-6515-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0676] The 231st target gene is the hsa-miR-6851-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as markers for breast cancer.

[0677] The 232nd target gene is the hsa-miR-6125 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0678] The 233rd target gene is the hsa-miR-4749-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0679] The 234th target gene is the hsa-miR-4726-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0680] The 235th target gene is the hsa-miR-4513 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0681] The 236th target gene is the hsa-miR-760 gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Non-Patent Document 3 mentioned above).

[0682] The 237th target gene is the hsa-miR-602 gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Patent Document 1 mentioned above).

[0683] The 238th target gene is the hsa-miR-423-5p gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Non-Patent Document 4 above).

[0684] The 239th target gene is the hsa-miR-92a-2-5p gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Patent Document 3 mentioned above).

[0685] The 240th target gene is the hsa-miR-16-5p gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Patent Document 4 mentioned above).

[0686] The 241st target gene is the hsa-miR-451a gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Patent Document 4 mentioned above).

[0687] The 242nd target gene is the hsa-miR-135a-3p gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Patent Documents 1 and 2 mentioned above).

[0688] The 243rd target gene is the hsa-miR-486-5p gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Non-Patent Document 4 above).

[0689] The 244th target gene is the hsa-miR-4257 gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Non-Patent Document 5 mentioned above).

[0690] The 245th target gene is the hsa-miR-92b-5p gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Patent Document 3 mentioned above).

[0691] The 246th target gene is the hsa-miR-1915-3p gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Non-Patent Document 5 mentioned above).

[0692] The 247th target gene is the hsa-miR-718 gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Non-Patent Document 5 mentioned above).

[0693] The 248th target gene is the hsa-miR-940 gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Non-Patent Document 6 mentioned above).

[0694] The 249th target gene is the hsa-miR-296-5p gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Patent Document 4 mentioned above).

[0695] The 250th target gene is the hsa-miR-23b-3p gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Patent Document 2 mentioned above).

[0696] The 251st target gene is the hsa-miR-92a-3p gene, its homologues, its transcription products, or its mutants or derivatives. It has been reported that changes in the expression of this gene or its transcripts can serve as markers for breast cancer (Patent Document 3 mentioned above).

[0697] The 252nd target gene is the hsa-miR-658 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0698] The 253rd target gene is the hsa-miR-6842-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcripts can serve as a marker for breast cancer.

[0699] The 254th target gene is the hsa-miR-6124 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0700] The 255th target gene is the hsa-miR-6765-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0701] The 256th target gene is the hsa-miR-7106-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0702] The 257th target gene is the hsa-miR-4534 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0703] The 258th target gene is the hsa-miR-92b-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0704] The 259th target gene is the hsa-miR-3135b gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0705] The 260th target gene is the hsa-miR-4687-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0706] The 261st target gene is the hsa-miR-762 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0707] The 262nd target gene is the hsa-miR-3619-3p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0708] The 263rd target gene is the hsa-miR-4467 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0709] The 264th target gene is the hsa-miR-557 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0710] The 265th target gene is the hsa-miR-1237-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0711] The 266th target gene is the hsa-miR-1908-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0712] The 267th target gene is the hsa-miR-4286 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0713] The 268th target gene is the hsa-miR-6885-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0714] The 269th target gene is the hsa-miR-6763-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of this gene or its transcript can serve as a marker for breast cancer.

[0715] The 270th target gene is the hsa-miR-6089 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of genes or their transcripts can serve as markers for breast cancer.

[0716] The 271st target gene is the hsa-miR-6816-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of genes or their transcripts can serve as markers for breast cancer.

[0717] The 272nd target gene is the hsa-miR-4466 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of genes or their transcripts can serve as markers for breast cancer.

[0718] The 273rd target gene is the hsa-miR-4488 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of genes or their transcripts can serve as markers for breast cancer.

[0719] The 274th target gene is the hsa-miR-6752-5p gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of genes or their transcripts can serve as markers for breast cancer.

[0720] The 275th target gene is the hsa-miR-4739 gene, its homologues, its transcription products, or its mutants or derivatives. To date, there has been no report that changes in the expression of genes or their transcripts can serve as markers for breast cancer.

[0721] 2. Nucleic acid probes or primers for breast cancer detection

[0722] In the present invention, a nucleic acid capable of specifically binding to the above-mentioned target nucleic acid as a breast cancer marker can be used as a nucleic acid for detecting or diagnosing breast cancer, such as a nucleic acid probe or primer.

[0723] In the present invention, the nucleic acid probe or primer that can be used for detecting or diagnosing breast cancer can qualitatively and / or quantitatively measure the presence, expression level or amount of the target nucleic acid as a breast cancer marker, such as hsa-miR-4783-3p, hsa-miR-4730, hsa-miR-1307-3p, hsa-miR-4634, hsa-miR-663a, hsa-miR-4532, hsa-miR-7704, hsa-miR-3178, hsa-miR-6729-5p, hsa-miR-6090, hsa-miR-4732-5p, hsa-miR-3184 -5p, hsa-miR-6727-5p, hsa-miR-6088, hsa-miR-4674, hsa-miR-8073, hsa-miR-4787-5p, hsa-miR-1469, hsa-miR-125a-3p, hsa-miR-1233-5p, hsa- miR-885-3p, hsa-miR-6802-5p, hsa-miR-328-5p, hsa-miR-6787-5p, hsa-miR-8069, hsa-miR-6875-5p, hsa-miR-1246, hsa-miR-4734, hsa-miR-675 7-5p, hsa-miR-6756-5p, hsa-miR-3665, hsa-miR-6836-3p, hsa-miR-6821-5p, hsa-miR-6805-5p, hsa-miR-4728-5p, hsa-miR-6726-5p, hsa-miR-19 7-5p, hsa-miR-149-3p, hsa-miR-6850-5p, hsa-miR-4476, hsa-miR-6858-5p, hsa-miR-564, hsa-miR-4763-3p, hsa-miR-575, hsa-miR-6771-5p, hsa -miR-1231, hsa-miR-1908-3p, hsa-miR-150-3p, hsa-miR-3937, hsa-miR-887-3p, hsa-miR-3940-5p, hsa-miR-4741, hsa-miR-6808-5p, hsa-miR-68 69-5p, hsa-miR-5090, hsa-miR-615-5p, hsa-miR-8072, hsa-miR-128-1-5p, hsa-miR-1238-5p, hsa-miR-365a-5p, hsa-miR-204-3p, hsa-miR-4492,hsa-miR-6785-5p, hsa-miR-6511a-5p, hsa-miR-4525, hsa-miR-1915-5p, hsa-miR-3180, hsa-miR-6879-5p, hsa-miR-1199-5p, hsa-miR-6746-5p sa-miR-711, hsa-miR-663b, hsa-miR-4707-3p, hsa-miR-6893-5p, hsa-miR-4675, hsa-miR-4638-5p, hsa-miR-4651, hsa-miR-6087, hsa-miR-4665-5 p、hsa-miR-4758-5p、hsa-miR-6887-5p、hsa-miR-3620-5p、hsa-miR-1909-3p、hsa-miR-7641、hsa-miR-6724-5p、hsa-miR-1343-3p、hsa-miR-6780b -5p、hsa-miR-4484、hsa-miR-4690-5p、hsa-miR-4429、hsa-miR-1227-5p、hsa-miR-4725-3p、hsa-miR-6861-5p、hsa-miR-6812-5p、hsa-miR-3197、hs a-miR-8059, hsa-miR-3185, hsa-miR-4706, hsa-miR-4497, hsa-miR-3131, hsa-miR-6806-5p, hsa-miR-187-5p, hsa-miR-3180-3p, hsa-miR-6848-5 p、hsa-miR-6820-5p、hsa-miR-6800-5p、hsa-miR-6717-5p、hsa-miR-6795-5p、hsa-miR-4632-5p、hsa-miR-665、hsa-miR-6778-5p、hsa-miR-3663-3p hsa-miR-4689, hsa-miR-211-3p, hsa-miR-6511b-5p, hsa-miR-4750-5p, hsa-miR-6126, hsa-miR-614, hsa-miR-7110-5p, hsa-miR-744-5p, hsa-mi R-6769a-5p、hsa-miR-4792、hsa-miR-5787、hsa-miR-6798-5p、hsa-miR-6781-5p、hsa-miR-4419b、hsa-miR-4446-3p、hsa-miR-4259、hsa-miR-5572、hsa-miR-6075, hsa-miR-296-3p, hsa-miR-6891-5p, hsa-miR-4745-5p, hsa-miR-6775-5p, hsa-miR-6870-5p, hsa-miR-920, hsa-miR-4530, hsa-miR -6819-5p、hsa-miR-6825-5p、hsa-miR-7847-3p、hsa-miR-6131、hsa-miR-4433-3p、hsa-miR-1228-5p、hsa-miR-6743-5p、hsa-miR-1268a、hsa-miR-3 917, hsa-miR-6786-5p, hsa-miR-3154, hsa-miR-638, hsa-miR-6741-5p, hsa-miR-6889-5p, hsa-miR-6840-3p, hsa-miR-6510-5p, hsa-miR-3188, hs a-miR-551b-5p、hsa-miR-5001-5p、hsa-miR-1268b、hsa-miR-7107-5p、hs a-miR-6824-5p、hsa-miR-6732-5p、hsa-miR-371a-5p、hsa-miR-6794-5p、h sa-miR-6779-5p、hsa-miR-4271、hsa-miR-5195-3p、hsa-miR-6762-5p、hsa-miR-939-5p、hsa-miR-1247-3p、hsa-miR-6777-5p、hsa-miR-6722-3p、h sa-miR-3656, hsa-miR-4688, hsa-miR-3195, hsa-miR-6766-5p, hsa-miR-4447, hsa-miR-4656, hsa-miR-7108-5p, hsa-miR-3191-3p, hsa-miR-1273g -3p、hsa-miR-4463、hsa-miR-2861、hsa-miR-3196、hsa-miR-6877-5p、hsa-miR-3679-5p、hsa-miR-4442、hsa-miR-6789-5p、hsa-miR-6782-5p、hsa- miR-486-3p, hsa-miR-6085, hsa-miR-4746-3p, hsa-miR-619-5p, hsa-miR-937-5p, hsa-miR-6803-5p, hsa-miR-4298, hsa-miR-4454, hsa-miR-4459hsa-miR-7150, hsa-miR-6880-5p, hsa-miR-4449, hsa-miR-8063, hsa-miR-4695-5p, hsa-miR-6132, hsa-miR-6829-5p, hsa-miR-4486, hsa-miR-680 5-3p, hsa-miR-6826-5p, hsa-miR-4508, hsa-miR-1343-5p, hsa-miR-7114-5p, hsa-miR-3622a-5p, hsa-miR-6765-5p, hsa-miR-7845-5p, hsa-miR-39 60. hsa-miR-6749-5p, hsa-miR-1260b, hsa-miR-6799-5p, hsa-miR-4723-5p, hsa-miR-6784-5p, hsa-miR-5100, hsa-miR-6769b-5p, hsa-miR-1207-5 p, hsa-miR-642a-3p, hsa-miR-4505, hsa-miR-4270, hsa-miR-6721-5p, hsa-miR-7111-5p, hsa-miR-6791-5p, hsa-miR-7109-5p, hsa-miR-4258, hsa- miR-6515-3p, hsa-miR-6851-5p, hsa-miR-6125, hsa-miR-4749-5p, hsa-miR-4726-5p, hsa-miR-4513, hsa-miR-6089, hsa-miR-6816-5p, hsa-miR-4466, hsa-miR-4488, hsa-miR-6752-5p or hsa-miR-4739, or a combination thereof, or a homologue thereof, a transcription product thereof, a mutant or derivative thereof, and hsa-miR-760, hsa-miR-602, hsa-miR-4739, which may be combined with the same as appropriate. hsa-miR-423-5p, hsa-miR-92a-2-5p, hsa-miR-16-5p, hsa-miR-451a, hsa-miR-135a-3p, hsa-miR-486-5p, hsa-miR-4257, hsa-miR-92b-5p, hsa-miR-1915-3p, hsa-miR-718, hsa-miR-940, hsa-miR-296-5p, hsa-miR-23b-3p or hsa-miR-92a-3p, or a combination thereof, a transcription product thereof, a mutant or derivative thereof, and hsa-miR-658, which may be further combined with them as appropriate.hsa-miR-6842-5p, hsa-miR-6124, hsa-miR-6765-3p, hsa-miR-7106-5p, hsa-miR-4534, hsa-miR-92b-3p, hsa-miR-3135b, hsa-miR-4687-3p, hsa-miR-762, hsa-miR-3619-3p, hsa-miR-4467, hsa-miR-557, hsa-miR-1237-5p, hsa-miR-1908-5p, hsa-miR-4286, hsa-miR-6885-5p and hsa-miR-6763-5p, or a combination thereof, or a homologue thereof, a transcription product thereof, a mutant or a derivative thereof.

[0724] Regarding the target nucleic acids described above, expression levels in subjects suffering from breast cancer may be increased or decreased (hereinafter referred to as "increased / decreased") depending on the type of target nucleic acid. Therefore, the nucleic acids of the present invention can be effectively used to detect breast cancer by measuring the expression levels of the target nucleic acids in body fluids derived from subjects suspected of suffering from breast cancer (e.g., humans) and in body fluids derived from healthy subjects, and comparing these results.

[0725] The nucleic acid probe or primer that can be ...

Claims

1. Use of a nucleic acid capable of specifically binding to a polynucleotide of miR-615-5p, which is a breast cancer marker, in the manufacture of a kit for detecting breast cancer.

2. The use according to claim 1, wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in any one of the following (a) to (c), (a) a polynucleotide consisting of the base sequence represented by SEQ ID NO: 56 or a base sequence in which u is t in the base sequence, (b) a polynucleotide consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 56 or a base sequence in which u is t in the base sequence, and (c) a polynucleotide that hybridizes with the polynucleotide of (a) or (b) under stringent conditions.

3. The use according to claim 1 or 2, wherein the kit further comprises a miR-4730, miR-1307-3p, miR-4634, miR-663a, miR-4532, miR-7704, miR-3178, miR-6729-5p, miR-6090, miR-4732-5p, miR-3184-5p, miR-6727-5p, miR-6088, miR-4674, miR-8073, miR-4787-5p, miR-1469, miR-125a-3p, miR-1233-5p, miR-885-3p, mi R-6802-5p,miR-328-5p,miR-6787-5p,miR-8069,miR-6875-5p,miR-1246,miR-4734,miR-6756-5p,miR-3665,miR-6836-3p,miR-6821-5p,miR-6805 -5p,miR-4728-5p,miR-6726-5p,miR-197-5p,miR-149-3p,miR-6850-5p,miR-4476,miR-6858-5p,miR-564,miR-4763-3p,miR-575,miR-6771-5p,mi R-1231,miR-1908-3p,miR-150-3p,miR-3937,miR-887-3p,miR-3940-5p,miR-4741,miR-6808-5p,miR-6869-5p,miR-5090,miR-8072,miR-128-1-5p ,miR-1238-5p,miR-365a-5p,miR-204-3p,miR-4492,miR-6785-5p,miR-6511a-5p,miR-4525,miR-1915-5p,miR-3180,miR-6879-5p,miR-1199-5p,m iR-6746-5p,miR-711,miR-663b,miR-4707-3p,miR-6893-5p,miR-4675,miR-4638-5p,miR-4651,miR-6087,miR-4665-5p,miR-4758-5p,miR-6887-5 p,miR-3620-5p,miR-1909-3p,miR-7641,miR-6724-5p,miR-1343-3p,miR-6780b-5p,miR-4484,miR-4690-5p,miR-4429,miR-1227-5p,miR-4725-3p,miR-6861-5p, miR-6812-5p, miR-3197, miR-8059, miR-3185, miR-4706, miR-4497, miR-3131, miR-6806-5p, miR-187-5p, miR-3180-3p, and miR-6848-5p miR-6820-5p, miR-6800-5p, miR-6717-5p, miR-6795-5p, miR-4632-5p, miR-665, miR-6778-5p, miR-3663-3p, miR-4689, miR-211-3p, and miR-6511b-5p miR-4750-5p, miR-6126, miR-614, miR-7110-5p, miR-744-5p, miR-6769a-5p, miR-4792, miR-5787, miR-6798-5p, miR-6781-5p, miR-4419b, miR-444 6-3p, miR-4259, miR-5572, miR-6075, miR-296-3p, miR-6891-5p, miR-4745-5p, miR-6775-5p, miR-6870-5p, miR-920, miR-4530, miR-6819-5p, miR-6 825-5p, miR-7847-3p, miR-6131, miR-4433-3p, miR-1228-5p, miR-6743-5p, miR-1268a, miR-3917, miR-6786-5p, miR-3154, miR-638, miR-6741-5p, m iR-6889-5p, miR-6840-3p, miR-6510-5p, miR-3188, miR-551b-5p, miR-5001-5p, miR-1268b, miR-7107-5p, miR-6824-5p, miR-6732-5p, and miR-371a-5p miR-6794-5p, miR-6779-5p, miR-4271, miR-5195-3p, miR-6762-5p, miR-939-5p, miR-1247-3p, miR-6777-5p, miR-6722-3p, miR-3656, miR-4688, mi R-3195, miR-6766-5p, miR-4447, miR-4656, miR-7108-5p, miR-3191-3p, miR-1273g-3p, miR-4463, miR-2861, miR-3196, miR-6877-5p, and miR-3679-5pA nucleic acid that specifically binds to at least one polynucleotide among miR-4442, miR-6789-5p, miR-6782-5p, miR-486-3p, miR-6085, miR-4746-3p, miR-619-5p, miR-937-5p, miR-6803-5p, miR-4298, miR-4454, miR-4459, miR-7150, miR-6880-5p, miR-4449, miR-8063, miR-4695-5p, miR-6132, miR-6829-5p, miR-4486, miR-6805-3p, miR-6826-5p, miR-4508, miR-1343-5p, miR-7114-5p, miR-3622a-5p, miR-6765-5p, miR-7845-5p, miR-3960, miR-6749-5p, miR-1260b, miR-6799-5p, miR-4723-5p, miR-6784-5p, miR-5100, miR-6769b-5p, miR-1207-5p, miR-642a-3p, miR-4505, miR-4270, miR-6721-5p, miR-7111-5p, miR-6791-5p, miR-7109-5p, miR-4258, miR-6515-3p, miR-6851-5p, miR-6125, miR-4749-5p, miR-4726-5p, miR-4513, miR-760, miR-602, miR-423-5p, miR-92a-2-5p, miR-16-5p, miR-451a, miR-135a-3p, miR-486-5p, miR-4257, miR-92b-5p, miR-1915-3p, miR-718, miR-940, miR-296-5p, miR-23b-3p, miR-92a-3p, miR-658, miR-6842-5p, miR-6124, miR-6765-3p, miR-7106-5p, miR-4534, miR-92b-3p, miR-3135b, miR-4687-3p, miR-762, miR-3619-3p, miR-4467, miR-557, miR-1237-5p, miR-1908-5p, miR-4286, miR-6885-5p, miR-6763-5p, miR-6089, miR-6816-5p, miR-4466, miR-4488, miR-6752-5p, and miR-4739.

4. The use according to claim 3, wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (d) to (f), (d) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 2 to 28, 30 to 55, 57 to 269, and 851 to 856, or a base sequence in which u is t in the base sequence, (e) a polynucleotide consisting of a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 2 to 28, 30 to 55, 57 to 269, and 851 to 856, or a base sequence in which u is t in the base sequence, and (f) A polynucleotide that hybridizes with the nucleotide of (d) or (e) under stringent conditions.

5. Use of a nucleic acid capable of specifically binding to a polynucleotide of miR-615-5p, which is a breast cancer marker, for producing a device for detecting breast cancer.

6. The use according to claim 5, wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (a) to (c), (a) a polynucleotide consisting of the base sequence represented by SEQ ID NO: 56 or a base sequence in which u is t in the base sequence, (b) a polynucleotide consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 56 or a base sequence in which u is t in the base sequence, and (c) a polynucleotide that hybridizes with the polynucleotide of (a) or (b) under stringent conditions.

7. The use according to claim 5 or 6, wherein the device further comprises a marker capable of being used with other breast cancer markers selected from miR-4730, miR-1307-3p, miR-4634, miR-663a, miR-4532, miR-7704, miR-3178, miR-6729-5p, miR-6090, miR-4732-5p, miR-3184-5p, miR-6727-5p, miR-6088, miR-4674, miR-8073, miR-4787-5p, miR-1469, miR-125a-3p, miR-1233-5p, miR-885-3p, miR-6802-5p, miR-328-5p, miR-6787-5p, miR-8069, miR-6875-5p, miR-1246, miR-4734, miR-6756-5p, miR-3665, miR-6836-3p, miR-6821-5p, miR-6805-5p, miR-4728-5p, miR-6726-5p, miR-197-5p, miR-149-3p, miR-6850-5p, miR-4476, miR-6858-5p, miR-564, miR-4763-3p, miR-575, miR-6771-5p, miR-1231, miR-1908-3p, miR-150-3p, miR-3937, miR-887-3p, miR-3940-5p, miR-4741, miR-6808-5p, miR-6869-5p, miR-5090, miR-8072, miR-128-1-5p, miR-1238-5p, miR-365a-5p, miR-204-3p, miR-4492, miR-6785-5p, miR-6511a-5p, miR-4525, miR-1915-5p, miR-3180, miR-6879-5p, miR-1199-5p, miR-6746-5p, miR-711, miR-663b, miR-4707-3p, miR-6893-5p, miR-4675, miR-4638-5p, miR-4651, miR-6087, miR-4665-5p, miR-4758-5p, miR-6887-5p, miR-3620-5p, miR-1909-3p, miR-7641, miR-6724-5p, miR-1343-3p, miR-6780b-5p, miR-4484, miR-4690-5p, miR-4429, miR-1227-5p, miR-4725-3p,miR-6861-5p, miR-6812-5p, miR-3197, miR-8059, miR-3185, miR-4706, miR-4497, miR-3131, miR-6806-5p, miR-187-5p, miR-3180-3p, and miR-6848-5p miR-6820-5p, miR-6800-5p, miR-6717-5p, miR-6795-5p, miR-4632-5p, miR-665, miR-6778-5p, miR-3663-3p, miR-4689, miR-211-3p, and miR-6511b-5p miR-4750-5p, miR-6126, miR-614, miR-7110-5p, miR-744-5p, miR-6769a-5p, miR-4792, miR-5787, miR-6798-5p, miR-6781-5p, miR-4419b, miR-444 6-3p, miR-4259, miR-5572, miR-6075, miR-296-3p, miR-6891-5p, miR-4745-5p, miR-6775-5p, miR-6870-5p, miR-920, miR-4530, miR-6819-5p, miR-6 825-5p, miR-7847-3p, miR-6131, miR-4433-3p, miR-1228-5p, miR-6743-5p, miR-1268a, miR-3917, miR-6786-5p, miR-3154, miR-638, miR-6741-5p, m iR-6889-5p, miR-6840-3p, miR-6510-5p, miR-3188, miR-551b-5p, miR-5001-5p, miR-1268b, miR-7107-5p, miR-6824-5p, miR-6732-5p, and miR-371a-5p miR-6794-5p, miR-6779-5p, miR-4271, miR-5195-3p, miR-6762-5p, miR-939-5p, miR-1247-3p, miR-6777-5p, miR-6722-3p, miR-3656, miR-4688, mi R-3195, miR-6766-5p, miR-4447, miR-4656, miR-7108-5p, miR-3191-3p, miR-1273g-3p, miR-4463, miR-2861, miR-3196, miR-6877-5p, and miR-3679-5pA nucleic acid that specifically binds to at least one polynucleotide among miR-4442, miR-6789-5p, miR-6782-5p, miR-486-3p, miR-6085, miR-4746-3p, miR-619-5p, miR-937-5p, miR-6803-5p, miR-4298, miR-4454, miR-4459, miR-7150, miR-6880-5p, miR-4449, miR-8063, miR-4695-5p, miR-6132, miR-6829-5p, miR-4486, miR-6805-3p, miR-6826-5p, miR-4508, miR-1343-5p, miR-7114-5p, miR-3622a-5p, miR-6765-5p, miR-7845-5p, miR-3960, miR-6749-5p, miR-1260b, miR-6799-5p, miR-4723-5p, miR-6784-5p, miR-5100, miR-6769b-5p, miR-1207-5p, miR-642a-3p, miR-4505, miR-4270, miR-6721-5p, miR-7111-5p, miR-6791-5p, miR-7109-5p, miR-4258, miR-6515-3p, miR-6851-5p, miR-6125, miR-4749-5p, miR-4726-5p, miR-4513, miR-760, miR-602, miR-423-5p, miR-92a-2-5p, miR-16-5p, miR-451a, miR-135a-3p, miR-486-5p, miR-4257, miR-92b-5p, miR-1915-3p, miR-718, miR-940, miR-296-5p, miR-23b-3p, miR-92a-3p, miR-658, miR-6842-5p, miR-6124, miR-6765-3p, miR-7106-5p, miR-4534, miR-92b-3p, miR-3135b, miR-4687-3p, miR-762, miR-3619-3p, miR-4467, miR-557, miR-1237-5p, miR-1908-5p, miR-4286, miR-6885-5p, miR-6763-5p, miR-6089, miR-6816-5p, miR-4466, miR-4488, miR-6752-5p, and miR-4739.

8. The use according to claim 7, wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (d) to (f), (d) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 2 to 28, 30 to 55, 57 to 269, and 851 to 856, or a base sequence in which u is t in the base sequence, (e) a polynucleotide consisting of a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 2 to 28, 30 to 55, 57 to 269, and 851 to 856, or a base sequence in which u is t in the base sequence, and (f) a polynucleotide that hybridizes with the polynucleotide of (d) or (e) under stringent conditions.

9. The use according to any one of claims 5 to 8, wherein the device is a device for performing assays by hybridization techniques.

10. The use according to claim 9, wherein the hybridization technology is nucleic acid array technology.

11. Use of a nucleic acid capable of specifically binding to a polynucleotide of miR-615-5p for the manufacture of a breast cancer diagnostic reagent for breast cancer detection.

12. The use according to claim 11, wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (a) to (c), (a) a polynucleotide consisting of the base sequence represented by SEQ ID NO: 56 or a base sequence in which u is t in the base sequence, (b) a polynucleotide consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 56 or a base sequence in which u is t in the base sequence, and (c) a polynucleotide that hybridizes with the polynucleotide of (a) or (b) under stringent conditions.

13. The use according to claim 11 or 12, wherein in the manufacture of the breast cancer diagnostic reagent, further using a miR-4730, miR-1307-3p, miR-4634, miR-663a, miR-4532, miR-7704, miR-3178, miR-6729-5p, miR-6090, miR-4732-5p, miR-3184-5p, miR-6727-5p, miR-6088, miR-4674, miR-8073, miR-4787-5p, miR-1469, miR-125a-3p, miR-1233-5p, miR- iR-885-3p,miR-6802-5p,miR-328-5p,miR-6787-5p,miR-8069,miR-6875-5p,miR-1246,miR-4734,miR-6756-5p,miR-3665,miR-6836-3p,miR-6821 -5p,miR-6805-5p,miR-4728-5p,miR-6726-5p,miR-197-5p,miR-149-3p,miR-6850-5p,miR-4476,miR-6858-5p,miR-564,miR-4763-3p,miR-575,mi R-6771-5p,miR-1231,miR-1908-3p,miR-150-3p,miR-3937,miR-887-3p,miR-3940-5p,miR-4741,miR-6808-5p,miR-6869-5p,miR-5090,miR-8072, miR-128-1-5p,miR-1238-5p,miR-365a-5p,miR-204-3p,miR-4492,miR-6785-5p,miR-6511a-5p,miR-4525,miR-1915-5p,miR-3180,miR-6879-5p,m iR-1199-5p,miR-6746-5p,miR-711,miR-663b,miR-4707-3p,miR-6893-5p,miR-4675,miR-4638-5p,miR-4651,miR-6087,miR-4665-5p,miR-4758-5 p,miR-6887-5p,miR-3620-5p,miR-1909-3p,miR-7641,miR-6724-5p,miR-1343-3p,miR-6780b-5p,miR-4484,miR-4690-5p,miR-4429,miR-1227-5p,miR-4725-3p, miR-6861-5p, miR-6812-5p, miR-3197, miR-8059, miR-3185, miR-4706, miR-4497, miR-3131, miR-6806-5p, miR-187-5p, and miR-3180-3p miR-6848-5p, miR-6820-5p, miR-6800-5p, miR-6717-5p, miR-6795-5p, miR-4632-5p, miR-665, miR-6778-5p, miR-3663-3p, miR-4689, miR-211-3p miR-6511b-5p, miR-4750-5p, miR-6126, miR-614, miR-7110-5p, miR-744-5p, miR-6769a-5p, miR-4792, miR-5787, miR-6798-5p, miR-6781-5p, and miR-4 419b, miR-4446-3p, miR-4259, miR-5572, miR-6075, miR-296-3p, miR-6891-5p, miR-4745-5p, miR-6775-5p, miR-6870-5p, miR-920, miR-4530, and miR-6 819-5p, miR-6825-5p, miR-7847-3p, miR-6131, miR-4433-3p, miR-1228-5p, miR-6743-5p, miR-1268a, miR-3917, miR-6786-5p, miR-3154, miR-638, m iR-6741-5p, miR-6889-5p, miR-6840-3p, miR-6510-5p, miR-3188, miR-551b-5p, miR-5001-5p, miR-1268b, miR-7107-5p, miR-6824-5p, and miR-6732-5p miR-371a-5p, miR-6794-5p, miR-6779-5p, miR-4271, miR-5195-3p, miR-6762-5p, miR-939-5p, miR-1247-3p, miR-6777-5p, miR-6722-3p, and miR-3656 miR-4688, miR-3195, miR-6766-5p, miR-4447, miR-4656, miR-7108-5p, miR-3191-3p, miR-1273g-3p, miR-4463, miR-2861, miR-3196, miR-6877-5pA nucleic acid that specifically binds to at least one polynucleotide among miR-3679-5p, miR-4442, miR-6789-5p, miR-6782-5p, miR-486-3p, miR-6085, miR-4746-3p, miR-619-5p, miR-937-5p, miR-6803-5p, miR-4298, miR-4454, miR-4459, miR-7150, miR-6880-5p, miR-4449, miR-8063, miR-4695-5p, miR-6132, miR-6829-5p, miR-4486, miR-6805-3p, miR-6826-5p, miR-4508, miR-1343-5p, miR-7114-5p, miR-3622a-5p, miR-6765-5p, miR-7845-5p, miR-3960, miR-6749-5p, miR-1260b, miR-6799-5p, miR-4723-5p, miR-6784-5p, miR-5100, miR-6769b-5p, miR-1207-5p, miR-642a-3p, miR-4505, miR-4270, miR-6721-5p, miR-7111-5p, miR-6791-5p, miR-7109-5p, miR-4258, miR-6515-3p, miR-6851-5p, miR-6125, miR-4749-5p, miR-4726-5p, miR-4513, miR-760, miR-602, miR-423-5p, miR-92a-2-5p, miR-16-5p, miR-451a, miR-135a-3p, miR-486-5p, miR-4257, miR-92b-5p, miR-1915-3p, miR-718, miR-940, miR-296-5p, miR-23b-3p, miR-92a-3p, miR-658, miR-6842-5p, miR-6124, miR-6765-3p, miR-7106-5p, miR-4534, miR-92b-3p, miR-3135b, miR-4687-3p, miR-762, miR-3619-3p, miR-4467, miR-557, miR-1237-5p, miR-1908-5p, miR-4286, miR-6885-5p, miR-6763-5p, miR-6089, miR-6816-5p, miR-4466, miR-4488, miR-6752-5p and miR-4739.

14. The use according to claim 13, wherein the nucleic acid is a polynucleotide selected from the polynucleotides shown in the following (d) to (f), (d) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 2 to 28, 30 to 55, 57 to 269, and 851 to 856, or a base sequence in which u is t in the base sequence, (e) a polynucleotide consisting of a base sequence complementary to the base sequence represented by any one of SEQ ID NOs: 2 to 28, 30 to 55, 57 to 269, and 851 to 856, or a base sequence in which u is t in the base sequence, and (f) A polynucleotide that hybridizes with any one of the polynucleotides of (d) or (e) under stringent conditions.

Images